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Abstract 
Immunoglobulin gamma monoclonal antibodies are glycoproteins that have emerged as powerful 
and promising protein therapeutics. During the process of production, storage and transportation, 
exposure to ambient light is inevitable, which can cause protein physical and chemical degradation. 
For mechanistic studies of photo-degradation, we have exposed IgG4-Fc to UV light. The 
photoirradiation of IgG4-Fc with monochromatic UVC light at λ = 254 nm and UVB light with 
λmax = 305 nm in air-saturated solutions revealed multiple photo-products originating from tyrosine 
side chain fragmentation at Tyr300, Tyr373 and Tyr436. Tyr side chain fragmentation yielded either 
Gly or various backbone cleavage products, including glyoxal amide derivatives. A mechanism is 
proposed involving intermediate Tyr radical cation formation, either through direct light 
absorption of Tyr or through electron transfer to an initial Trp radical cation, followed by 
elimination of quinone methide. In previous studies we discovered that the exposure of IgG4-Fc 
and IgG1 to UV light resulted in the side chain cleavage of specific Tyr and Trp residues, 
converting these amino acids into a series of products, including Gly (Haywood et al. Mol. Pharm. 
2013, 10, 1146-1150; Kang et al. Mol. Pharm. 2019, 16, 258-272). In order to evaluate the physico-
chemical consequences of such photochemical transformations, we prepared a series of IgG4-Fc 
mutants, in which Trp and Tyr residues were mutated to Gly, i.e., Y300G, Y373G, Y436G, W381G, 
and W381A for biophysical studies. Among these mutants, Y373G displayed significantly lower 
melting temperatures compared to wild-type IgG4-Fc, as analyzed by differential scanning 
calorimetry and fluorescence spectroscopy, indicating a decrease of thermal stability of both the 
CH2 and CH3 domains. In contrast, W381G and W381A showed no thermal transitions, indicating 
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a significant loss of overall thermal stability. Both, W381A and Y300G IgG4-Fc displayed ca. 10-
fold reduction of binding affinity to FcγRIIIA as compared to wild-type IgG4-Fc. Interestingly, 
W381A and W381G IgG4-Fc did not only contain N-linked glycans but also high levels of O-
mannose (> 60%) at Ser375. Furthermore, a series of well-defined N-glycosylated IgG4-Fc variants 
were utilized as model to investigate the effect of glycan structure on the physico-chemical 
properties (conformational stability and photostability) and interaction with FcɣRIIIA. The size of 
glycans at Asn297 affects the yields of light-induced Tyr side chain fragmentation products, where 
the yields decreased in the following order: N297Q > GlcNAc1 > Man5 > HM. These yields 
correlate with the thermal stability of the glycoforms. The presence of HM and Man5 reveals 
increased affinity for FcɣRIIIA by at least 14.7-fold, as compared to GlcNAc1 IgG4-Fc. N297Q 
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1.1. IgG4 as therapeutics 
Monoclonal antibodies (mAbs), primarily immunoglobulin Gs (IgGs), have evolved as effective 
therapeutics, owing to their target specificity and long serum half-life1. IgGs are composed of four 
subclasses, including IgG1, 2, 3, and 4, named in order of decreasing abundance in serum. The 
four IgG subtypes differ in their constant region, particularly upper hinge region and CH2 domain2. 
Among the four subclasses, IgG1, 2, and 4 have been developed into therapeutics. IgG3 is rarely 
used due to its shorter half-life and bioprocessing issues associated with IgG3’s long hinge region3. 
Since the first antibody approved in 1986, approximately 80 mAb-based therapeutics have been 
marketed in the USA and the EU (data collected at the end of 2018)4, 5. IgG4 is utilized in more 
than 10 mAbs (including IgG4-based Fc-fusion protein)4, 5. So far, IgG4 has been utilized for 
several indications, e.g., migraine prevention, HIV infection, allergy and cancers5. The IgG4 
subclass is preferably selected when the recruitment of host effector functions is undesired or 
unnecessary. For example, IgG4-based mAbs developed for targeting programmed cell death 
protein 1 (PD1) are utilized to block the binding between PD1 on patients’ immune cells and the 
ligand for PD1 on tumor cells6, referred to as immune-check point therapy. Such therapy does not 
require the deletion of patients’ immune cells. A similar example is the development of an IgG4-
based ibalizumab targeting CD4 on immune cells, approved for HIV infection5. IgG4 is an 
important ‘blocking antibody’ in immune-checkpoint therapy, HIV infection, and allergy. 
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1.2. Structures of IgG4  
IgG4 is a dimer composed of two heavy chains and two light chains, connected by inter-chain 
disulfide bonds in the hinge region7. The light chain is composed of one variable domain (VL) and 
one constant domain (CL), while the heavy chain is composed of one variable domain (VH) and 
three constant domains (CH1, CH2, and CH3)2. The IgG4 structure can also be divided into two 
fragments: the antigen-binding fragment (Fab, including VL, CL, VH, and CH1 domains) and the 
crystallizable fragment (Fc, including CH2 and CH3 domains). IgG4 reveals several unique 
properties as compared to other subclasses. First, it is capable to form hinge isomers (e.g., intra-
chain disulfides and inter-chain disulfides) due to the presence of the sequence CPS228C (instead 
of the equivalent sequence CPP228C in IgG12; Eu numbering8). Second, it reveals relatively weak 
hydrophobic interactions between the CH3 domains due to the presence of Arg409 (instead of an 
equivalent Lys409 in IgG1). Based on these properties, wild type IgG4 can undergo half-molecule 
exchange, and predominantly exists as a monovalent bispecific antibody in vivo9, 10. 
 
1.3. The importance of Fc fragment in IgGs  
The importance of the Fc fragment in an IgG can be rationalized in various factors. First, it is 
critical in extending IgG serum half-life through binding to the neonatal Fc receptor (FcRn), 
rescuing it from lysosomal degradation11. Second, it contributes to elicit antibody dependent cell 
cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) through binding to cell 
surface Fcɣ receptors (FcɣRs) and complement protein 1 q (C1q), respectively. The binding 
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affinity to FcɣRs and C1q is significant for IgG biological functions12. Third, the Fc fragment eases 
the purification of IgGs from cell media due to its high affinity to protein G/A columns at neutral 
pH, and reduced binding affinity at acidic pH. Fourth, previous biophysical analysis indicates that 
the Fc domain folds independently, and improves solubility and stability of the partner molecule 
in vivo and in vitro13. So far, approximately twenty Fc-fusion proteins and peptides have been 
approved by regulatory authorities14. Fc-fusion proteins have been developed for autoimmune 
diseases and enzyme replacement therapy15. 
 
1.4. Effector function of IgG4 
Antibodies present two important functions: (i) antigen-binding functions though binding to 
specific antigens with their Fab region, and (ii) effector functions through binding to complement 
proteins and FcɣRs with their Fc region16. IgG1 and IgG3 typically trigger effector functions, while 
IgG2 and IgG4 induce more subtle ones. IgG4 presents no binding affinity to C1q, resulting in a 
lack of CDC activity2. For ADCC responses, IgG4 displays low affinity to activating receptor, 
FcɣRIIIA, while comparatively high affinity to inhibiting FcɣRs (e.g., FcɣR IIB and IIC). This 
prevents IgG4 excessive host effector functions against targeting antigen. Hence IgG4 has been 
utilized as a “blocking antibody”2.  
 
There are three types of FcɣR: FcɣRI, FcɣRII (IIA, IIB and IIC), and FcɣRIII (IIIA and IIIB). 
Among these, FcɣRIIB and IIC are inhibitory receptors, and all others are activating receptors17. 
FcɣRIIIA is the only activating Fc receptor present on natural killer cells and essential in eliciting 
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ADCC. The interaction between the Fc-domain and FcɣRIIIA involves carbohydrate-carbohydrate 
interactions, and is sensitive to the glycosylated state of the Fc fragment and FcɣRIIIA18.   
 
 1.5. Photostability 
Light exposure is inevitable during the stages of pharmaceutical processing19 from upstream 
production, downstream purification, visual inspection, storage, transportation to administration 
to patients20. The light conditions can be categorized into ultraviolet (UV) and visible-light 
exposure. Three types of UV radiation include UVA (315-400 nm), UVB (280-315nm) and UVC 
(100-280 nm), where UVA accounts for ca. 95% of the UV radiation reaching the Earth’s surface, 
while UVB and UVC are primarily absorbed by the ozone layer and the atmosphere21. UVB and 
UVC exposure can be encountered during purification and analysis steps. For instance, 
chromatography analysis commonly uses UV (214 nm, 254 nm or 280 nm) absorbance for 
analytical detection22. Under these conditions, photo-sensitive amino acids, e.g., Trp, Tyr, Phe, Cys, 
and cystine can directly absorb light23, which induce photochemical degradation. Such 
mechanisms will be discussed in sections 1.5.1 and 1.5.2, summarizing the photochemistry of Tyr 
and Trp, respectively. Visible light exposure, on the other hand, is difficult to avoid. The small-
scale production of proteins using clear glass bioreactors can potentially result in the exposure to 
ambient light. Visual inspection for visible particles in parenteral leads to light exposure. The usage 
of prefilled syringes and IV bags for medication administration can increase the risk of light 
exposure. Ambient light sources (e.g., cool white fluorescence light and LED white lamp) emit 
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primarily visible light (400 nm-800 nm)24, 25. Both UV and visible light sources can negatively 
impact protein stability24, 26, although the mechanisms of protein degradation can be different. 
Therefore, the International Conference for Harmonization guideline on photostability (ICH Q1B) 
suggests the exposure of a combination of a minimum of 200 Whr/m2 of UVA (320 nm-400 nm) 
and 1.2 million lux hours of visible light (400-800 nm) at room temperature to cover the potential 
light exposure conditions27. 
 
1.5.1. Photochemistry of Tyr 
The photochemistry of Tyr is summarized in Scheme 128, 29. Ground state Tyr directly absorbs light 
at wavelengths below 290 nm with an absorption maximum at ca. 275 nm30. Upon absorption, 
ground state Tyr is excited to its singlet state 1Tyr, which is highly reactive31. 1Tyr undergoes 
several degradation pathways32. First, it can fluoresce back to ground state Tyr. Second, 1Tyr 
undergoes intersystem crossing (ICS) forming triplet 3Tyr. 3Tyr reacts with 3O2, generating reactive 
oxygen species (ROS), such as 1O2 and/or O2.-, and in parallel, yielding Tyr and Tyr radical cation 
(Tyr+.), respectively. Third, 1Tyr can undergo photoionization yielding Tyr+. and a solvated electron 
(e-aq). The Tyr+. radical cation can potentially eliminate its side chain, yielding carbon-center glycyl 
radical33. Alternatively, the Tyr+. radical cation can deprotonate and yield the tyrosyl radical 
(TyrO.). The addition of 3O234, peroxyl radical (ROO.)35 and hydroxyl radicals (RO.)36 on TyrO. 
subsequently yields dihydroxyphenylalanine (DOPA). On the other hand, TyrO. can dimerize and 
yield dityrosine (Di-Tyr). DOPA reveals a mass addition of 16 Da compared to native Tyr, which 
can be detected by HPLC-MS. Recently, a fluorogenic derivatization protocol of DOPA with 4-
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amino methyl benzenesulfonic acid (ABS) was reported to be a potential fast screening approach35, 
considering the fact that HPLC-MS/MS analysis requires method development, which can be time-
consuming. Di-Tyr has been extensively studied in biological sample and recognized as an 
important biomarker of oxidative stress37-39; however to our knowledge is rarely reported in mAbs. 
The formation of Di-Tyr depends on the proximity of two Tyr, the solvent accessibility of Tyr, and 
the higher order structure of proteins40. Analytical methods for the detection and quantification of 
Di-Tyr have been reviewed41, including fluorescence spectroscopy37 (e.g., excitation at 284 nm 



























































Trp represents the strongest UV chromophore in proteins, predominantly absorbing light below 
310 nm (the maxima absorption at 280 nm). The photochemistry of Trp is summarized in Scheme 
2, revealing similar pathways as Tyr. Common oxidation products of Trp such as 
hydroxytryptophan (OH-Trp), N-formylkynurienine (NFK), and kynurenine (Kyn) were observed 
during the UV exposure of mAbs (e.g., at 254 nm) and near UV-visible light at 300-700 nm42. 
These products need to be carefully characterized and controlled. It was reported that Kyn is 
associated with the color-change in an IgG142. In addition, the absorption of these Trp oxidation 
products shifts to a longer wavelength, and results in additional susceptibility of proteins to photo-
degradation43. Various studies have reported novel Trp degradation products in mAbs upon 
exposure to UV irradiation. These products include the conversion of Trp309 and Trp377 into Gly/ 
Gly hydroperoxide in an IgG144. The resultant Trp side chain (3-methyleneindolenine, e.g., 3-MEI) 
crosslinks with an adjacent nucleophilic Lys residue45. In addition, Trp plays important roles in 


















1.5.3. Consequences of photo-induced chemical modifications of mAbs 
Photo-induced modifications of mAbs potentially result in alterations of the primary, secondary, 
tertiary and quaternary structures. The perturbed structures can subsequently lead to unfolding of 
the hydrophobic region, resulting in additional oxidation. For example, the CH2 domain of a photo-
stressed IgG1 was considerably destabilized57. In addition, the aggregation hotspot (segment 247-
256) in the heavy chain of an IgG1 revealed increased flexibility after irradiation with UVA light 
for 72 hr58. In the above two cases, Met sulfoxide (MetSO) at Met252 and Met428 were proven to 
be the major products. Moreover, photo-induced chemical instability of mAbs can contribute to 
charge heterogeneity50, 59, discoloration (e.g., oxidation of His51, 60 or Trp42, 61), immunogeneicity62, 
reduced affinity to protein A, FcRn, and FcɣRs63, and loss of binding to antigen47.  
1.5.4. Mitigation strategies to protect from light 
The majority of marketed therapeutic antibodies contains the warning label “protect from light” 
due to the intrinsic susceptibility of protein drugs to light. From the pharmaceutical development 
perspective, mitigation strategies can be designed such as applications of primary and secondary 
packaging containers (e.g., cardboard boxes)61, installation of safe lights (e.g., exclusion of the 
potential damaging wavelengths) during manufacturing and storage25, and addition of excipients 
(e.g., Met or N-acetyl- tryptophan as free radical or oxygen scavengers)64, 65. Mallela et al., 
reported that the addition of Met mitigates the photo-oxidation of an IgG157. Stroop et al., reported 
that light prevention, pH modification, and oxygen depletion are effective migration strategies for 
His buffer-mediated photo-degradation of a monoclonal antibody51. Hence, in order to select a 
proper mitigation strategy, the photo-degradation pathway needs to be fully understood.  
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1.6. Glycosylation and its role in effector function and physicochemical properties of mAbs 
Glycosylation is a heterogeneous post-translational modification (PTM) composed of two types, 
N- and O-linked ones. N-glycosylation has been extensively studied in IgGs. All IgG subclasses 
contain N-glycans at Asn297 in the CH2 domain. Crystal structures reveal that Asn297 glycans are 
shielded and occupy the inner space between the CH2 domains, maintaining the optimal ‘open’ 
conformation of the Fc domain66. In contrast, biophysical characterization with size exclusion 
chromatography indicates that the hydrodynamic radius of non-glycosylated IgGs is slightly larger 
than that of glycosylated ones67. Such discrepancy of observation indicates the potential different 
states of IgGs in crystal structures and in solution. The presence and the unique forms of Asn297 
glycans are essential in preserving IgGs conformations, enhancing their binding to FcɣRs, and 
maintaining long serum half-life15, 68, 69. In addition, N-glycans are present in approximately 20% 
of Fab regions in human IgG. These N-glycans can positively and negatively affect their binding 
to antigens70, 71. The glycoforms in the Fab regions contain high galactose, sialic acid, and high 
mannose as compared to the Fc region72, suggesting the increased exposure and accessibility of 
Fab regions for cellular glycosylation enzymes. N-glycans in the Fab regions are resistant to 
PNGase F treatment, and require the treatment with endoglycosidase F for release of the Fab 
glycans73, 74. Moreover, N-glycans are reported to be present in Fab variable regions in some 
therapeutic mAbs (e.g., Cetuximab)73, 75. The selection of expression host cells for such mAbs 
needs to be carefully considered, since Fab regions preferably present elongated glycoforms. 
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Atypical N-glycans at Asn in a CH1 domain of human antibodies were observed in non-consensus 
sequences at a quantity of 0.5-2.0%76. O-linked glycosylation in IgGs is not as common, but has 
been characterized in the hinge region of human serum-derived IgG377, or in the complementarity-
determining regions (CDRs) of recombinant mAbs (rMAb), e.g., O-fucosylation78, 79 and O-
glucosylation (~10%) at Ser in an IgG1, or O-mannosylation in an IgG280.  
 
Table 1 summarizes the previously characterized N-glycosylation in IgGs, and their potential role 
for the pharmacokinetic (PK) profile, referred to as clearance; for the pharmacodynamic (PD) 
profile, referred to as ADCC; and for the physicochemical profile of mAbs, referred to as “other 
effect”15, 81, 82. Generally, Asn297 glycans impact IgG half-life83 via the presence of specific 
carbohydrate patterns. For example, terminal mannose, GlcNAc, and galactose correlate with a 
faster removal of antibodies from the circulation, due to their binding to glycan receptors (e.g., the 
mannose and the asialoglycoprotein receptors)15. Asn297 glycans play an essential role in the 
binding to FcɣRIIIA, attributed to carbohydrate-carbohydrate interactions84. The binding between 
therapeutic mAbs and FcɣRIIIA is strongly associated with mechanisms of action for cancer 
therapy and autoimmunity. The role of individual glycan structure in binding to FcɣRIIIA is 
summarized in Table 1. It has to be noted that heterogeneous glycoforms can be caused by culture 
media components85, host cell lines86, and protein primary sequences, etc87. The glycoforms of 
therapeutic mAbs, which potentially lead to increased clearance, low ADCC, and reduced thermal 
stability78, belong to important critical quality attributes (CQAs). These glycoforms need to be 
controlled within strict limits (Table 1). Studies regarding the impact of different glycans on the 
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safety, quality and efficacy profiles of IgGs can help guide process optimization studies to ensure 
the antibody is being produced with appropriate and consistent glycosylation88, 89.  
 
1.7. Aim and outline of the dissertation 
As outlined in the introduction, photo-induced chemical modifications and glycosylation 
potentially introduce heterogeneity in mAb-based therapeutics. A thorough characterization of 
these modifications will help fill in the gap to understand their impact on the quality and efficacy 
of mAb therapeutics. The goal of this dissertation was to utilize IgG4-Fc as the model system to 
investigate the undiscovered photo-induced chemical modifications and post-translational 
modifications (e.g., glycosylation) induced microheterogeneity, and their correlation with 
physicochemical stability and receptor binding.  
1.7.1. Dissertation outline  
Chapter 2 investigates photo-induced Tyr side chain fragmentation in IgG4-Fc upon exposure to 
UVB and UVC irradiation with respect to mechanisms and solvent isotope effects 
Chapter 3 studies the impact of photo-induced Trp and Tyr side chain fragmentation of IgG4-Fc 
on its physicochemical stability, receptor binding, and the effects of N- and O-linked glycosylation 
on product formation 
Chapter 4 explores effect of glycan structure on the physicochemical stability and receptor 
binding of IgG4-Fc 
Chapter 5 reports a reaction between acetonitrile and N-terminal Cys of IgG4-Fc, which leads to 
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the formation of a cyclic product 
Chapter 6 investigates the role of Amicon filter bias a hydrolysis reaction during sample 
preparation 
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Table 1. Summary of N-glycan sites and impact in IgGs and Fc-fusion proteins. Adapted from Liu 














Chapter 2. Photo-induced tyrosine side chain fragmentation in IgG4-Fc: mechanisms and 












Light exposure represents an important stress condition for proteins in vivo, i.e. in the eye1, and in 
vitro, i.e. for protein pharmaceuticals2-3. Within proteins, photo-sensitive amino acids (Trp, Tyr, 
Phe, Cys) can be converted into various photodegradation products via several distinct 
mechanisms, including photoionization and the generation of reactive oxygen species.4 The 
formation of photodegradation products can change the physical-chemical properties of proteins5-
6. In pharmaceutical protein formulations, the chemical modification of proteins can lead to 
potency loss7-8 and, possibly, cause safety issues9. Therefore, the International Conference on 
Harmonization guidelines (Q5C)10 requires photostability tests for biomolecules, which are forced 
degradation studies, although some modifications have been recommended regarding the photo-
irradiation conditions11. 
  
The potential for immunogenicity is a major concern for the development of protein 
pharmaceuticals12-13. Numerous studies have reported on the importance of aggregate and particle 
formation for immunogenicity14. However, more recent studies have recognized an additional, 
critical role of chemical, and especially oxidative9, 15 and light–induced9, 16, protein modifications 
for immunogenicity. Importantly, when Boll et al.17 analyzed immunogenic samples of an oxidized 
monoclonal antibody (mAb) for common oxidation products of Met and Trp, they concluded that 
these did not contribute significantly to immunogenicity. Therefore, there is a need to identify 
chemical modifications other than conventional oxidation products, which may lead to potentially 
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immunogenic neo-epitopes. In this regard, we recently reported on the light-induced side chain 
fragmentation of Trp in a mAb18, several Fc-fragments of mAbs (mAb-Fc)19, and Trp-containing 
peptides20. Earlier mass spectrometry experiments with Trp and Trp-containing peptides had 
documented such fragmentation reactions under specific conditions in the gas phase21, detecting 
3-methyleneindolenine (3-MEI) as an important product22. In our solution studies with peptides 
and a protein, we detected that the electrophilic 3-MEI added to nucleophilic amino acid side 
chains, i.e. of Lys19, 23. Hence, the side chain cleavage of Trp did not only modify the Trp residue 
but also an adjacent Lys residue. These Trp side fragmentation are responsible for a variety of 
novel Trp-derived products, which should be monitored in addition to other common 
photoproducts from Trp such as kynurenine24-25, N-formylkynurenine25, and hydroxytrptophan25. 
Gas phase experiments also demonstrated the side chain cleavage of radical ions from Tyr-
containing peptides, leading to the elimination of para-quinone methide (p-QM; 4-
methylenecyclohexa-2,5-dien-1-one)26-27. This finding motivated us to evaluate whether such 
reaction could occur during the light-exposure of a protein in solution. We report here, that Tyr 
side chain cleavage proceeds selectively for three Tyr residues out of a total of eight Tyr residues 
in the Fc- domain of immunoglobulin G4 (IgG4-Fc) exposed to UV light. These studies with UV 
light enable us to formulate a reaction mechanism, which will be useful for future studies on 
protein degradation under ambient light, the predominant light experienced by protein 
pharmaceuticals during manufacturing, storage and transportation.  
 
Immunoglobulin G (IgG) is a dimer composed of two heavy chains and two light chains, connected 
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by inter-chain disulfide bonds in the hinge region28. The light chain is composed of one variable 
domain (VL) and one constant domain (CL), while the heavy chain is composed of one variable 
domain (VH) and three constant domains (CH1, CH2, and CH3)29. The IgG structure can also be 
divided into two fragments: the antigen-binding fragment (Fab, including VL, CL, VH, and CH1 
domains) and the crystallizable fragment (Fc, including CH2 and CH3 domains). For our 
experiments, we used the Fc domain of an IgG subtype, IgG4. IgG4 has unique properties 
compared to other subtypes, which can undergo half-molecule exchange30 due to its capability of 
forming intra-chain disulfide bonds in the hinge region as well as relatively weak interactions 
between the CH3 domains31. The Fc domain of an IgG can interact with cell surface Fc binding 
receptors, complement proteins, and, therefore, plays an important role in IgG effector function, 
in vivo half-life and the efficacy of IgGs29.   
 
IgG4-Fc is a dimer containing 444 amino acid residues including the hinge region (Chart 1), with 
2 inter-chain disulfide and 4 intra-chain disulfide bonds. We produced IgG4-Fc from the yeast 
Pichia pastoris32, which, due to incomplete glycosylation site occuopancy, initially yields non-
glycosylated, mono-glycosylated, and di-glycosylated forms of IgG4-Fc. The di-glycosylated 
IgG4-Fc (shown in Chart 1) can be purified from the other glycoforms by hydrophobic interaction 
chromatography (HIC)33. The glycan, located at Asn297 in the CH2 domain34-35, was of the high 
mannose (HM) structure, containing GlcNAc2-Man (8+n) (n = 0-4). These covalently bound glycans 
are critical for the physical and chemical stability, and biological functions of IgG4-Fc36. However, 
the micro-heterogeneity of the glycan, including the presence of GlcNAc2-Man(8+n) (n=0-4) on 
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Asn297 (Fig. S1A), introduces complexity in the characterization of photo-degradation products. 
For that reason, also a nonglycosylated N297Q mutant of IgG4-Fc was prepared. HM IgG4-Fc and 
N297Q IgG4-Fc, formulated in 20 mM sodium phosphate (pH 7.1), were photoirradiated with UV 
light at either λ = 254 nm or λ = 295–360 nm (λmax = 305 nm) in air- or Ar- saturated solutions. 
Mechanistic details of the photo-induced Tyr side chain fragmentation were examined by 
comparison of wild-type IgG4-Fc (WT) with several mutants, and by quantification of product 






























Chart 1. High mannose (GlcNAc2Man(8+n) (n=0-4)) WT IgG4-Fc structures with intra–hinge 
disulfide bonds (A) or inter-hinge disulfide bonds (B), where Asn297 is glycosylated. The 








2.2. EXPERIMENTAL SECTION  
2.2.1. Materials. The SacI-HFâ enzyme for cDNA linearization was supplied by New England 
BioLabs (Ipswich, MA). Dextrose, sodium chloride, sodium phosphate (monobasic, anhydrous) 
and glycine were supplied by Fisher (Fair Lawn, NJ). Yeast nitrogen base (YNB) was purchased 
from Sunrise Biosciences (San Diego, CA). Bacto Tryptone and Yeast Extract were obtained from 
Becton Dickinson and Company (Franklin Lakes, NJ). Zeocin was supplied by Invitrogen 
(Carlsbad, CA). His-Protein G was expressed from E. coli Rosetta (Novagen, Burlington, MA) 
and purified on a Ni2+- nitrilotriacetic acid (NTA)-agarose column. Protein G resin was then 
produced by coupling recombinantly-expressed protein G with Sepharose CL-4B (Sigma-Aldrich, 
Saint Louis, MO) using divinyl sulfone as a coupling reagent37-38. Ethylenediaminetetraacetic acid 
(EDTA) was supplied by EM Science (Gibbstown, NJ, USA). Ammonium sulfate (Ultra pure 
grade) was supplied by AMRESCO (Solon, OH). Rabbit anti-antigen human IgG (Fc) Pierce 
antibody® for dot plot analysis was supplied by Thermo Scientific (Rockford, IL, USA). Antifoam 
204, 2-mercaptoethanol, dithiothreitol (DTT), iodoacetamide (IAA), ammonium bicarbonate, 
guanidine hydrochloride, sodium phosphate (dibasic), N-acetyl-L-tyrosine and L-glutathione 
disulfide (GSSG) were provided by Sigma-Aldrich (Saint Louis, MO). GluC was supplied by 
Promega Corporation (Madison, WI). The SDS gradient gels (Mini-PROTEANâ TGXTM Gels, 4-
20%) were provided by Bio-Rad (Richmond, CA, USA).  
 
2.2.2. Production of WT IgG4-Fc. WT IgG4-Fc, including non-glycosylated, mono-glycosylated, 
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and di-glycosylated forms, was produced in an OCH1/PNO1 deleted and STT3D added Pichia 
pastroris yeast strain as described elsewhere33. Briefly, IgG4-Fc cDNA cloned in a pPICZaA 
Pichia vector (Invitrogen, Carlsbad, CA) was sequenced with 100% accuracy and linearized with 
the SacI-HF enzyme (Table S1). The yeast was then transformed with the linearized IgG4-Fc 
cDNA through electroporation39. Colonies transformed with IgG4-Fc cDNA were screened by 
Yeast Extract Peptone Dextrose (YPD) plate containing 100 µg/mL zeocin. The YPD plate 
contains 1% yeast extract (w/v), 2% peptone (w/v), 2% dextrose (w/v), and 1.5% agar (w/v). High 
expression colonies were screened by dot blot analysis with rabbit anti-antigen human IgG (Fc) 
using small scale (2.5 mL) expression systems. A selected high expression colony was used for 1L 
scale IgG4-Fc production.  
 
The selected colony was inoculated with 2.5 mL of 100 µg/mL zeocin-containing YPD medium 
as a starting culture and grown under shaking at 26 ̊C for 72 hr. The 2.5 mL culture was transferred 
to 50 mL of YPD media (100 µg/mL zeocin) and grown under shaking at 26 ̊C for 72 hr. Then, the 
50 mL cell culture was transferred to a 1 L spinner flask containing BMGY (buffered glycerol-
complex media, 1% yeast extract, 2% peptone, 2% glycerol, 0.34% of yeast nitrogen base and 1% 
ammonium sulfate, and 4 x 10-5 % biotin)40 buffered with 100 mM potassium phosphate at pH 6.0. 
The 1L cell culture was grown at room temperature under constant delivery of air for 72 hr. Then 
2% of methanol (v/v) was added every 24 hr for inducing protein expression for 3 times before 
harvesting.   
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2.2.3. Purification of high mannose (HM) IgG4-Fc. Yeast cells were harvested and centrifuged 
at 4629 g for 20 min on an AvantiTM J-25I centrifuge (Beckman Coulter, Palo Alto, CA) using a 
JLA 10500 rotor (Beckman Coulter, Palo Alto, CA). The supernatant was collected and filtered 
with 5 layers of 90 mm Whatman filter pads to remove insoluble particles. An in-house prepared 
protein G affinity column (15 mL column volume) was equilibrated with 10 column volumes (CV) 
of 20 mM sodium phosphate, pH 6.0. The filtered supernatant was loaded onto the equilibrated 
column to allow IgG4-Fc to bind to the column. The column was then washed with 5 CV of 500 
mM NaCl in 20 mM sodium phosphate (pH 6.0) to minimize nonspecific protein binding to the 
column. IgG4-Fc was then eluted with 100 mM glycine/HCl at pH 2.7, and the protein fraction 
was immediately neutralized with 1M Tris/HCl (pH 9.0), and subsequently dialyzed into 20 mM 
sodium phosphate at pH 7.0 at 4°C for 24 hrs before freezing at -80°C. 
 
The protein G-purified IgG4-Fc was further purified by hydrophobic interaction chromatography 
(HIC) to separate di-glycosylated IgG4-Fc from mono-glycosylated and non-glycosylated IgG4-
Fc. Samples (25 mg) were dissolved in 1 M ammonium sulfate and 20 mM sodium phosphate at 
pH 7.0 and filtered through a 0.2 µm filter (“Nalgene” Rapid-Flow 75 mm Filter Unit, Thermo 
Scientific, Rockford, IL) before loading onto the HIC column.  
 
For HIC purification on an ÄKTAmicro chromatographic system, 125 mL of phenyl sepharose 
high performance resin (GE Healthcare, Uppsala, Sweden) were packed into an XK 26 column 
(GE Healthcare) and washed with 600 mL of filtered double-distilled water. Mobile phase A was 
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1 M ammonium sulfate in 20 mM sodium phosphate at pH 7.0, and mobile phase B was 20 mM 
sodium phosphate at pH 7.0. All buffers were filtered before loading onto the column. A volume 
of 675 mL mobile phase A was loaded to equilibrate the column. IgG4-Fc samples, dissolved in 
mobile phase A, were injected onto the column, followed by 50 mL of mobile phase A to wash the 
sample loop. In the following, unbound proteins were washed off with 240 mL of 100% mobile 
phase A. Subsequently, a linear gradient changing mobile phase B from 0% to 33% within 144 
minutes was applied at 2 mL/min, followed by changing mobile phase B from 33% to 55% within 
141 minutes. Then the column was washed with 55% of 750 mL containing mobile phase B. A 
flow rate of 2 mL/min was used for the full gradient. The eluate was monitored at 214 nm. The 
protein fractions were collected with a fraction collector. The collected fractions were dialyzed 
into 20 mM sodium phosphate, pH 7.0, for 24 hr. After characterization by LC-MS analysis and 
SDS-PAGE, HM IgG4-Fc fractions were combined and then dialyzed into 5 mM EDTA in 20 mM 
sodium phosphate, pH 7.0, to eliminate trace amounts of transition metals. After 12hr, HM IgG4-
Fc (0.22 mg/mL) was dialyzed back into 20 mM sodium phosphate (pH 7.0) and stored at -80°C.   
 
2.2.4. Cloning, expression and purification of N297Q-IgG4-Fc, H435R/Y436F-IgG4-Fc and 
W381F-IgG4-Fc. A forward primer, 5’-CGGGAGGAGCAGTTCCAGAGCACGTACCGTGTG-
3’, and a reverse primer, 3’-GCCCTCCTCGTCAAGGTCTCGTGCATGGCACAC-5’, were 
designed for the mutant N297Q-IgG4-Fc.  A forward primer, 5'-
gcatgaggctctgcacaacagattcacacagaagagcctctccc-3', and a reverse primer, 3'-
cgtactccgagacgtgttgtctaagtgtgtcttctcggagaggg-5', were designed for the double mutant 
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H435R/Y436F-IgG4-Fc. A forward primer, 5’-gacatcgccgtggagttcgagagcaatgggcag-3’, and a 
reverse primer, 3’-ctgtagcggcacctcaagctctcgttacccgtc-5’, were designed for the mutant W381F-
IgG4-Fc. The primers were synthesized by Eurofins Genomics (Louisville, KY). A QuikChange 
Lightning Site-Directed Mutagenesis Kit (Agilent Technologies, Inc., Santa Clara, CA) was used 
for mutagenesis. Successfully mutated cDNA-transformed colonies were selected with 25 µg/mL 
zeocin-containing low salt lysogeny broth (LB) plate (1% tryptone, 0.5% NaCl, and 0.5% yeast 
extract) and inoculated in 6 mL LB culture overnight. The plasmids of the selected colonies were 
extracted with a miniprep kit (QIAGEN, Valencia, CA), and sequenced by the University of 
California Berkeley DNA Sequencing Facility (Berkeley, CA) with 100% accuracy. The plasmids 
were then linearized with the SacI-HF enzyme and transformed to an 
OCH1/STT3D/PNO1/Bmt1/Bmt2 KO yeast strain following the same procedures as for WT IgG4-
Fc. All mutant IgG4-Fc were purified by protein G chromatography as described for WT IgG4-Fc. 
Since the two mutants, H435R/Y436F-IgG4-Fc and W381F-IgG4-Fc, contained >90% of HM 
structure [GlcNAc2Man(8+n) (n=0-4)] after affinity column purification (Figures S6 and S7), the 
two mutants were not further purified by HIC.  
 
2.2.5. Characterization of WT, W381F, and H435R/Y436F IgG4-Fc by intact protein LC-MS 
analysis. Intact protein mass spectra were obtained under reducing conditions. An aliquot of 100 
µg of IgG4-Fc was reduced with 10 mM DTT for 10 min at room temperature, and injected onto 
a C4 column (50 mm, 4.6 mm i.d.; 300-Å pore size, 5 µm particle size, Vydac 214 MS, Grace, 
Deerfield, IL), connected to an Agilent 1200 series LC (Agilent Technologies, Santa Clara, CA) 
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coupled to an Agilent 6520 Quadrupole Time-of-Flight mass spectrometer (Agilent Technologies, 
Santa Clara, CA). The mass spectrometer was operated with an electrospray ionization source in 
the positive ion mode with the mass range acquired from m/z 300 to m/z 3000 at a scan rate of 1 
spectrum/second. Mobile phase A was 99.9% H2O, 0.08 % formic acid, and 0.02 % trifluoroacetic 
acid, mobile phase B was 99.9% acetonitrile, 0.08% formic acid, and 0.02% trifluoroacetic acid. 
A linear gradient changing mobile phase B from 5 to 90% within 7 minutes was applied and the 
intact protein eluted at 5.5 minutes at a flow rate of 0.5 mL/min. The Agilent MassHunter 
Acquisition software was used for data collection, and the Agilent Mass Hunter Qualitative 
Analysis software (version B.03.01) was applied to data analysis. The obtained m/z values were 
de-convoluted through a maximum entropy deconvolution function through the Agilent Mass 
Hunter Qualitative Analysis software.  
 
2.2.6. Sodium dodecyl sulfate - polyacrylamide gel electrophoresis (SDS-PAGE). For SDS-
PAGE under non-reducing conditions, 20 µL of 0.22 mg/mL HM IgG4-Fc were combined with 20 
µL of 2X loading dye (2x Laemmli sample buffer, BIO-RAD, Richmond, CA) and loaded onto the 
SDS gradient gel (Mini-PROTEANâ TGXTM Gels, 4-20%, BIO-RAD, Richmond, CA). For SDS-
PAGE under reducing conditions, 1 µL of 2-mercaptoethanol was added to 20 µL solution, and the 
mixture was boiled in a water bath for 5 min prior to loading the mixture onto the gradient gel. For 
calibration, 4 µL of a Precision Plus Protein Dual Color standard marker (BIO-RAD, Richmond, 
CA) was used in lane 1 of the SDS-PAGE. The electrophoresis was run at 200 volt until the front 
dye arrived at the bottom of the gel. When the run finished, the gel was stained with 0.05% 
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Coomassie Brilliant Blue (BIO-RAD, Hercules, CA) for 30 min and destained with 30% methanol, 
10% acetic acid and 60% water (v:v:v). The Canon solution menu EX software and canoscan 
(Canon, Costa Mesa, CA) were used to record the gel images. 
 
2.2.7. Peptide mapping with GluC. Control and photo-irradiated samples were processed side by 
side for enzymatic digestion by GluC. Aliquots of 500 µL were denatured by addition of 500 µL 
of 6M guanidine hydrochloride in 50 mM ammonium bicarbonate, pH 8, and subsequently reduced 
by addition of 10 µL of 500 mM DTT in 50 mM ammonium bicarbonate (pH 8.0) for 1hr at 37 °C. 
The reduced samples were then alkylated with 50 µL of 500 mM IAA in 200 mM ammonium 
bicarbonate for 1 hr at 37 °C. The samples were then transferred to Amicon Ultra Centrifugal Filter 
Units with 3kDa cutoff, and centrifuged at 16,900 g for 15 min at 4°C until the whole solution was 
concentrated to about 200 µL. Volumes of 250 µL of 5mM ammonium bicarbonate (pH 8.0) were 
added twice to the filter and centrifuged to wash out residual denaturing and alkylating agents. The 
filters were reverse-flipped, and the proteins on the top were collected at 300 g for 4 min at 4°C. 
The collected proteins were digested with GluC in 5 mM ammonium bicarbonate, pH 8, with a 
protein: enzyme ratio of 10:1 (w/w) for 5 hr at 37°C. The GluC was divided into two aliquots 
containing 11 µg each. The first aliquot was added and the mixture was incubated at 37°C. After 
2 hours, the second aliquot was added. The digested peptides were collected by centrifugation with 
Microcon Centrifugal Filters with 10kDa cutoff at 16,900 g for 10 min to eliminate undigested 




2.2.8. HPLC-MS/MS analysis. HPLC-MS/MS analysis was performed on two different systems, 
a nanoAcquity ultra performance liquid chromatography system (Waters Corporation, Milford, 
MA), coupled to a Waters Xevo-G2 mass spectrometer (Waters Corporation, Milford, MA) and a 
nanoAcquity ultra performance liquid chromatography system (Waters Corporation, Milford, MA) 
coupled to a Synapt-G2 mass spectrometer (Waters Corporation, Milford, MA). 
2.2.8.1 Analysis on the Xevo-G2 mass spectrometer. Aliquots of 4 µL of enzymatic digests were 
loaded and desalted on a trap column (nanoACQUITY UPLC 2G-V/M Trap 5 µm Symmetry C18 
180 µm x 20 mm, Waters, Milford, MA), eluted at 4 µL/min for 3 min with 97% of mobile phase 
A (0.1% formic acid in water, Optima, Fisher Chemical, Fair Lawn, NJ) and 3% of mobile phase 
B (0.1% formic acid in acetonitrile, Optima, Fisher Chemical, Fair Lawn, NJ). The eluted peptides 
were moved at a velocity of 300 nL/min to an analytical column (ACQUITY UPLC Peptide CSH 
C18 NANOACQUITY column 10K psi, 1.7 µm, 75 µm x 250mm, Waters, Milford, MA), and 
eluted with a linear gradient changing mobile phase B from 3% to 35% within 50 min, followed 
by a linear gradient changing mobile phase B from 35% to 95% within 20 min. Subsequently, the 
column was washed with 95% mobile phase B for 10 min, before re-equilibrating to 97% of mobile 
phase A. Mass spectra were collected for 80 min in the positive electrospray ionization mode at a 
scan rate of 1 scan/second, with a mass range of m/z 200 to m/z 2000. MS/MS analysis was 
performed in the MSE mode with the collision energy switching between 18 V and 45 V. Since no 
major peaks co-eluted with the observed photo-products under our chromatographic conditions, 
all the CID spectra collected from Xevo-G2 were obtained in the MSE mode.  
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2.2.8.2 Analysis on the Synapt-G2 mass spectrometer. Aliquots of 5 µL of enzymatic digests 
from N297Q IgG4-Fc were loaded onto a CSH C18 column (1.7 µm, 300 µm x 100 mm, Waters, 
Milford, MA) with 99% mobile phase A (0.8% formic acid in water) and 1% mobile phase B 
(acetonitrile: isopropanol; 95: 5; v: v) for 1 min at 10 µL/min. The column was equilibrated with 
a linear gradient changing mobile phase B from 1% to 6% at 10 µL/min. Subsequently, the injected 
peptides were eluted with successive gradients changing mobile phase B from 6% to 21% within 
35 min at 10 µL/min, from 21% to 26% within 16 min at a flow rate of 10 µL/min, and from 26% 
to 95% of mobile phase B for 1 min at 11 µL/min. The column was washed with 95% mobile phase 
B for 4 min at 11 µL/min, followed by a change of mobile phase B from 95% to 60% within 1 min 
at a velocity of 14 µL/min. The column was then washed with 60% mobile phase B for 2 min at 
10 µL/min, before it was re-equilibrated to 99% of mobile phase A. Mass spectra were collected 
in the positive electrospray ionization mode at a scan rate of 1 scan/2 seconds 
, with a mass range of m/z 50 to m/z 2000. MS/MS analysis was performed in the data dependent 
acquisition (DDA) mode with the collision energy ramped from 18 V to 28 V for low masses of 
250 Da to 880 Da, and ramp from 30 V to 55 V for high masses of 880 Da to 2000 Da.  
 
The data collected on the Xevo-G2 and Synapt-G2 instruments were analyzed with Protein 
Prospector (http://prospector.ucsf.edu/) and the MassLynx software (Waters Inc., Milford, CA). 
All assignments were conducted manually. 
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2.2.9. Photoirradiation of WT, N297Q, W381F and H435R/Y436F IgG4-Fc. Photoirradiation 
was performed in a UV irradiator (Rayonet®, The Southern New England Ultraviolet Company, 
Branford, CT) equipped with 4 UV lamps emitting at λ =254 nm (Rayonet®, catalog # RPR-2537Å) 
or with λmax = 305 nm (Rayonet®, catalog# RPR-3000 Å; these lamps emit 95% of light between 
λ =265-340 nm). We used the iodide-iodate actinometer41-42 to quantify the photon flux at 254 nm 
for 4 RPR 2537A lamps to 1.5x10-8 einstein/s. Due to the broad spectrum of the RPR-3000A 
lamps, an actinometry was not performed for photo-irradiation at λmax = 305 nm. For light exposure 
at 254 nm, 500 µL air-saturated solutions of 0.22 mg/mL HM IgG4-Fc in 20 mM sodium phosphate, 
pH 7.1, were placed in ca. 13x100 mm quartz vials (Product #8683; Ace Glass Inc.; Vineland, NJ), 
sealed with rubber stoppers, and irradiated for 0, 15 or 30 min. For light-exposure with λmax = 305 
nm, 500 µL of air-saturated solution of 0.22 mg/mL HM IgG4-Fc in 20 mM sodium phosphate, 
pH 7.1, were placed in 13x100 mm borosilicate vials (Fisher Scientific) sealed with rubber 
stoppers and irradiated for 0, 30 or 60 min. The cutoff for UV light of borosilicate glass is at λ=295 
nm. Control, non-irradiated samples were kept in a dark place. For comparison, photo-irradiation 
was also performed in Ar-saturated solutions. Here, 500 m l solutions in either quartz or borosilicate 




2.3.1. WT IgG4-Fc production and initial characterization. The average yield of HM IgG4-Fc 
	 40	
from spinner flasks was 10 mg/L. To express sufficient protein for HIC purification, WT IgG4-Fc 
was expressed in 10 one liter spinner flasks. Due to incomplete glycosylation at Asn297 by Pichia 
pastoris, protein G-purified WT IgG4-Fc contained non-glycosylated, mono-glycosylated and di-
glycosylated IgG4-Fc. Different batches of affinity column-purified IgG4-Fc were analyzed by 
MS and SDS-PAGE, and batches of similar quality were combined and subjected to HIC 
purification. Di-glycosylated HM IgG4-Fc, mainly containing GlcNAc2Man(8+n) (n= 0-4), eluted 
in the early fractions of HIC, and was collected. The quality of HM IgG4-Fc used for photostability 
studies was initially characterized by LC-MS analysis after reduction (Supporting Information, 
Fig. S1A) and by SDS-PAGE under reducing and non-reducing conditions (Fig. S1B). The purity 
of HM IgG4-Fc was calculated by addition of the peak areas for all detected HM forms 
[GlcNAc2Man(8+n) (n= 0-4)], divided by the sum of the peak area recorded for both non-
glycosylated protein and IgG4-Fc [GlcNAc2Man(8+n) (n= 0-4)]. The theoretical and observed 
masses for each glycoform are listed in Fig.S1A. The WT HM IgG4-Fc utilized for our 
photostability studies was of 99.1% purity, and showed a single band during SDS-PAGE under 
reducing conditions (Fig. S1B, lane 1), migrating with an apparent molecular weight between 25 
kDa and 37 kDa. However, when analyzed by SDS-PAGE under non-reducing conditions, two 
bands were obtained (Fig. S1B, lane 2), migrating with apparent molecular weights between 25 
kDa and 37 kDa and between 50 kDa and 75 kDa, respectively. These indicate the presence under 
denaturing conditions of both monomers (with intra-disulfide bond formation in the hinge region; 
see Chart 1) and dimers (with inter-disulfide bonds in the hinge region). The content of dimers of 
IgG4-Fc is about 76%, while the content of monomers is about 24%, based on a densitometry 
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analysis with ImageJ (National Institutes of Health, Washington D.C., USA). 
 
2.3.2. Photoirradiation of WT HM IgG4-Fc and N297Q IgG4-Fc. WT HM IgG4-Fc (0.22 
mg/mL) and the nonglycosylated N297Q IgG4-Fc (0.22 mg/mL) in 20 mM sodium phosphate, pH 
7.1, were photoirradiated at 254 nm in quartz tubes or at λmax = 305 nm in Pyrex tubes under air or 
Ar atmosphere. Ar saturation was achieved by placing protein samples in quartz or Pyrex vials, 
sealed with rubber stoppers, and saturated through headspace equilibration with Ar for 90 min. We 
confirmed that the absence or presence of 5 mM EDTA had no effect on product formation, so that 
all subsequent experiments were carried out in the absence of EDTA. IgG4-Fc (control and photo-
irradiated) were then reduced with DTT, alkylated with IAA, and digested with GluC side by side, 
prior to analysis by HPLC-MS/MS.  
 
Three Tyr-containing peptides from GluC-treated IgG4-Fc revealed Tyr side chain fragmentation 
under light exposure: Tyr373 in the sequence MTKNQVSLTC(+57)LVKGFY373PSDIAVE/WE, 
referred to as peptide 1 (where the subsequence E/WE indicates that we detected peptides without 
and with one missed cleavage between E and W; the mass adduct of + 57 Da indicates that Cys is 
carbamidomethylated), Tyr436 in the sequence ALHNHY436TQKSLSLSLGK, referred to as 
peptide 2, and Tyr300 in the sequence QFN297STY300RVVSVLTVLHQDWLNGKE (where Asn297 
is glycosylated), referred to as peptide 3. To elucidate the influence of glycosylation on 
photoproduct formation, the N297Q mutant was photoirradiated; in N297Q IgG4-Fc the Tyr300-
containing sequence QFQ297STY300RVVSVLTVLHQDWLNGKE is referred to as peptide 3’. All 
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photoproducts derived from Tyr side chain fragmentation were identified by HPLC-MS/MS 
analysis on the Xevo-G2 in the MSE mode or on the Synapt-G2 in the DDA mode, and are 
summarized in Table 1. The characterization of the products is described in more detail in the 
following sections.  
 
2.3.2.1. MS/MS identification of photoproducts from Tyr373 side chain cleavage. 
Fragmentation of the Tyr373 side chain from peptide 1 yields three peptide backbone cleavage 
products, MTKNQVSLTC(+57)LVKGF-NH2, M(+16)TKNQVSLTC(+57)LVKGF-NH2, and 
MTKNQVSLTC(+57)LVKGFG373PSDIAVE, referred to as products 1, 2, and 3, respectively, in 
Table 1.  
i) Product 1 (m/z 575.61): The MS/MS analysis of product 1 shows nearly a complete series of b 
and y ions, which are presented in Fig. 1A (Xevo-G2) and Fig.S2A (Synapt-G2). Specifically, the 
b14 fragment and the series of y ions from y2 to y9, and y13, indicate the presence of a C-terminal 
amide group (-CONH2).   
ii) Product 2 (m/z 580.96): Product 2 is a secondary oxidation product resulting from product 1, 
where Met358 is oxidized to methionine sulfoxide. The MS/MS spectrum of product 2 is shown in 
Fig. 1B (Xevo-G2) and Fig. S2B (Synapt-G2). The presence of b3 confirms a mass addition of 
+16 to the sequence MTK. The loss of 64 amu from the b4 and a10 ions (resulting in b4-64 and 
a10-NH3-64) reflects the loss43 of CH3SOH from the side chain of methionine sulfoxide, indicating 
that the +16 mass addition is located on the Met residue of the sequence MTK. Specifically, the 
y14-NH3 fragment ion in Fig. S2B is consistent with methionine sulfoxide on the N-terminal Met. 
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Overall, the MS/MS spectra of product 2 are very similar to those of product 1, confirming the 
peptide backbone cleavage between Phe372 and Tyr373 during light exposure. 
 
Figure 1. Collision-induced dissociation (CID) spectra of products 1 and 2 derived from Tyr373 
side chain fragmentation collected from Xevo-G2 in the MSE mode. Product information is listed 











Fig. 1A. MS/MS spectrum of product 1 resulting from peptide backbone cleavage induced by 






















Fig. 1B. MS/MS spectrum of product 2 with an oxidized methionine, a secondary oxidation 
product of product 1, analyzed with Xevo-G2 in the MSE mode. 
 
iii) Product 3 (m/z 832.08): The MS/MS spectrum of product 3 is presented in Fig. S2C (Synapt-
G2 DDA), indicating the photo-induced side chain conversion of Tyr373 into Gly373, specifically 
through the characteristic b15 and b16 ions. 
 
2.3.2.2. MS/MS identification of photoproducts from Tyr436 side chain cleavage. Side chain 
fragmentation of Tyr436 from the sequence ALHNHY436TQKSLSLSLGK (peptide 2) yielded four 
products, referred to as products 4, 5, 6, and 7, respectively, which are listed in Table 1. 
i) Product 4 (m/z 448.50): The MS/MS spectra of product 4, where Tyr436 is converted into Gly436 










consistent with a mass loss of 106 amu from the original Tyr-containing sequence 
ALHNHY436TQKSLSLSLGK. The fragment ions b5, b8 and y9 reveal that the loss of 106 amu 
does not originate from the peptide sequences ALHNH and KSLSLSLGK, indicating that the mass 
loss of 106 is derived from the peptide sequence YTQ. The only amino acid in this sequence, 
which can lose 106 amu, is Tyr, and, therefore, we propose the conversion of Tyr into Gly, 
analogous to the conversion of Tyr373 to Gly373 characterized for product 3 (see above). 
ii) Products 5 and 6 (m/z 609.30 and m/z 618.30): The MS/MS spectra of product 5 (O=CH-CO-
TQKSLSLSLGK) and of its hydrated form, product 6 ((OH)2CH-CO-TQKSLSLSLGK) are 
presented in Fig. S3B (Synapt-G2) and Fig. 2B (Xevo-G2). The nature of the y9 fragment indicates 
that there is no modification on the sequence KSLSLSLGK. Therefore, the modification is located 
on the N-terminal sequence TQ. Based on the observation of both a free aldehyde (product 5) and 
a hydrated form (product 6), we propose the formation of a glyoxal amide derivative on the N-
terminal sequence TQ. As expected, both products 5 and 6 show many similar fragment ions (y3, 
y7, y8, y9). MS/MS spectra of peptide aldehyde hydrates have been reported44-46.   
iii) Product 7 (m/z 387.89): The MS/MS spectra of product 7 are displayed in Fig. 2C (Xevo-G2) 
and Fig. S3C (Synapt-G2), and show a nearly complete series of fragment ions from y2 to y10. 






Figure. 2. CID spectra of products 4, 6, and 7 derived from Tyr436 side chain fragmentation 
collected from the Xevo-G2 mass spectrometer in the MSE mode. Product information is listed in 











Fig. 2A. MS/MS of product 4 derived from Tyr436 side chain fragmentation and conversion into 


























Fig. 2B. MS/MS spectrum of product 6 resulting from peptide backbone cleavage forming a 
glyoxal amide derivative, induced by Tyr436 side chain fragmentation, analyzed on the Xevo-G2 




























Fig. 2C. MS/MS spectrum of product 7 derived from peptide backbone cleavage induced by side 





















2.3.2.3. MS/MS identification of photoproducts from Tyr300 side chain cleavage. Side chain 
fragmentation of Tyr300 from QFN297STY300RVVSVLTVLHQDWLNGKE (peptide 3 in WT 
IgG4-Fc) and QFQ297STY300RVVSVLT VLHQDWLNGKE (peptide 3’ in N297Q IgG4-Fc) 
yielded two products, products 8 and 9, which are listed in Table 1.  
i) Product 8 (m/z 686.11): The MS/MS spectrum of product 8 is shown in Fig. S4A. This product 
is generated by photo-induced conversion of Tyr300 into Gly300 in peptide 3’, showing a loss of 106 
amu from the native peptide, similar to the data presented for product 4. The nature of the y16 and 
b3 ions indicate no modification on the sequences QFQ and VSVLTVLHQDWLNGKE, and the 
nature of the y19 and b8 fragment ions locate the mass loss of 106 amu to the original sequence 
YRV. Hence, we propose the conversion of the sequence YRV to GRV. Product 8 was detected 
only after photo-irradiation of N297Q IgG4-Fc.  
ii)Product 9 (m/z 723.05): The MS/MS spectrum of product 9 is presented in Fig. S4B. Specifically, 
the nature of the y17 fragment locates a glyoxal amide modification on the N-terminal amino acid 
Arg. The mass spectrum presented in Fig. S4B shows data derived from the hydrated form of the 
glyoxal amide-containing product. 
 
2.3.2.4. Other photoproducts. A number of additional chemical modifications, including 
methionine sulfoxide at Met252, Met358 and Met426; asparagine deamidation at Asn315; tryptophan 
oxidation, e.g. N-formylkynurenine formation at Trp313, tryptophan side chain cleavage product, 
VVSVLTVLHQD-NH2, at Trp313; and vinyl thiols generated from Cys261, Cys321, Cys367, and 
Cys425, were observed during photo-irradiation. These products are summarized in Table S2. The 
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yields of oxidation products generated from Met and Trp were significantly lower in Ar-saturated 
compared to air-saturated solutions. The formation of oxidation products under Ar is likely due to 
the presence of residual oxygen in Ar-saturated solutions. We also detected the formation of di-
tyrosine cross-links by fluorescence spectroscopy, monitoring the characteristic fluorescence 
emission around 420-425 nm47. However, to date we could not identify these cross-links by mass 
spectroscopy in our proteolytic digests. 
 
2.3.3. Quantification of the photodegradation products. Our photo-irradiation experiments 
were conducted mainly in air-saturated conditions. In the presence of oxygen, peptide back bone 
cleavage is the main degradation pathway induced by Tyr side chain fragmentation, represented 
by products 1, 2, 5, 6, 7 and 9. In contrast, the product yields for photo-induced Tyr conversion 
into Gly (products 3, 4, 8) were relatively low in air-saturated solutions. Hence, we did not include 
products 3, 4, and 8 in the quantification of reaction products under air atmosphere. In addition, 
we excluded product 9 from the quantification as its native peptide (peptide 3) is glycosylated at 
Asn297 in HM WT IgG4-Fc, which leads to uncertainties in obtaining the peak area of the native 
peptide 3.  
 
The yields of the respective photoproducts were calculated by means of MassLynx. Briefly, 
extracted ion chromatograms (XIC) of the photo-products were generated from base peak intensity 
chromatograms based on their respective m/z values (+/-0.05 Da) to include all the peaks of 
interest. The XIC were further integrated with a peak-to-peak noise amplitude of 500 to calculate 
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the areas of the extracted peaks, which were used as numerators referred to as “area of 
photoproduct” in equation 1. The peak areas for the respective native peptides were obtained in 
the same way as those of the photo-products; these are referred to as the “area of the native peptide” 
in equation 1. All quantitative data are displayed in Table 2. 
  
𝑦𝑖𝑒𝑙𝑑	 % 	𝑟𝑒𝑙𝑎𝑡𝑖𝑣𝑒	𝑡𝑜	𝑐𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛	𝑜𝑓	𝑛𝑎𝑡𝑖𝑣𝑒	𝑝𝑒𝑝𝑡𝑖𝑑𝑒 = 3453	67	896:6846;<=:	>	?@@
3453	67	896:6846;<=:	A	3453	67	B3:CD5	858:C;5
 Equation 1 
 
2.3.4. Conformational effects on photo-product formation. The role of protein conformation on 
photo-product formation was examined by photo-irradiation of WT HM IgG4-Fc at λmax = 305nm 
in the presence of 0, 10, 25 and 40% (v/v) 1-propanol. The effect of 1-propanol on the secondary 
structure of WT HM IgG4-Fc was determined by circular dichroism (CD) spectroscopy, as 
displayed in Fig. S5. For 0% and 10% (v/v) 1-propanol, the CD spectra demonstrate similar 
patterns, where the range of 220 - 230 nm shows the lowest ellipticity. However, the presence of 
25% and 40% 1-propanol, respectively, leads to significantly decreased ellipticity in the range of 
200 – 240 nm, indicating that the secondary structure of the IgG4-Fc is altered from a beta sheet 
to a random coil structure48 in the presence of increasing amount of 1-propanol. Three 
photoproducts resulting from Tyr side chain fragmentation, products 1, 2, and 7, show overall 
decreasing yields with increasing 1-propanol content (Fig. 3). In contrast, products 5 and 6 respond 
differently, showing an initial increase of yields with a change of 1-propanol between 0 and 10% 
(v/v), followed by a decrease of yields upon raising the 1-propanol content to 40% (v/v). Common 
to all products is the decrease of yields upon increasing the 1-propanol content from 10 to 40% 
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(v/v), suggesting that the co-solvent disrupts a conformation and/or pathway critical for Tyr side 
chain cleavage. Note, that in order to remove 1-propanol quantitatively for digestion and MS 
studies, the photo-irradiated samples were subjected to Amicon filtration twice, resulting in some 
loss of products, reflected in the generally lower percentages of yields compared to those listed in 
Table 2. Qualitatively similar results were obtained when acetonitrile was added between 10 and 

































































Figure 3. Conformational role in Tyr side chain fragmentation photoirradiated at wavelength > 
295 nm for 60 min in the presence of 0%, 10%, 25% and 40% of 1-propanol. For 0%, 10% and 










2.3.5. Solvent isotope effects (SIE). HM IgG4-Fc (0.22 mg/mL) in 20 mM sodium phosphate in 
either H2O or D2O solutions (pH, pD = 7.1) was photoirradiated at 254 nm for 20 min in quartz 
tubes under air. After photo-irradiation, samples were buffer-exchanged to 20 mM sodium 
phosphate in H2O, followed by denaturation, reduction and alkylation as described in section 2.7. 
The photolytic conversion (%) of native peptides in H2O and D2O is plotted in Fig. 4, where either 
no (product 1) or inverse product solvent isotope effects (products 2, 5, 6 and 7) are observed. The 
numerical values for product yields and the inverse product isotope effects are displayed in Table 
2. Interestingly, product 1 (MTKNQVSLC(+57)LVKGF-NH2) reveals no SIE while the Met-
oxidized product, product 2 (M(+16)TKNQVSLC(+57)LVKGF-NH2), shows an inverse SIE of 
1.46. This inverse SIE may reflect Met sulfoxide formation through a singlet oxygen pathway, 
where singlet oxygen has a longer life time in D2O than in H2O49. Products 5, 6 and 7 from Tyr436 
from peptide 2 show significant inverse SIE between 1.89 and 2.02, indicating a potential role for 
proton transfer in the mechanism leading to the cleavage of Tyr436. The mechanism will be 































































Figure 4. Product solvent isotope effects on HM WT IgG4-Fc Tyr side chain fragmentation during 
photoirradiation at 254 nm for 20 min. The sequences of the products are listed in Table 1. The 










2.3.6. Comparison of WT HM and W381F HM IgG4-Fc. WT and W381F IgG4-Fc at 0.71 
mg/mL in 20 mM sodium phosphate (pH 7.1) were placed in quartz vials sealed with rubber 
stoppers and saturated through headspace equilibration with air or Ar for 90 min. Photo-irradiation 
of WT and W381F IgG4-Fc was conducted side by side at λ = 254 nm for 15 min. Products 1, 2, 
5, 6 and 7 were quantified under air, and the results are shown in Fig. 5A. Furthermore, the 
conversion (%) of Tyr373 and Tyr436 into Gly373 and Gly436, products 3 and 4, was quantified in Ar-
saturated solution and the data are shown in Fig. 5B. The yields of photo-products under air for 
W381F IgG4-Fc are at least three-fold lower compared to the yields for WT IgG4-Fc (Fig. 5A). In 
addition, the photo-products observed under Ar are lower by a factor of 2.0 -4.0 in W381F 
compared to WT IgG4-Fc (Fig.5B). These data suggest that Trp381 plays a critical role in the 


































Figure 5. Quantification of light-induced Tyr side chain fragmentation product yields in WT and 
W381F IgG4-Fc for photoirradiation at 254 nm for 15 min. (A) Air-saturation. (B) Ar-saturation. 
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2.3.7. Comparison of WT HM and H435R/Y436F HM IgG4-Fc. The double mutant 
H435R/Y436F was characterized by intact protein LC-MS under reducing conditions (Fig. S7). 
The double mutant H435R/Y436F IgG4-Fc was initially designed to change the chromatographic 
behavior during purification. However, for our mechanistic investigation only the replacement of 
Tyr436 by Phe436 is important while we do not expect any effect of the replacement of His435 by 
Arg435, under our photoirradiation conditions (λmax = 305 nm). WT and H435R/Y436F IgG4-Fc 
(0.22 mg/mL) in 20 mM sodium phosphate (pH 7.1) in Pyrex tubes were photoirradiated at λmax = 
305 nm for 1 hr. Fig. 6 summarizes the yields of photo-products from WT and H435R/Y436F 
IgG4-Fc. The Tyr373 cleavage products, products 1 and 2, from peptide 1, 
MTKNQVSLTC(+57)LVKGFY373PSDIAVE, where Tyr is not mutated, show similar yields for 
WT and in the double mutant H435R/Y436F IgG4-Fc (Fig. 6). However, Tyr436 cleavage products, 
products 5, 6 and 7, from peptide 2, ALHNH435Y436TQKSLSLSLGK, were only observed for WT 
IgG4-Fc. In contrast, these products were not observed for the double mutant, which contains a 
modified peptide sequence, ALHNR435F436TQKSLSLSLGK of H435R/Y436F IgG4-Fc (Fig. 6). 






























































Figure 6. Quantification of light-induced Tyr side chain fragmentation product yields from non-
mutated MTKNQVSLTC(+57)LVKGFY373PSDIAVE in WT and H435R/Y436F mutant, as well 
as product yields from ALHNH435Y436TQKSLSLSLGK in WT and from 
ALHNR435F436TQKSLSLSLGK in the mutant. Photoirradiation was conducted at λmax = 305 nm. 








2.3.8. Photo-irradiation of N-acetyl-tyrosine (N-Ac-Tyr) in the presence of oxidized 
glutathione (GSSG). The identification of Tyr side chain fragmentation products in photo-
irradiated IgG4-Fc solutions suggests the elimination of quinone-methide from Tyr residues. For 
mechanistic confirmation, we photo-irradiated N-Ac-Tyr in the presence of GSSG. In this 
experiment, GSSG serves to accept an electron generated by photo-ionization of N-Ac-Tyr, 
ultimately yielding GS-/GSH. Any one-electron oxidized N-Ac-Tyr can undergo side chain 
cleavage, eliminating a protonated quinone-methide, which can be trapped by GS-/GSH, generated 
from GSSG, yielding an addition product. The efficient addition of quinone methides to thiols had 
been demonstrated before50-52.  
 
1 mM N-Ac-Tyr and 200 µM GSSG were dissolved in 20 mM sodium phosphate buffer, pH 6.8. 
The mixtures were placed in quartz vials sealed with rubber stoppers, saturated with Ar for 1hr, 
and subsequently irradiated for 30 min at λ = 254 nm. Control, non-irradiated samples were 
saturated with Ar for 1hr and then placed in the dark. Experiments were conducted in triplicates. 
The resultant photoproducts were analyzed by HPLC-MS/MS on a Xevo-G2 mass spectrometer. 
The product expected from the addition of GS-/GSH to quinone methide has a theoretical m/z of 
414.13 amu, which was identified in the photo-irradiated solutions by data dependent acquisition 
(DDA). MS/MS data, together with the proposed fragment structures are displayed in Fig. 7. The 
fragment ions mainly result from the fragmentation of peptide bonds and the newly formed 
thioether bond of the glutathionyl moiety. However, specifically, the ion with m/z 285.14 
represents a fragment from the addition product. The adduct of GS-/GSH to quinone methide (m/z 
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414.19) was only observed when both GSSG and N-Ac-Tyr were photo-irradiated together, and 
not in controls lacking either GSSG or N-Ac-Tyr. When we performed photo-irradiations in the 






























Figure7. MS/MS of the precursor ion with m/z 414, which corresponds to the adduct of GS-/GSH 



















Under light exposure, Tyr300 in the CH2 domain and Tyr373 and Tyr436 in the CH3 of IgG4-Fc were 
observed to undergo αC- βC cleavage of the Tyr side chain. The corresponding photo-degradation 
products, including several peptide backbone cleavage products, and Gly, were identified by 
peptide mapping and HPLC-MS/MS analysis. Based on these degradation products, a mechanism 
for Tyr side chain fragmentation is proposed and displayed in Scheme 1.        
2.4.1. Tyr side chain fragmentation mechanism. We propose that the photolytic side chain 
cleavage of Tyr involves an intermediate Tyr radical cation (TyrOH+.) (Scheme 1, reaction 1). In 
reaction 1, the Tyr radical cation is generated directly via photo-ionization of Tyr. However, an 
alternative pathway involves electron-transfer from Tyr to another photochemically generated 
radical cation, i.e., from Trp (see below). Formation of the Tyr radical cation is followed by the 
elimination of a protonated quinone methide and the formation of a carbon-centered glycyl radical 
(Scheme 1, reaction 2). Under Ar, the electron generated via reaction 1 can reduce an adjacent 
disulfide bond (RSSR), leading to a thiol (RSH) and a thiyl radical (RS.)53. The glycyl radical 
generated in reaction 2 can, therefore, abstract a hydrogen atom from RSH, producing Gly 
(Scheme 1, reaction 3). The conversion of Tyr into Gly was detected for Tyr373 (product 3), Tyr436 
(product 4), and Tyr300 (product 8) (Table 1). In the presence of O2, the glycyl radical converts into 
a peroxyl radical (Scheme 1, reaction 4). The latter can eliminate superoxide to generate a 
carbocation (Scheme 1, reaction 5)54, which, in water, cleaves the HN-αC bond into glyoxal amide 
and a C-terminal amide (Scheme 1, reaction 6). Evidence for this mechanism is provided by the 
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generation of products 1, 2, 5, 6 and 9 under our experimental condition. Alternatively, two peroxyl 
radicals can recombine and generate alkoxyl radicals (Scheme 1, reaction 7)55. These alkoxyl 
radicals further react via reactions 8 and 9 (Scheme 1) to yield an isocyanate derivative, which can 
react with water (Scheme 1, reaction 10). Evidence for this mechanism is provided by the 
formation of product 7 (Table 1).  
 
2.4.2. Effect of IgG4-Fc conformation on Tyr side chain cleavage. The role of IgG4-Fc 
conformation on photo-induced Tyr side chain fragmentation was examined through the addition 
of various amounts of 1-propanol, which has been shown to alter protein structure56-57. We used 
CD spectroscopy (Fig. S2) to demonstrate that 1-propanol induced changes in the IgG4-Fc 
secondary structure when present in the solution at ≥ 25% (v/v). The structural change caused by 
≥ 25% (v/v) 1-propanol is sufficient to lower the yields of Tyr side chain fragmentation. 
Mechanistically, the reduced efficiency of Tyr side chain cleavage can be rationalized in multiple 
ways: first, a solvent-induced conformational change can affect the formation of TyrOH+., for 
example by electron transfer to a photo-ionized Trp residue, Trp+. (Reactions 12-14). Second, a 
solvent-induced conformational change may affect the life-time of TyrOH+., which, through 
deprotonation, can convert into the neutral tyrosyl radical (TyrO.) (Scheme 1, reaction 11), which 
should be resistant to side chain fragmentation. 
   
In order to evaluate a role of electron transfer from Tyr to Trp+. for the initiation of Tyr side chain 
cleavage, we inspected the crystal structure of IgG4-Fc (PDB 4C54)31, 58. The structure revealed 
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three Trp residues located adjacent to Tyr373, Tyr436 and Tyr300, respectively, displayed in Fig. 8: 
Trp313 is located 11.3 Å from Tyr373, Trp381 is located 12.1 Å from Tyr436, and Trp313 is located 18.1 
Å from Tyr300. These spatial distances are reported to be sufficiently close for electron transfer 
between Tyr and Trp residues59. We then representatively mutated Trp381 into Phe381, which 
resulted in a significant reduction of Tyr side chain cleavage (Figure 5A and 5B). The remaining, 
low yields of Tyr cleavage products are likely the result of electron transfer from Tyr to alternative 





























Figure 8. Tyr373 (A), Tyr436 (B), and Tyr300 (C) in the crystal structure of IgG4-Fc (PDB 4C54) 




























In order to evaluate, whether the yield and/or the lifetime of TyrOH+. influences the yields of Tyr 
side chain cleavage products, we measured the product solvent isotope effects. Interestingly, 
products 5-7 showed significant inverse product solvent isotope effects between 1.89 and 2.02. 
These products originate from side chain cleavage of Tyr436. However, no significant product 
solvent isotope effect was measured for product 1, resulting from side chain cleavage of Tyr373 (the 
inverse product solvent isotope effect for product 2, revealing oxidation of Met to Met sulfoxide, 
is likely the result of singlet oxygen reaction with Met). The increased yields of products 5-7 in 
D2O can be rationalized with a slower rate constant of deprotonation of TyrOD+. via reaction 11, 
allowing for a more efficient side chain cleavage (reaction 2). In general, slower rates of D+ transfer 
vs H+ transfer have been observed for proton-coupled electron transfer reactions of tyrosyl 
radicals60-62. While these reactions concern proton/deuterium transfer to a tyrosyl radical prior to 
reduction, a similarly slower deuterium vs proton transfer to base can be expected for the 
deprotonation of TyrOD+. vs deprotonation of TyrOH+.. However, we also need to discuss some 
additional aspects of potential relevance to the observed product solvent isotope effect. First, it 
was reported that the reverse electron transfer from Trp to tyrosyl radical is slower in D2O62. 
Considering that tyrosyl radical and tyrosyl radical cation exist in equilibrium 11, the efficiency of 
such reverse electron transfer may affect the yields of side chain cleavage products. However, such 
reverse electron transfer from Trp to tyrosyl radical occurs predominantly in the acidic and alkaline 
pH region62-63 and not at the pH/pD =7.1 of our experiments. Second, deprotonation of Trp+. to the 
neutral Trp. radical may affect the yield of TyrOH+., which can be directly generated by electron 
transfer reaction 14 (Scheme 2). It can be expected that deprotonation of Trp+. occurs slower in 
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D2O as compared to H2O, potentially resulting in higher yields of TyrOH+. in D2O as compared to 
H2O. 
 
The general possibility for Tyr side chain cleavage following the one-electron oxidation of Tyr was 
confirmed in a model experiment where N-acetyl-tyrosine (NATS) was photo-irradiated in the 
presence of GSSG. Here, photo-induced electron transfer from NATS to GSSG leads to the 
generation of TyrOH+. and GS-/GSH. The quinone methide generated through side chain cleavage 
of TyrOH+. has electrophilic properties, amenable to the addition of GS-/GSH. The reaction 
product of this addition was detected by HPLC-MS/MS analysis.  
 
2.5. CONCLUSION 
The present paper discovers three Tyr residues undergo side chain cleavage under UV light stress, 
and result in peptide back bone cleavages and conversion into Gly. Based on our knowledge, the 
photo-induced Tyr side chain cleavage reaction is first reported in a protein solution. These 
reactions may be relevant to light-induced inactivation, aggregation, fragmentation or 
immunogenicity of protein therapeutics. 
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Scheme 1. Proposed photolytic processes of Tyr side chain fragmentation in IgG4-Fc under air-

























Scheme 3. Proposed mechanism of photo-irradiation of N-acetyl-tyrosine (NATS) in the presence 







Table 1. Photoproducts derived from Tyr side chain fragmentation in HM WT and N297Q IgG4-
Fc at λ =254 nm and λmax =305 nm. The label “√” indicates the corresponding photoproduct is 
observed, whereas “x” indicates that the photoproduct is not observed under the condition. 
Products 1- 7, and 9 were observed in photoirradiated HM WT IgG4-Fc. All the products were 
observed in N297Q IgG4-Fc under irradiation. 
 
 
                                                 
  
Product Photoproducts Position λ =254 nm 
Ar   air 
λmax=305 nm 






Tyr373 √     √ √      √ 575.61 3 
2 M(+16)TKNQVSLTC(+57)L
VKGF-NH2 
Tyr373 √     √ √      √ 580.96 3 
3 MTKNQVSLTC(+57)LVKGF
GPSDIAVE 
Tyr373 √     √ X      X 832.08 3 
4 ALHNHGTQKSLSLSLGK Tyr436 √     X √      X 448.50 4 
5           TQKSLSLSLGK Tyr436 √     √ √      √   609.30 2 
6  
[        TQKSLSLSLGK]+
18 
Tyr436 √     √ √      √ 618.30 2 
7 TQKSLSLSLGK Tyr436 √     √ √      √ 387.89 3 
8 QFQSTGRVVSVLTVLHQD
WLNGKE 
Tyr300 √     √ √      X 686.11 4 
9   [        RVVSVLTVLHQ
DWLNGKE]+18 
Tyr300 √     √ √      √ 723.05 3 
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Table 2. Deprotonation mechanistic studies on HM WT IgG4-Fc Tyr side chain fragmentation 





























native peptide in 
H2O (±SE) 
%conversion of 





1 Tyr 373 76.2 ± 3.4 78.5 ± 1.9 1.03 
2 Tyr 373 47.8 ± 4.6 68.8 ± 2.8 1.44 
5 Tyr 436 8.6 ± 0.98 16.3 ± 0.79 1.89 
6 Tyr 436 7.6 ± 1.3 14.6 ± 0.39 1.92 
7 Tyr 436 11.0 ± 0.26 22.3 ± 1.3 2.02 
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Table 3: Photoproduct formation under Ar- and air-saturated conditions at λ=254 nm or λmax =305 
nm for WT and several mutants. Product details are displayed in Table 1. Photo-products of WT 





















 N297Q (254nm) W381F (254nm) 
H435R/Y436F 
(305nm) 
Tyr residue Ar air Ar air air 
Tyr373 1,2,3 1,2,3 1,2,3 1,2 1,2 
Tyr436 4,5,6,7 5,6,7 4,5,6,7 5,6,7 Very little or NA 
Tyr300 8,9 9 9 9 9 
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Supplementary Figures 
































Figure S1. Characterization of WT HM IgG4 –Fc. (A) Intact IgG4-Fc MS analysis under reducing 
conditions; (B) Intact IgG4-Fc characterization on SDS-PAGE under reducing (lane 1) and non-




























Figure S2. Collision-induced dissociation(CID) mass spectra of products 1, 2, and 3 resulting from 























Fig. S2A. MS/MS spectrum of product 1 resulting from peptide backbone cleavage induced by 








































Fig. S2B. MS/MS spectrum of product 2 with an oxidized methionine, a secondary oxidation 











































Fig. S2C. MS/MS spectrum of product 3 resulting from Tyr373 conversion into Gly373, analyzed 




























Figure S3. CID mass spectra of products 4, 5, and 7 resulting from Tyr436 side chain fragmentation 
















Fig. S3A. MS/MS spectrum of product 4 derived from Tyr436 conversion into Gly436, analyzed with 


















































Fig. S3B. MS/MS spectrum of product 5 resulting from peptide backbone cleavage forming a 













































Fig. S3C. MS/MS spectrum of product 7 derived from peptide backbone cleavage induced by side 


























Figure S4. CID mass spectra of products 8 and 9 resulting from Tyr300 side chain fragmentation 

































Fig. S4A. MS/MS spectrum of product 8 derived from Tyr300 conversion into Gly300, analyzed with 


















































Fig. S4B. MS/MS spectrum of product 9 resulting from peptide backbone cleavage forming a 
























































































































Figure S6. Intact protein MS characterization of the W381F HM IgG4-Fc mutant. The protein was 




















































Figure S7. Intact protein MS characterization of the H435R/Y436F HM IgG4-Fc mutant. The 





































































































































































































































































































































Chapter 3. Photo-induced Trp and Tyr side chain cleavage in IgG4-Fc: impact on 



















3.1. Introduction.  
The exposure of proteins to UV and visible light1-2 leads to chemical modifications, which may 
impact function, and/or cause aggregation and potentially immunogenicity3-5. An important study 
by Boll et al.5 suggests that chemical modifications of proteins contribute to the immunogenicity 
of protein aggregates. However, this study also concludes that it is not routinely observed chemical 
modifications, such as Met sulfoxide or common Trp oxidation products, which are responsible 
for this contribution to immunogenicity5. Therefore, there is a need to identify other, potentially 
new, chemical modifications, which may predispose proteins to aggregation and/or 
immunogenicity. 
 
In prior work we reported that protein Trp residues are prone to side chain fragmentation induced 
by UV light6-9, including the exposure to ICH light stress in an Atlas SUNTEST CPS+ system 
operated in the ID65 configuration10. This reaction converts Trp into a series of products including 
Gly. In a monoclonal antibody (mAb) of the IgG1 subclass this side chain fragmentation targets 
specific Trp residues such as Trp191 in the light chain (LC) and Trp309 and Trp373 in the heavy chain 
(HC)6, 10. Trp residues are frequently part of residue clusters important for protein folding and 
stability11-14. Hence, the conversion of Trp to Gly can induce a cavity in the three-dimensional 
structure of a protein, which may result in (local) unfolding and destabilization15. The extent of 
such destabilization will depend on the exact location of the targeted Trp residue and its chemical 
environment15. More recently, we reported for IgG4-Fc that also protein Tyr residues undergo side 
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chain fragmentation during UV light exposure, likely induced by electron transfer to a 
photochemically generated Trp radical cation16. This reaction converts Tyr into a number of 
products, including Gly, suggesting that also such reaction may lead to the unfolding of protein 
domains containing these Tyr residues.  
 
The purpose of the present work was to examine the consequences of photo-induced conversion 
of Trp and Tyr to Gly on the physicochemical properties and receptor binding of the constant 
region of an antibody, IgG4-Fc. For these experiments we generated Tyr-to-Gly mutants for all 
three Tyr residues on IgG4-Fc, which are target for photochemical conversion to Gly, and the Trp-
to-Gly mutant at position Trp381. Unfortunately, the expression yields of the Trp381Gly mutant were 
low, so that we also prepared the Trp381Ala mutant as a surrogate for the Trp381Gly mutant, which 
provided larger yields of protein required for some of our biophysical studies. To our surprise, we 
noted that both Trp381Gly and Trp381Ala mutations introduced an atypical glycosylation, where > 
60% of the glycoprotein was O-glycosylated at Ser375, confirmed by MS analysis under reducing 
conditions. This necessitated the characterization of any differences induced by O-glycosylation, 
and provided an opportunity for addressing the effects of N- vs. O-glycosylation on the 
physicochemical properties of IgG4-Fc and on its photo-induced degradation. For these studies 
additional mutants, IgG4-Fc S375A and W381A/S375A (Chart 1 and 2) were generated. 
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Chart 1: Wild-type (A), S375A (B), W381A (C), and S375A/W381A (D) IgG4-Fc structures with 
inter-hinge disulfide bonds (intra-hinge disulfide not shown), where Asn297 is glycosylated with 
high mannose (GlcNAc2Man(8+n) (n=0-4)) in all four IgG4-Fc, while Ser375 in W381A is O-












Chart 2: N-de-glycosylated structures WT_degly (A), S375A_degly (B), W381A_degly (C), and 
S375A/W381A _degly (D) IgG4-Fc shown with inter-hinge disulfide bonds (intra-hinge disulfide 
bonds not shown), where Ser375 in W381A is glycosylated with mannose with ~61% occupancy to 








Glycosylation represents a heterogeneous post-translational protein modification (PTM), which is 
a critical determinant of intrinsic protein properties.8, 17-18 In antibodies, glycosylation affects the 
physicochemical stability and therapeutic efficacy19-20. Of the approximately 400 FDA- approved 
therapeutic proteins21, the majority are glycoproteins, where monoclonal antibodies (mAbs) 
represent a dominant fraction22. The glycans of glycoproteins are complex and (bio)synthetically 
difficult to control. They can vary for different expression systems, processing conditions (e.g., 
temperature, pH), and the native properties of proteins23. Studies on the effect of glycosylation on 
the stability and function of protein pharmaceuticals are important for glycoengineering and 
development of therapeutic proteins18, 24.  
 
The two main types of glycosylation are N- and O-linked glycosylation25. N-glycosylation 
involves the attachment of a carbohydrate group to the side chain N atom of Asn within a 
consensus sequence Asn-X-Thr/Ser, where X can be any amino acid except Pro26. N-glycosylation 
has been extensively studied, especially in mAbs27. Specifically immunoglobulin G (IgG), has 
become an important therapeutic for the treatment of cancer, immune, and infectious diseases due 
to its specificity, efficacy, long serum half-life and largely reduced side effects. IgGs consist of two 
heavy chains, including variable (VH) and constant heavy chain domains (CH1, CH2, and CH3), and 
two light chains containing the VL and CL domains. The heavy and light chains, are connected by 
inter-chain disulfide bonds, where the VH, VL, CH1, and CL domains compose the antigen-binding 
region (Fab), while CH2 and CH3 are parts of the constant region (which is part of the crystallizable 
fragment, Fc). All IgG subclasses are glycosylated at Asn297 in the CH2 domain. Crystal structures 
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of the IgG-Fc domain have shown that the attached N-glycans at Asn297 can influence the 
conformation of the CH2 domain28-29, and therefore affect the interactions between Fc domain and 
Fc receptors. N-linked glycosylation contains a uniform core structure, GlcNAc2Man3, which can 
be further modulated by Golgi enzymes30. This modulation of the glycan core structure affects the 
biological activity31-33 and physico-chemical properties8, 29, 34-35 of IgG1. In contrast to IgG1, the 
effect of glycan modulation on the physico-chemical properties of IgG4 has not been extensively 
studied, even though also this subtype has been developed into biotherapeutics.36-37 
 
O-glycosylation involves the covalent attachment of a carbohydrate to the hydroxyl group of Ser, 
Thr, or Tyr38. Mammalian O-glycosylation can involve Fuc, GalNAc, GlcNAc, Man, and Glc38. 
The lack of a consensus sequence for O-glycosylation39-40 leads to difficulties in the prediction and 
characterization of O-glycosylation. IgGs have been reported to be O-glycosylated both in vivo 
and in vitro41. For example, ca. 8% of IgG3, extracted from human serum revealed O-glycosylation 
in the hinge region42. Recombinant human mAb therapeutics expressed in Chinese hamster ovary 
(CHO) can be O-glycosylated, e.g., via O-fucosylation41, 43 and O-glucosylation (~10%)29 in IgG1, 
as well as O-mannosylation at Ser in the variable regions of IgG244. These unexpected observations 
suggest that the introduction of structural heterogeneity by enzymatic O-glycosylation during the 
process of antibody engineering and manufacturing may be inevitable. Therefore, molecular 
features which predispose mAbs to O-glycosylation, and its potential consequences, need to be 
addressed and thoroughly characterized.  
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In the present work, we examined the impact of N- and O-linked glycans on the physico-chemical 
properties of IgG4-Fc variants. The IgG4-Fc variants containing Asn297 N-glycans, are referred to 
as WT, S375A, W381A, and S375A/W381A IgG4-Fc (Chart 1) (For WT, S375A, and 
S375A/W381A, the attached N-glycans are N-GlcNAc2Man(8+n), n= 0-4; for W381A, the attached 
glycans are a mixture of N- and O-glycans, predominantly N-GlcNAc2Man(8+n) or N-
GlcNAc2Man(8+n) /O-Man1, n = 0-4). These glycoforms are named as high mannose (HM). The 
PNGase F-treated IgG4-Fc variants are referred to as WT_degly, S375A_degly, W381A_degly, 
and S375A/W381A_degly (Chart 2). 
 
3.2. Materials.  
Yeast extract and peptone were purchased from Becton Dickinson and Company (Franklin Lakes, 
NJ). Dextrose, sodium phosphate, sodium chloride, methanol, and glycerol were purchased from 
Fisher (Fair Lawn, NJ). Zeocin was obtained from Invitrogen (Carlsbad, CA). Yeast nitrogen base 
(YNB) was obtained from Sunrise Biosciences (San Diego, CA). Rmp protein A sepharoseTM fast 
flow was purchased from GE Healthcare Bio-Sciences (Uppsala, Sweden). Potassium phosphate, 
biotin, citric acid, dithiothreitol (DTT), iodoacetamide (IAA), iodoacetic acid (IAC), ammonium 
bicarbonate, and guanidine hydrochloride were purchased from Sigma-Aldrich (Saint Louis, MO). 
The SacI-HF was bought from New England BioLabs (Ipswich, MA). GluC and Trypsin/LysC 
were purchased from Promega Corporation (Madison, WI). Tris (2-carboxyethyl) phosphine 
(TCEP) was obtained from Thermo Fisher Scientific (Waltham, MA). D2O, D 99.9%, was 
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purchased from Cambridge Isotope Laboratories (Tewksbury, MA). 
3.2.1. Cloning of WT, W381A, S375A, S375A/W381A, Y300G, Y373G, Y436G, and W381G. 
A forward primer, 5’- CGACATCGCCGTGGAGGCTGAGAGCAATGGGCAGC-3’, and a 
reverse primer, 5’-GCTGCCCATTGCTCTCAGCCTCCACGGCGATGTCG-3’, were designed 
for W381A. WT IgG4-Fc cDNA cloned in a pPICZaA vector (Invitrogen, Carlsbad, CA) was used 
as W381A parent plasmid. A forward primer, 5’-AAGGCTTCTACCCCGCCGACATCGC 
CGTGG-3’, and a reverse primer, 5’-CCACGGCGATGTCGGCGGGGTAGAAG CCTT-3’, were 
designed for S375A and S375A/W381A. A forward primer, 5’-GCAGTTCAACAGCACG 
GGCCGTGTGGTCAGCCTC-3’, and a reverse primer, 5’-GACGCTGACCACACGGCCCGT 
GCTGTTGAACTGC-3’, were designed for Y300G. A forward primer, 5’-CTGGTCAAAGGC 
TTCGGCCCCAGCGACATCGC-3’, and a reverse primer, 5’-GCGATGTCGCTGGGGCCGA 
AGCCTTTGACCAG-3’ were designed for Y373G. A forward primer, 5’-
GGCTCTGCACAACCACGGCACACAGAAGAGCCTC-3’, and a reverse primer, 5’-
GAGGCTCTTCTGTGTGCCGTGGTTGTGCAGAGCC-3’ were designed for Y436G. A forward 
primer, 5’-GACATCGCCGTGGAGGGTGAGAGCAATGGGCAG-3’, and a reverse primer, 5’-
CTGCCCATTGCTCTCACCCTCCACGGCGATGTC-3’ were designed for W381G. WT cDNA-
containing plasmid was used for S375A, Y300G, Y373G, and Y436G, W381A, and W381G 
cDNA-containing plasmid was used as W381A/S375A parent plasmid. The primers were bought 
from Eurofins Genomics (Louisville, KY). The mutagenesis was achieved with a QuikChange 
Lightning Site-Directed Mutagenesis Kit (Agilent Technologies, Inc., Santa Clara, CA).  
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Mutated cDNA-plasmids were transferred to XL10-Gold ultracomplement cells, provided by 
Agilent Technologies, by means of heat shock. The cells were grown in low salt lysogeny broth 
(LB) medium (1% tryptone, 0.5% NaCl, and 0.5% yeast extract) at 37°C for 1hr, and then plated 
onto a 25 µg/mL zeocin-containing LB for colony selection. The plate was incubated at 37°C 
overnight, and colonies grown with zeocin resistance were selected. The plasmids of selected 
colonies were inoculated in 6 mL of zeocin-contaning LB medium (25 µg/mL), amplified by 
shaking at 250 rpm at 37°C overnight, purified with a miniprep Kit (QIAGEN, Valencia, CA), and 
sequenced by the University of California Berkeley DNA Sequence Facility (Berkeley, CA). Those 
cDNA-plamids showing 100% sequence accuracy were linearized with SacI-HF, and 
electroporation transferred to a pno11/och1 KO and STT3D added Pichia pastroris yeast strain33. 
Those yeast colonies grown with zeocin resistance (100 µg/mL) were selected for IgG4-Fc 
production.  
 
3.2.2. Expression of IgG4-Fc. For IgG-Fc expression we followed a procedure which was 
described previously33. Briefly, a starting medium of 2.5 mL YPD containing 1% yeast extract 
(w/v), 2% peptone (w/v), 2% dextrose (w/v), and 2.5 mg zeocin was inoculated with the selected 
yeast colonies and shaken in an incubator (New Brunswick Innova 4200 Incubator-Shaker, Edison, 
NJ, USA) at 250 rpm at 26°C. After 72 hr, the 2.5 mL yeast cells were transferred to 50 mL YPD 
medium placed in a 250 mL Erlenmeyer flask, and the yeast culture was grown under shaking at 
26°C. After 72 hr, the 50 mL yeast cells were transferred to a 1 L spinner flask containing buffered 
glycerol-complex media, referred to as BMGY45 (1% yeast extract, 2% peptone, 2% glycerol,  
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0.34% of yeast nitrogen base and 1% ammonium sulfate, 4 x10-5% biotin, and 100 mM potassium 
phosphate, pH 6.0), followed by addition of two drops of sterilized antifoam. The 1L yeast cell 
culture was grown at room temperature (RT) for 72 hr on a stir plate under a constant flow of air, 
which was filtered by a 0.2 µm Millipore ExpressÒ PES membrane. The protein production was 
induced by addition of a final content of 1% methanol (v:v) to the 1 L spinner flask every 24 hr 
for 3 times. After 72 hr of induction, the yeast cells were harvested, and IgG4-Fc was purified. 
 
3.2.3. Purification of IgG4-Fc using affinity chromatography. The yeast cells were transferred 
to centrifuge bottles and centrifuged in an AvantiTM J-25I centrifuge (Beckman Coulter, Palo Alto, 
CA) with a JLA-10500 rotor (Beckman Coulter, Palo Alto, CA) at 6,693 g for 20 min at 4°C. After 
the centrifugation, the supernatant was collected and filtered by six layers of 90 mm Whatman 
filter pads. IgG4-Fc was purified from the supernatant with a pre-packed column containing rmp 
Protein A SepharoseTM Fast Flow resin. The mobile phase was controlled by a Masterfles L/S 
economy pump system (Cole Parmer Instrument, Chicago, IL), and the eluting fractions were 
monitored by an ISCO model UA-5 absorbance detector at 214 nm. The column (10 mL) was 
initially equilibrated with 10 column volumes (CV) of 20 mM sodium phosphate (pH 7.0). 
Afterwards, the filtered supernatant was applied to the column at a flow rate of 1.5 mL/min, 
followed by wash with high salt concentration (500 mM NaCl in 20 mM sodium phosphate, pH 
7.0) until the intensity of the UV absorption at 214 nm dropped to baseline level. Then equilibration 
buffer (10 CV) was applied to wash off residual salt. Bound IgG4-Fc was eluted with 50 mM citric 
acid (pH 3.0) and immediately dialyzed in 2 L of 20 mM sodium phosphate (pH 7.0). The dialysis 
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buffer was exchanged twice. IgG4-Fc of good quality (evaluated by HPLC-MS and SDS-PAGE 
gel analysis) was aliquoted and stored at -80°C for further analysis.  
 
3.2.4. PNGase F digestion of WT, S375A, W381A, S375A/W381A IgG4-Fc. The N-linked 
glycans of 500 µL aliquots of proteins (0.2 mg/mL, pH 7.0) were deglycosylated by mixing with 
0.5 µL N-glycosidase F (PNGase F) in a protein to enzyme ratio of 500:1 (w/w) and incubating at 
RT for 24 hrs. The extent of the enzymatic reaction was monitored by mass spectrometry, as 
described in section 2.5. PNGase F was expressed in E.coli, purified with a Nickel column46, and 
stored in 50% glycerol at -20°C for further use. Deglycosylated proteins are from here on indicated 
by the label “-degly”. 
 
3.2.5. Characterization of WT, S375A, W381A, S375A/W381A, Y300G, Y373G, and Y436G 
IgG4-Fc by LC-MS analysis of intact proteins. The masses of intact WT and the six IgG4-Fc 
mutants were initially analyzed by LC-MS. Briefly, 20 µg of each protein was dissolved at 0.2 
mg/mL in 20 mM sodium phosphate, pH 7.0, and reduced with 10 mM DTT for 10 min at RT. The 
reduced proteins were injected onto a C4 column (50 mm, 4.6 mm i.d.; 300-Å pore size, 5 um 
particle size, Vydac 214 MS, Grace, Deerfield, IL), operated by an Agilent 1200 series LC system 
(Agilent Technologies, Santa Clara, CA). A linear gradient was operated at a flow rate of 0.5 
mL/min, changing mobile phase B (99.9% acetonitrile, 0.08% formic acid, and 0.02% 
trifluoroacetic acid) from 5 to 90% within 7 min. Mobile phase A contained 99.9% H2O, 0.08 % 
formic acid, and 0.02 % trifluoroacetic acid. The reduced protein eluted at approximately 5.5 min 
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and was analyzed with an online-coupled Agilent 6530 Quadrupole Time-of-Flight mass 
spectrometer (Agilent Technologies, Santa Clara, CA). The mass spectrometer was operated with 
an electrospray ionization source (ESI) in the positive mode, scanning from mass/charge (m/z) 
values of m/z 300 to m/z 3000 at a scan rate of 1 scan/second. The collected chromatographic data 
were extracted and de-convoluted with the Agilent MassHunter Qualitative Analysis software. 
 
3.2.6. Characterization of IgG4-Fc with sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE). The characterization of IgG4-Fc with SDS-PAGE (Mini-
PROTEAN TGXTM Gels, 4-20%, BIO-RAD, Richmond, CA) was performed under non-reducing 
and reducing conditions. Initially, about 3.3 µg of each protein (0.2 mg/mL) in 15 µL of 20 mM 
sodium phosphate was mixed with 15 µL of 2x concentration of Laemmli sample buffer, 
containing 20-35% of glycerol and 1-2.5% of SDS (BIO-RAD, Richmond, CA). For non-reducing 
conditions, the mixtures were immediately loaded onto the SDS-PAGE. For reducing conditions, 
1.5 µL of 2-mercaptoethanol (14.3 M) were added, followed by boiling in a water bath for 2 min, 
and subsequently loaded onto the SDS-PAGE. 3 µL of a Precision Plus Dual Color standard marker 
(BIO-RAD, Richmond, CA) were loaded in the first lane. The gel was run at 200 volts for about 
40 min until the front dye ran to the bottom of the gel. The gel was stained with 0.25% Coomassie 
Brilliant blue (50% methanol, 0.25% Coomassie blue, 10% acetic acid and 40% water) for 10 min, 
followed by staining with 0.05% Commassie blue for 10 min, and de-staining with 30% methanol, 
10% acetic acid and 60% water until the bands were clear.  
 
	 112	
3.2.7. Peptide mapping with GluC and Trypsin/LysC. Control and light-exposed protein 
samples were subjected to peptide mapping side by side. Aliquots of 500 µL reaction mixtures 
containing 0.2 mg/mL protein (in 20 mM sodium phosphate) were denatured by the addition of 
500 µL of 6 M GdnHCl (in 50 mM NH4HCO3, pH 8.0) and reduced with 10 µL of 500 mM DTT 
(in 50 mM NH4HCO3) for 1 hr in a water bath maintained at 37°C. Free thiols resulting from the 
reduction step were alkylated by reaction with 40 µL of 500 mM IAA (in 50 mM NH4HCO3 for 
GluC digestion) or IAC (in 50 mM NH4HCO3 for Trypsin/LysC digestion) for 1 hr in a water bath 
maintained at 37 °C. After 1 hr, the denaturing, reducing, and alkylating agents were removed by 
exchange with 5 mM NH4HCO3, pH 8.0, using a 3kDa filter unit (Amicon Ultra Centrifugal Filter, 
County Cork, Ireland), and the protein solution was concentrated to about 200 µL through 
centrifugation at 16,900 g for 10 min. The concentrated protein solution was finally collected by 
reverse-flip of the filter, and centrifuged at 300 g for 4 min. For GluC treatment, aliquots of 40 µL 
(~20 µg protein) were digested. GluC solutions were prepared by dissolving 10 µg GluC in 50 µL 
of 5 mM NH4HCO3. Two aliquots of GluC (5 µL each) with 2 µg in total were added. The first 
aliquot was added, and incubated at 37 °C for 3 hrs, followed by the second aliquot and incubation 
at 37 °C for another 3 hr. The protein to GluC ratio was about 10:1 (w:w). For Trypsin/LysC 
digestion, aliquots of 100 µL (~62.5 µg protein) were used. Trypsin/LysC solutions were prepared 
by dissolving 20 µg Trypsin/LysC in 220 µL of 5 mM NH4HCO3. Two aliquots of Trypsin/LysC 




3.2.8. HPLC-MS/MS. Proteolytic IgG4-Fc peptides were analyzed with a nanoAcquity ultra 
performance liquid chromatography system (Waters Corporation, Milford, MA), coupled to a 
Xevo-G2 mass spectrometer (Waters Corperation, Milford, MA). A volume of 2 µL was injected 
onto a C18 guard column (nanoACQUITY UPLC 2G-V/M Trap 5 µm Symmetry C18 180 µm x 
20mm, Waters, Milford, MA), and washed with 97% mobile phase A (0.1% formic acid in H2O, 
Optima, Fisher Chemical, Fair Lawn, NJ) and 3% mobile phase B (0.1% formic acid in CH3CN, 
Optima, Fisher Chemical, Fair Lawn, NJ) for 3 min at a flow rate of 4 µL/min. After the washing 
step, the following gradient program was applied to move and separate the peptides onto an 
analytical column (ACQUITY UPLC Peptide CSH C18 NANOACQUITY column 10K psi, 1.7 
µm, 75 µm x 250 mm, Waters, Milford, MA) at a flow rate of 300 nL/min: between 0 to 50 min, 
mobile phase B was linearly increased from 3% to 35%; after 50 min, mobile phase B was linearly 
increased from 35% to 95% within 20 min; after 70 min, the column was washed with 95% mobile 
phase B for 10 min prior to equilibration with 97% of mobile phase A. The peptides were ionized 
in an electrospray ionization (ESI) source, and analyzed in the positive mode within a m/z range 
of 200-2000 at a scan rate of 1 scan/second. The peptide fragment ions were analyzed in the MSE 
mode, with the collision energy ramping from 18 V to 45 V, or in the data-dependent acquisition 
(DDA) mode with the collision energy ramping from 15 V to 40 V for low masses and ramping 
from 30 V to 55 V for high masses.  
 
3.2.9. Differential scanning calorimetry (DSC). DSC was performed using a MicroCal VP-
capillary calorimeter (Malvern, UK). Protein samples (0.22 mg/mL) were kept in a 96-well plate, 
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which was sealed using a plastic cover and stored at 5˚C during the DSC run. Samples were 
scanned from 10 to 90˚C at a scan rate of 1˚C/min using a filtering period of 16 sec. Raw DSC 
thermograms were processed using the Origin software (Origin Lab, Northampton, MA). Buffer 
subtraction, baseline correction, and concentration normalization were first performed. The 
processed thermograms were then fit to a non-two-state equilibrium model to derive Tm values for 
WT, S375A, WT_degly, S375A_degly, Y300G, Y373G, and Y436G IgG4-Fc. 
 
3.2.10. Intrinsic fluorescence. The intrinsic fluorescence spectra of the protein variants were 
collected using a fluorescence plate reader (Fluorescence Innovations, Inc., Minneapolis, MN), as 
previously described47. This instrument is equipped with a dye laser (280-300 nm), a temperature-
controlled sample plate, and a charge-coupled device detector. Samples (0.22 mg/mL) were loaded 
into a 384 well plate, and silicon oil was added to avoid sample evaporation during thermal 
ramping. The sample plate was centrifuged at 2,000 rpm for 1 min to remove air bubbles. Proteins 
were excited at 295 nm (>95% of the absorbance by Trp) and their emission spectra were collected 
from 300 to 400 nm. The temperature was ramped from 10 to 90 ᵒC with an increment of 2.5 ᵒC 
per step and an equilibration time of 2 min. The moments of spectra at each temperature were 
calculated employing the ThermoSpec software (Fluorescence Innovations, Inc., Minneapolis, 
MN) according to the following equation: 
Moment = E F FGF
E F GF
 
where x and I(x) are the wavelength and fluorescence intensity, respectively. The moments were 
then plotted as a function of temperature to generate melting curves. The melting temperature (Tm) 
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was calculated using a first derivative method using the Origin software (OriginLab Corporation, 
Northampton, MA).  
 
3.2.11. FTIR analysis. A Tensor-27 FTIR spectrometer (Buker, Billerica, MA) equipped with a 
Bio-ATR cell was used to acquire the FTIR spectra. The detector was cooled with liquid nitrogen 
prior to use. The interferometer was continuously purged with N2 gas to void the cell of CO2. 
Samples were equilibrated for ten minutes at 20 °C prior to acquisition. Spectra were recorded 
from 4000 to 800 cm-1 with a resolution of 4 cm-1. Scans were performed in triplicate; for each 
replicate a total of 256 scans were averaged. Buffer subtraction, atmospheric compensation and 
baseline subtraction were executed using the OPUS V6.5 software (Buker, Billerica, MA). Spectra 
were fit as the sum of pseudo-Voigt bands (linear combinations of Gaussian and Lorentzian). 
Secondary structures were assigned according to Kong et al48. Second derivative spectra were 
calculated using a 13 point, 2nd order Savitzgy-Golay algorithm.  
 
3.2.12. Hydrogen Exchange (HX) -Mass spectrometry analysis of WT and W381A IgG4-Fc. 
The procedures used for HX mass spectrometry analysis are described in detail elsewhere49. Briefly, 
HX was achieved with an H/DX PAL robot (LEAP Technologies, Carrboro, NC), and the mass 
differences were measured through an online Agilent 1260 Infinity LC system (Agilent 
Technologies, Santa Clara, CA) coupled to a quadrupole-time-of-flight mass spectrometer (Agilent 
6530, Santa Clara, CA). Aliquots of 10 µL of 3.7 µM WT and W381A (in 20 mM sodium 
phosphate, pH 7.1) were deuterium-labeled by injection of 36 µL deuterated labeling buffer (20 
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mM sodium phosphate in D2O, pH 7.1) at six time points (20 s, 100 s, 500 s, 2500 s, 12500 s, and 
62500 s). Each labeling time point was conducted in triplicates. The HX reaction was conducted 
at the pre-set time points at room temperature, followed by combination of 43 µL labeling mixture 
with 35 µL of quench buffer, containing 200 mM sodium phosphate, 0.5 M TCEP, pH 2.5, at 1˚C. 
Subsequently, a volume of 75 µL was injected and analyzed by HPLC-MS. 
 
An injected sample was desalted on a C8 trap column through a linear gradient ranging from 0% 
to 50% of mobile phase B (0.1% formic acid in acetonitrile) within 1 min, followed by another 1 
min elution with 50% mobile phase B. Subsequently, the mobile phase was re-equilibrated to 100% 
of mobile phase A (0.1% formic acid in water) within 1 min. The collected mass spectra were 
deconvoluted and analyzed by a built-in software, BioConfirm B.08 (Agilent 6530, Santa Clara, 
CA). Specifically the signals for the N-GlcNAc2Man9 glycoform of WT and the N-GlcNAc2Man9 
or N-GlcNAc2Man8/O-Man1 glycoforms of W381A were monitored for HX, due to their high 
respective intensity and abundance.  
 
3.2.13. Deuteration controls. The maximum deuterium incorporation into both WT and W381A 
IgG4-Fc was evaluated separately with thoroughly denatured proteins. 10 µL of 3.7 µM WT and 
W381A stock solution, respectively, were denatured with 4 M GdnDCl for 2 hr at room 
temperature, followed by labeling with deuterated labeling buffer containing 20 mM 
Na2HPO4/NaH2PO4, 4 M GdnDCl, 20 mM TCEP, pH 7.1, and incubation for 4 hr at room 
temperature. Fully deuterated samples were then quenched and analyzed by HPLC-MS as 
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described below. GdnDCl was prepared in-house by dissolving 1.5 g of GdnHCl in 15 mL of D2O, 
followed by lyophilization with a Labconco freezone 2.5 lyophilizer (Labconco Corporation, 
Kansas City, MO) until the powder was dried completely. The dissolution and lyophilization steps 
were repeated three times. 
 
3.2.14. Photoirradiation of glycosylated and deglycosylated WT, S375A, W381A and 
S375A/W381A IgG4-Fc. Photo-irradiation of the 8 IgG4-Fc proteins (4 glycosylated and 4 
deglycosylated variants) was conducted in a UV irradiator (RayonetÒ, The Southern New England 
Ultraviolet Company, Branford, CT) equipped with 4 lamps emitting between 265 nm and 340 nm, 
with λmax= 305 nm. The ferrioxalate actinometer50-51 was utilized to quantify the photon flux for 
four RPR-300A lamps to 1.87E-8 Einstein/s. A volume of 500 µL of each protein (0.22 mg/mL, pH 
7.0) in 20 mM sodium phosphate was placed in Pyrex tubes, sealed with rubber stoppers, and 
photo-irradiated for 45 min at RT. Pyrex tubes have a wavelength-cutoff of around 295 nm. These 
photo-irradiation conditions correspond to light intensities of <25 Whr/m2, i.e., less than 12.5% of 
the minimal intensity (200 Whr/m2) recommended for UV photostability testing by the ICH Q1B 
guideline52. Two independent experiments were performed. Control, non-irradiated samples were 
wrapped in aluminum foil and placed in the dark at RT.  
 
3.2.15. Binding assays of WT, Y300G, Y373G, Y436G and W381A IgG4-Fc. The affinity of 
WT, Y300G, Y373G, Y436G and W381A to Fcγ receptor IIIA (FcγR IIIA) was evaluated by 
immobilizing biotinylated FcγRIIIA (the Val158 polymorph; prepared as previously described33) on 
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a streptavidin (SA) tip (ForteBio, Menlo Park, CA). The binding assays were described in detail 
elsewhere33. Briefly, the SA tips were prepared by hydration in PBS buffer (150 mM NaCl, 50 mM 
sodium phosphate, pH 7.4) for 10 min, followed by hydration in PBS kinetic buffer (PBS buffer 
containing 1mg/mL bovine serum albumin (VWR Chemicals, Solon, OH)) for 30 min. The 
hydrated tip was then assembled to a ForteBio BLItz system (Menlo Park, CA), and the tip was 
held in a black microcentrifuge tube (Argos Technologies, Vernon Hills, IL) containing 250 µL 
PBS kinetic buffer. The BLItz system, protein and buffer solutions were kept in a 25 ºC incubator 
during the binding assays.  
 
For receptor loading, an initial baseline (30 s) was established with PBS kinetic buffer. In the 
association step (3 min), 0.02 µM FcγR IIIA in PBS kinetic buffer was loaded to a response level 
of Δnm ca. 0.4, then the tube was switched to the PBS kinetic buffer. The response level was 
measured by a wavelength shift of reflected white light, referred to as light interference, recorded 
as binding responses (Δnm). Last, the dissociation step (3 min) was performed with PBS kinetic 
buffer. For baseline collection, the baseline (30s), association (3 min) and dissociation (3 min) 
steps performed with PBS kinetic buffer. For sample loading, an initial baseline (30 s) was 
established with PBS kinetic buffer. In the association step (3min), protein solution in PBS kinetic 
buffer was loaded to the biosensor tip. The dissociation step (3 min) was performed with PBS 
kinetic buffer. Based on the binding affinity of different proteins, a series of five protein 
concentrations was used for each variant. For WT, a concentration series of 0.2 µM, 0.4 µM, 0.8 
µM, 1.6 µM, and 3.2 µM was prepared in PBS kinetic buffer. For Y300G, a concentration series 
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of 1.8 µM, 3.6 µM, 7.2 µM, 14.4 µM, and 28.8 µM was prepared in PBS kinetic buffer. For Y373G, 
a concentration series of 0.5 µM, 1.0 µM, 2.0 µM, 4.0 µM, and 8.0 µM was prepared in PBS 
kinetic buffer. For Y436G, a concentration series of 1.1 µM, 2.2 µM, 4.5 µM, 8.9 µM, and 26.7 
µM was prepared in PBS kinetic buffer. For W381A, a concentration series of 0.78 µM, 1.56 µM, 
3.125 µM, 6.25 µM, and 12.5 µM was prepared in PBS kinetic buffer. The protein solutions were 
loaded from low concentration to high concentration. The tip was regenerated with 1 mM NaOH 
for 30 s, followed by washing with PBS kinetic buffer for 2 min. For each sample, experiments 
were performed in triplicates. The tip was replaced between each replicate.  
 
For data analysis, each run was exported as a CSV file with binding response (Δnm) and time (s), 
and baseline subtracted. The sensorgram data were fitted with a two-exponential association model 
using the program XL fit analysis (IDBS, Boston, MA) in the excel (Microsoft Corporation, 
Redmond, WA) software. The data were fit to the equation: 
y = A(1-exp(-Bx)) + C(1-exp(-Dx)) 
where x corresponds to time, and B and D correspond to kobs of the slow and fast phase, 
respectively. For the iteration, B and D were constrained to be ≥ 0.  
 
3.3. Results.  
All samples of IgG4-Fc utilized for the experiments were 0.22 mg/mL in 20 mM sodium phosphate 
(pH 7.0), unless specifically stated otherwise. 
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3.3.1 Characterization of Y300G, Y373G, and Y436G IgG4-Fc. Y300G, Y373G, and Y436G 
IgG4-Fc were expressed in the Pichia pastroris yeast strain, purified with protein A 
chromatography, and initially characterized by MS analysis after reduction with DTT. PNGase F-
treated Y300G, Y373G and Y436G presented one major peak (Supporting Information, Fig. S1A), 
suggesting that N-glycosylation at Asn297 represents the major glycosylation site. The MS spectra 
of glycosylated IgG4-Fc are presented in Fig. S1B, and the corresponding percentages of N-linked 
glycoforms are summarized in Table S1. Y300G reveals a higher amount of bulky HM glycoforms, 
e.g., a total of 37.6% comprising GlcNAc2Man11 to GlcNAc2Man16 as compared to WT, Y373G, 
and Y436G (which contain ≤ 21.61% GlcNAc2Man11 to GlcNAc2Man16). 
 
The overall conformational stability of WT, Y300G, Y373G, and Y436G was examined by DSC, 
scanning from 10 to 90˚C, and the obtained thermograms were de-convoluted into two Tm values, 
denoted as Tm1 and Tm2 (Fig. 1A, Table 1). The mutation Y373G caused an approximate 10˚C 
decrease in both Tm1 and Tm2 values compared to WT. The mutant Y436G presented a similar Tm1 
value, but a decrease of 5.6˚C for Tm2 compared to WT. Instead, the mutant Y300G revealed no 
significant differences of Tm1 and Tm2 compared to WT. In addition, the characterization of tertiary 
structure was achieved by intrinsic fluorescence spectroscopy increasing the temperature from 10 
to 90˚C, where the fluorescence moments (defined in Section 2.10) were plotted as a function of 
temperature (Fig. 1B). The corresponding Tm values are listed in Table 1. Overall, WT and Y300G 
present a similar Tm, while the Y436G mutant displays a 1˚C decrease in Tm; instead, the mutant 























Fig. 1. (A) Representative DSC thermograms and (B) representative intrinsic fluorescence 
thermograms of Y300G, Y373G and Y436G. The corresponding Tm values are displayed in Table 
1.  
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3.3.2 Initial characterization of WT, S375A, W381A, S375A/W381A, WT_degly, 
S375A_degly, W381A_degly, and S375A/W381A_degly IgG4-Fc by MS and SDS-PAGE. WT, 
S375A, W381A, S375A/W381A, WT_degly, S375A_degly, W381A_degly, and 
S375A/W381A_degly, were initially characterized by MS analysis after chemical reduction with 
DTT. The respective theoretical and observed masses are summarized in Table S2. The mass 
differences of 1701- 2512 Da between WT_degly and the series of glycosylated WT forms (Fig. 
S2 and S3) correspond to the presence of various mannosylated forms of the HM glycoform, 
GlcNAc2Man(8+n) (n=0-4). WT, S375A, W381A and S375A/W381A all yield HM glycoforms (Fig. 
S2). WT_degly, S375A_degly and S375A/W381A_degly IgG4-Fc present one major peak (Fig. 
S3), indicating that they were mainly N-glycosylated at Asn297 prior to PNGase F treatment. 
W381A_degly, on the other hand, presents two major peaks, where one of them corresponds to a 
non-glycosylated form, and the other one corresponds to an O-glycosylated form, indicated by a 
mass addition of 162 ion (Table S2). The percentages of O-glycosylated WT, S375A, W381A, 
S375A/W381A proteins were calculated after PNGase F treatment based on the signal intensities 
for the O-glycosylated forms, divided by the sum of the signal intensities for de-glycosylated and 
O-glycosylated forms (+162) (Fig. S3). We calculate about 8.1% O-glycosylation in WT, 1.4% O-
glycosylation in the S375A mutant, 61.4% O-glycosylation in W381A and 4.9% O-glycosylation 
in S375A/W381A. The double mutant S375A/W381A displays a significantly reduced intensity of 
the signal for the O-glycosylated form, suggesting that Ser375 is O-glycosylated in W381A. O-
linked glycosylation was further confirmed by peptide mapping and HPLC-MS/MS analysis, as 
described in Section 3.3. On the other hand, the S375A mutant still reveals 1.4% O-glycosylation, 
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a relatively lower quantity as compared to WT. This indicates the potential presence of other O-
glycation sites besides Ser375. We also calculated the relative fraction of non-glycosylated proteins 
(prior to PNGase F treatment), which were generally <5%, using the de-convoluted MS intensities 
of non-glycosylated forms, divided by the sum of the intensities of non-glycosylated forms and 
those of all glycosylated IgG4-Fc forms (GlcNAc2Man(8+n) (n=0-4)). 
 
We used SDS-PAGE under reducing and non-reducing conditions to further monitor the purity of 
the glycoforms (Fig. S4). Lanes 2, 3, 4, and 5 were run under reducing conditions, and displayed 
single bands, respectively, indicating that proteins were obtained with good purity. Lanes 7, 8, 9 
and 10 were run under non-reducing conditions, and showed two major bands, indicating the 
existence of intra- and inter-disulfide bonds in the hinge regions of the IgG4-Fc glycoforms53. The 
formation of intra-disulfide bonds of IgG4-Fc subtype is mainly due to the presence of a Ser instead 
of a Pro residue in the core-hinge region, which leads to increased flexibility54. Densitometry 
analysis with Image J (National Institutes of Health, Washington D.C., USA) quantifies about 63% 
inter-chain disulfide and 37% intra-chain disulfide in WT, 67% inter-chain and 33% inter-chain 
disulfide in W381A, 67% inter-chain disulfide and 33% intra-chain disulfide in S375A, and 77% 
inter-chain disulfide and 24% intra-chain disulfide in S375A/W381A.   
 
3.3.3. HPLC-MS/MS analysis of O-mannosylation at Ser375 in W381A IgG4-Fc. The 
localization of the additional O-mannosylation site in W381A was determined by peptide mapping. 
W381A IgG4-Fc was reduced with DTT, alkylated with IAA, and digested with GluC. The GluC 
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digested peptides were analyzed with HPLC-MS/MS and covered 100% of the W381A IgG4-Fc 
primary sequence. The O-mannosylated proteolytic peptide 
MTKNQVSLTC(+57)LVKGFYPS(+162)375DIAVE (m/z 921.47, z=3) and the corresponding non-
O-mannosylated peptide MTKNQVSLTC(+57)LVKGFYPS375DIAVE (m/z 867.45, z=3) are 
referred to as peak 1 and peak 2, respectively, in Fig. S5, where +57 represents a Cys residue 
alkylated with IAA. Peak 1 elutes about 0.5 min before peak 2, indicating the increased 
hydrophilicity of peak 1 due to the additional O-mannosylation. The collision-induced dissociation 
(CID) MS/MS spectrum of MTKNQVSLTC(+57)LVKGFYPS (+162)375DIAVE, collected in the 
data-dependent acquisition (DDA) mode, is presented in Fig. 2. The m/z values of the b15 and b16 
ions indicate that the carbohydrate is not located on the subsequence 
MTKNQVSLTC(+57)LVKGFY. Additionally, the y3, b19, b19-162, b20, b20-162, b21, b21-162, 
b22 and b22-162 fragment ions indicate that the carbohydrate is located on the sequence PSD. 
Since O-glycosylation is mainly targeting Ser or Thr residues, our results are consistent with the 
























Fig. 2. MS/MS spectra of the O-glycosylated peptide MTKNQVSLTC(+57)LVKGFYPS375(+162) 
DIAVE (m/z 921.47) of W381A IgG4-Fc, where +162 indicates that Ser375 is mannosylated, and 



















3.3.4. Thermal stability of WT, S375A, W381A, S375A/W381A, WT_degly, S375A_degly, 
W381A_degly, and S375A/W381A_degly IgG4-Fc. The overall conformational stability of the 
various IgG4-Fc variants was examined by DSC. The thermograms of WT, S375A, W381A, 
S375A/W381A, WT_degly, S375A_degly, W381A_degly, and S375A/W381A_degly IgG4-Fc 
are shown in Fig. 3A and 3B, respectively. The thermograms of WT and S375A were de-
convoluted into three transitions, represented by melting temperatures (Tm) referred to as Tm1, Tm2, 
and Tm3. All Tm values are summarized in Table 2. The Tm1 of WT_degly is 5.8 °C lower compared 
to WT, Tm2 is 3°C lower, and Tm3 is 2°C lower. The Tm1 of S375A_degly is 1 °C higher compared 
to S375A, Tm2 is 2.4°C higher, and Tm3 is 0.1°C higher. Importantly, the thermograms of W381A 
and W381A/S375A present no transitions in the temperature range 30 – 80°C, regardless of the 
presence or absence of N-linked glycans, indicating that the mutation of Trp381 to Ala381 results in 
a loss of conformation. A similar loss of conformation was detected by DSC analysis of W381G 
IgG4-Fc (Fig. S6A). In addition, we tried rescuing the conformational structures of W381A and 
W381G IgG4-Fc by the addition of indole. Such a chemical rescue approach has been recently 
described where a Trp to Gly mutation of a single-chain variable fragment was structurally and 
functionally rescued by the addition of 1000-fold concentration of indole15, 55. However, the 
W381A and W381G IgG4-Fc (3.5 µM) were not rescued by the addition of up to 4 mM indole 





Fig. 3. Representative DSC thermograms of WT, S375A, W381A, and S375A/W381A (A) and 
WT_degly, S375A_degly, W381A_degly, and S375A/W381A_degly (B). All the derived Tm 






3.3.5. Tertiary structure of WT, S375A, W381A, S375A/W381A, WT_degly, S375A_degly, 
W381A_degly, and S375A/W381A_degly IgG4-Fc. The tertiary structures of the IgG4-Fc 
variants were evaluated by intrinsic fluorescence spectroscopy with a temperature ramp from 10 
to 90°C. The fluorescence moments were plotted on the y axis as a function of temperature, as 
shown in Fig. 4. Between 10 and 90°C, the S375A mutant displays a slight blue shift compared to 
WT IgG4-Fc (Fig. 4A), regardless of the presence of N-linked glycans (Fig. 4B), indicating that 
S375A has a relatively more compact tertiary structure compared to WT, consistent with our DSC 
analysis (Table 2). At 10°C, the fluorescence moments of W381A and S375A/W381A show a 2 
nm-red shift compared to WT. The Tm values obtained by intrinsic fluorescence are displayed in 
Table 2, with 63.6 °C for glycosylated WT and S375A, and 62.6°C and 62.8°C for PNGase F-
treated WT and S375A, respectively. W381A and W381A/S375A demonstrate no transition upon 
increasing the temperature from 10 to 90°C, indicating that the mutation of Trp381 to Ala381 causes 
a perturbation of tertiary structure in both W381A and S375A/W381A. We did not observe any 
differences between O-glycosylated W381A and the non-glycosylated double mutant 





Fig. 4. Tertiary structure characterization through intrinsic fluorescence spectroscopy of (A) 
glycosylated WT, S375A, W381A and S375A/W381A and (B) PNGase F-treated WT_degly, 
S375A_degly, W381A_degly and S375A/W381A_degly. The shaded areas represent standard 
deviations from four independent measurements.  
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3.3.6. Secondary structure of WT, S375A, W381A, S375A/W381A, WT_degly, S375A_degly, 
W381A_degly, and S375A/W381A_degly IgG4-Fc. Fig. 5 shows the second-derivative amide I 
spectra of WT, S375A, W381A, and S375A/W381A IgG4-Fc and their respective N-
deglycosylated forms. These spectra are stacked to facilitate comparison. All proteins reveal an 
overall β-sheet structure (~1630 cm-1). Here, W381A and S375A/W381A shift the β-sheet bands 
by 1 - 2 cm-1 to lower wavenumbers compared to WT and S375A. There are no substantial 
differences induced by PNGase F treatment for WT, W381A, and S375A, but the N- 
deglycosylation of the double mutant S375A/W381A IgG4-Fc induces a significant absorbance 
increase at wavenumbers around 1650 cm-1 and 1680 cm-1, characteristic of random coil and β-
turn structures based on the second-derivative analysis48. Spectra were also deconvoluted and fit 




























Fig. 5. Secondary-derivative amide I spectra from FTIR analysis of (A) glycosylated and (B) 







3.3.7. Backbone flexibility of WT and W381A IgG4-Fc examined by HX-MS. Maximally 
deuterated reference proteins were generated by deuterium-labeling of denatured WT and W381A 
IgG4-Fc, respectively, referred to as deuteration controls. The deuteration controls of WT and 
W381A revealed similar deuterium incorporation of approximate 100-110 Da (data not shown). 
These values were utilized for the calculation of % deuteration for native WT and W381A IgG4-
Fc, plotted on the y-axis as a function of HX time in Fig. 6. Two species, IgG4-Fc-GlcNAc2Man8 
and IgG4-Fc-GlcNAc2Man9, were tracked for HX measurements, because of their high abundance 
(Fig. S2). The two GlcNAc2Man8 and GlcNAc2Man9 glycoforms demonstrate the same trend. 
W381A displays a constantly higher incorporation of deuterium compared to WT at the six times 
sampled, where for the last two HX times (12500 s and 62500 s), W381A is close to full deuteration 
with a % deuteration of 96.86% - 100%. This indicates that W381A presents higher backbone 
flexibility compared to WT. Moreover, W381A does not reach a full deuteration between 10 s and 
10000s sampling time, suggesting that also this mutant is characterized by some structure, 

















Fig. 6. HX exchange of W381A (red) and WT (blue) IgG4-Fc, showing %deuteration vs labeling 
time, where %deuteration is normalized on deuteration controls. (A) represents the GlcNAc2Man8 
glycoform, whereas (B) represents the GlcNAc2Man9 glycoform. The error bars represent the 
standard deviation from three independent HX experiments.  
 
 
3.3.8. Photo-degradation of WT, S375A, W381A, S375A/W381A, WT_degly, S375A_degly, 
W381A_degly, and S375A/W381A_degly IgG4-Fc. The photostability of the IgG4-Fc variants 
was evaluated by comparison of the yields of photo-products after photoirradiation at λmax = 305 
nm for 45 min under air. All yields are reported as the conversion of native peptides (in %), 
quantified as the ratio of the peak areas of the products to the sum of peak areas for products and 
native peptides. The peak areas of the native and modified peptides were extracted by Masslynx 
(Waters Corporation, Milford, MA). As a complementary method, the total ion count (TIC) was 
(A). (B). GlcNAc2Man8 GlcNAc2Man9 
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also utilized for relative quantification, which demonstrated a similar trend (data not shown). A 
total of 16 photo-products resulting from the photo-degradation of several Tyr, Met, Cys, and Trp 
residues were identified and quantified, as shown in Fig. 7-11 (where the products from Tyr, Met 
and Cys degradation were characterized after GluC digestion, and the products from Trp 
degradation were characterized after Trypsin/LysC digestion). All detected photo-degradation 
products are listed in Table 3.  
 
During the exposure of WT IgG4-Fc to UV light, three Tyr residues, including Tyr300, Tyr373, and 
Tyr436, undergo side chain fragmentation to yield Gly and several peptide backbone cleavage 
products16. For WT and mutant IgG4-Fc, the side chain fragmentation products of Tyr373 and Tyr436 
are summarized in Table 3 (products 1-5) and their relative yields in Fig. 7. These compilations do 
not contain data on photo-products from Tyr300, which are typically observed best in the absence 
of oxygen16. As photo-irradiation was in the present work performed under air, the photo-products 
from Tyr300 were not included. The transformation of Met252, Met358, and Met426 to Met sulfoxide 
(MetSO) is summarized in Fig. 8, and the transformation of Cys321, Cys367 and Cys425 to vinyl 
cysteine (vinyl Cys) is presented in Fig. 9. The photo-degradation products from Trp313 and Trp417 
are summarized in Fig. 10 and 11.  
3.3.8.1. Photo-induced Tyr side chain fragmentation. The photo-induced Tyr side chain 
fragmentation of WT IgG4-Fc was previously documented by us16. Here, the peptide backbone 
cleavage products (products 1-5; Table 3) dominate for photo-irradiation under air atmosphere, 
where products 1-2 resulted from the cleavage of Tyr373, and products 3, 4 and 5 result from the 
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cleavage of Tyr436. The yields of products 1-5 from S375A are similar to those of WT, but W381A 
and S375A/W381A show between 2.6- and 13.5-fold reduction of the yields of photoproducts 1-5 
(Fig. 7A and 7B). Hence, the W381A mutation has a similar effect as our previously reported 
W381F mutation16. The thermal stability of W381F IgG4-Fc was evaluated by DSC and displayed 
in Fig. S8.  
 
The yields of products 1 and 2 originating from Tyr373 are higher in WT_degly and S375A_degly 
as compared to the glycosylated WT and S375A. For example, product 1 accounts for a relative 
yield of 22.1% in WT, 22.8% in S375A, 30.7% in WT_degly, and 33.0% in S375A_degly, while 
product 2 accounts for 3.8% in WT, 4.1% in S375A, 5.5% in WT_degly, and 5.0% in S375A_degly, 
respectively. This indicates that the presence of N-glycans has an effect on the formation of photo-
products from Tyr373, but less from Tyr436 (products 3-5), other than the fact that a two-fold 
reduction of product 5 was observed in S375A compared to S375A_degly. We attempted to 
monitor the formation of di-tyrosine by MS analysis, but could not detect it. Hence, the yields were 
probably below the detection limit. As an alternative, fluorescence emission between 370 and 500 
nm (excitation at 320 nm) was utilized, where an emission maximum at 410-425 nm corresponds 
to the formation of di-tyrosine56. As displayed in Fig. S9, we note that the fluorescence maximum 
shifts to ca. 430 nm for WT, Y300G, Y373G, Y436G, and to ca 439 nm for W381A, suggesting 
the contribution of N-formylkynurenine to the fluorescence emission, which perturbs the analysis 




Fig. 7. Relative yields of products 1-5 originating from photo-induced side chain fragmentation of 
Tyr373 (products 1-2) and Tyr436 (products 3-5). Photo-irradiation was performed at λmax =305 nm 
for 45 min under air. (A) Product formation from WT, S375A, W381A, and W381A/S375A IgG4-
Fc. (B) Product formation from WT_degly, S375A_degly, W381A_degly, and 
W381A/S375A_degly. Products 1-5 are displayed in Table 3.  
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3.3.8.2. Formation of MetSO. Three Met residues in IgG4-Fc are transformed into MetSO after 
photo-irradiation under air. These include Met252 in the CH2 domain, and Met358 and Met426 in the 
CH3 domain. Representative yields of MetSO, referred to as products 6, 7, 8, are displayed in Fig. 
8. For WT, S375A, W381A and S375A/W381A, the relative yields of MetSO rank as follows: 
MetSO252> MetSO426> MetSO358. This may be due to the differences of their solvent accessibility, 
based on previously reported structres of WT IgG1 and IgG257-58. The most significant differences 
between WT and the mutants are observed for product 7 (both glycosylated and N-deglycosylated 
forms), and for product 8 (Fig. 8B) 
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Fig. 8. Relative yields of MetSO originating from Met252, Met358, and Met426, referred to as 
products 6, 7, and 8. Detailed peptide sequences are presented in Table 3. (A) Product yields from 
WT, S375A, W381A, and W381A/S375A. (B) Product yields from WT_degly, S375A_degly, 




3.3.8.3. Formation of vinyl Cys. The yields of photo-chemically generated vinyl Cys from Cys321, 
Cys367 and Cys425 are displayed in Fig. 9. These products are referred to as products 9, 10, and 11, 
respectively. Vinyl Cys forms about 1.4 -1.9 fold more in WT compared to S375A, and about 1.3- 
2.9 fold more in WT_degly compared to in S375A_degly. O-mannosylation does not have much 
of an effect on vinyl Cys formation derived from a comparison between the product yields from 
W381A and S375A/W381A. 
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Fig. 9. Relative yields of vinyl Cys originating from Cys321, Cys367, and Cys425, referred to as 
products 9, 10, and 11. Detailed peptide sequences are presented in Table 3. (A) Product yields 
from WT, S375A, W381A, and W381A/S375A. (B) Product yields from WT_dehly, S375A_degly, 
W381A_degly, and W381A/S375A_degly. 
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3.3.8.4. Photo-degradation of Trp. The yields of hydroxytryptophan (Trp-OH) (product 12 from 
Trp313 and product 14 from Trp417) and N-formylkynurenine (NFK) (product 13 from Trp313) from 
the IgG4 variants are displayed in Fig. 10. The yields of kynurenine (Kyn) (product 15 from Trp313) 
and Trp side chain fragmentation (product 16 from Trp313) are displayed in Fig. 11. Overall, the 
mutation of Trp381 to Ala381 results in ca. 1.5 – 3 fold increase in the yields of Trp313 and Trp417 
oxidation. The product yields for W381A and S375A/W381A are similar, suggesting that the 
presence of an O-glycan at Ser375 does not have much of an effect on Trp313 and Trp417 degradation. 
Interestingly, products 12, 13, 15, and 16 resulting from Trp313 degradation consistently 
demonstrate slightly higher yields for N-glycosylated IgG4-Fc (p values <0.05, one-tailed paired 
t-test with Excel), while product 14 from Trp417 reveals slightly higher yields in N-deglycosylated 



























Fig. 10. Relative yields of Trp oxidation products originating from Trp313 (product 12 and 13)and 
Trp417 (product 14). Detailed peptide sequences are presented in Table 3. (A) Product yields from 
WT, S375A, W381A, and W381A/S375A. (B) Product yields from WT_degly, S375A_degly, 




















Fig. 11. Relative yields of Trp degradation originating from Trp313, referred to as products 15 and 
16. Detailed peptide sequences are presented in Table 3. (A) Product yields from WT, S375A, 








3.3.9. Binding of WT, Y300G, Y373G, Y436G, and W381A IgG4-Fc to FcɣRIIIA. The affinity 
of the IgG4-Fc variants to FcγRIII A was obtained with a BLItz system by immobilizing FcgRIIIA 
on SA tips. The binding responses (Δnm) as a function of time (s) were then fit to a two-exponential 
association model with XLFit. Two representative examples of the fits for WT and Y300G, are 
shown in Fig. 12A and 12B, respectively, and the fits for Y373G, Y436G and W381A are presented 
in Fig. S10. A dilution series of five concentrations was applied to each sample protein sample.  
 
The experimental sensorgram of association reveals a deviation from mono-exponential kinetics 
(Fig. 12)59-60, requiring two parallel equilibria (Reaction 1 and 2) for kinetic analysis. 
 
 
Here, L1 and L2 represent two forms of FcɣRIIIA, based on the potential for heterogeneity of 
FcγR61. The variable P represents the concentration of the IgG4-Fc variants, k1 and k2 represent 
the kon values, and k-1 and k-2 represent the koff values for Reactions 1 and 2. Reaction 1 stands for 
the fast phase, and reaction 2 stands for the slow phase. Based on the relative concentrations where 
[FcɣRIIIA] « [IgG4-Fc], the association reactions are of pseudo first order. We obtained 
 [L1P] + [L2P] = [L1P]∞(1-exp(-(k1[P0]+ k-1)t) + [L2P]∞(1-exp(-(k2[P0]+ k-2)t), 
where [L1P] and [L2P] represent the concentrations of the complexes L1P and L2P at time t as 
dependent variables, respectively; [P0] represents the initial and approximately constant 
concentration of P. [L1P]∞ and [L2P]∞ represent the concentrations of L1P and L2P at infinite 
reaction time. A two-exponential association fit was applied using XL fit analysis: y = A(1-exp(-
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Bx)) + C(1-exp(-Dx)), where A =[L1P]∞; B = k1[P0]+ k-1; C=[L2P]∞; D = k2[P0]+ k-2. Therefore, the 
fitting parameters, B and D correspond to kobs of the fast (Fig. 13) and the slow phases (Fig. S11), 
which can be plotted as a function of the concentration of [P0].  From the slope, we derive kon (M-
1s-1) (k1 or k2), and from the intercept, we derive koff (s-1) (k-1 or k-2) (Fig. 14). The plots of kobs vs. 
[P0] of the fast phase display a linear relation for the five IgG4-Fc variants (Fig. 13). However, the 
plots of kobs vs. [P0] of the slow phase show linearity only for WT, Y373G, and Y300G (Fig. S11). 
The kon and koff values derived from the fast phase are consistent with the specific binding affinity 
between Fc and FcγRIII33, 62. Therefore, in the following we compare the binding affinity of the 
IgG4-Fc variants based on the rate constants obtained from the fast phase. 
 
By comparison, we observed the following trend of the kon values: WT > Y373G > Y436G > 
Y300G > W381A, where kon of WT is about 11.5-fold higer than kon for W381A. On the other 
hand, the trend of koff values is as follows: Y373G < W381A< WT < Y300G< Y436G, where 
Y373G, W381A and WT present similar koff values within a 1.5-fold difference, while Y300G and 
Y436G display (2.0- 3.5)-fold increased koff values with respect to Y373G, W381A, and WT. The 
equilibrium dissociation constants (KD) were obtained by calculating the ratio of koff over kon, and 
the trend was as follows: WT <Y373G <Y436G <Y300G <W381A, where WT and Y373G present 
similar KD values (1.6 -1.9 µM), while Y436G, Y300G, and W381A display ca. 9-10 fold increased 
KD values as compared to WT and Y373G, indicating that WT and Y373G have about a 10-fold 







































Fig. 12. BLI association sensorgrams for (A) WT and FcγRIII A, and (B) Y300G and FcγRIII A in 
PBS kinetic buffer (pH 7.4), where the red line corresponds to a two-phase exponential association 


















































Fig. 13. Plot of kobs of the fast phase as a function of concentrations of the IgG4-Fc variants. The 
















































Fig. 14. kon (A), koff (B) and KD (C) values of the fast phase for WT, Y300G, Y373G, Y436G, and 
W381A IgG4-Fc.  
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3.4. Discussion.  
Physico-chemical stability and biological function are central for safety, potency, and 
comparability assessment of protein therapeutics. These properties depend on the intrinsic 
(primary sequence, structure, glycosylation) and extrinsic factors (pH, temperature, exposure to 
light, formulation additives). Here, we examined the consequences of photo-induced conversion 
of Trp and Tyr of IgG4-Fc to Gly6, 19 on the structure, backbone flexibility, and receptor binding. 
During preparation of the various Tyr to Gly and Trp to Gly/Ala mutants, we realized that these 
mutations led to a change of glycosylation, especially the formation of atypical O-glycosylation. 
Therefore, we designed additional mutants to evaluate the effect of N- vs O-glycosylation, and N-
deglycosylation on protein structure, receptor binding, and photochemical product formation. Our 
results show that: (1) The conversion of Tyr373 to Gly373 significantly decreased the thermal 
stability of both the CH2 and CH3 domains of IgG4-Fc; (2) the single conversion of Trp381 to Ala381 
or Gly381 in the CH3 domain of IgG4-Fc- caused overall conformational and tertiary structure 
perturbation; (3) the conversion of Tyr300 to Gly300 and Trp381 to Ala381 results in a ca. 10-fold 
reduction of binding affinity to the FcγRIII A; (4) an O-linked glycosylation site at Ser375 was 
enriched to more than 60% in W381A and W381G IgG4-Fc; (5) both, the mutation of a single Trp 
and the introduction of N-glycans have an effect on the yields of photo-induced product formation. 
Therefore, it is critical to characterize and control Trp and Tyr degradation during processing and 
storage of protein therapeutics. 
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3.4.1. The impact of photo-induced conversion of Tyr to Gly on the conformational stability 
of IgG4-Fc.  
Three Tyr residues in IgG4-Fc, Tyr300, Tyr373, and Tyr436, were representatively mutated to Gly, to 
investigate the impact of photo-induced transformation of Tyr to Gly on the physical stability of 
IgG4-Fc. We observed reduced conformational stability for Y373G and Y436G, but not for Y300G, 
evaluated by DSC and intrinsic fluorescence spectroscopy (Fig. 1 and Table 1). However, based 
on our MS analysis, the mutant Y300G contains a larger fraction of bulky glycoforms (i.e., Man12-
Man16; Table S1). The presence of bulkier glycoforms may compensate for any loss of stability 
possibly resulting from Tyr300Gly mutation63. The reduced thermal stability of Y373G and Y436G 
indicates that the photo-induced conversion of Tyr373 and Tyr436 into Gly can lead to destabilization 
of conformational structures of IgG4-Fc. 
 
3.4.2. Thermal stability of WT, S375A, W381A, and S375A/W381A IgG4-Fc.  
Upon photoirradiation, Trp381 (Eu numbering64-65) in IgG4-Fc16 and IgG16 can be photoionized, 
resulting in the loss of the indole side chain, and convert to Gly and several peptide backbone 
cleavage products. Therefore, we evaluated the effect of such degradation on physical properties 
utilizing IgG4-Fc as model protein. An atypical O-glycosylation at Ser375 was detected in the Trp381 
mutants, W381A and W381G IgG4-Fc, and to evaluate the impact of O-glycans, S375A and the 
S375A/W381A mutants were prepared. During the production of W381A and W381G, the 
expression yields of W381A were significantly higher than of the W381G mutant. Hence, W381A 
was selected for some of the biophysical experiments requiring larger amounts of protein. 
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The thermal unfolding of IgG4-Fc was monitored by DSC, and the thermograms were fit to two 
or three transitions depending on the IgG4-Fc variants17, 66. WT IgG4-Fc presents a similar thermal 
stability of the CH2 domain as IgG4-Fc17, but an approximate 10°C reduction of Tm217, 
corresponding to the unfolding of the CH3 domain17 (Table 2). The reduced thermal stability of the 
CH3 domain in IgG4-Fc can be explained by the weak CH3-CH3 interactions53, 67-68, which are about 
three orders of magnitude weaker69 as compared to IgG1-Fc.  
 
The DSC and intrinsic fluorescence thermograms (10-90°C) of W381A and S375A/W381A are 
similar and reveal no thermal transitions, indicating that the overall conformation and tertiary 
structures are disrupted by the mutation of Trp381 to Ala381. Trp381 sits in the hydrophobic core of 
CH3 domain, and the loss of the hydrophobic side chain leads to reduced protein conformational 
stability. A similar observation was reported for a four-helix-bundle protein, Rop, where the 
unpacking of its hydrophobic core caused not only the loss of protein activity but decreased protein 
stability70. Additionally, the CH3-CH3 interaction is critical for the assembly of the Fc domain69, 
and, therefore, disruption of the inter-chain CH3 interactions can perturb the folding of the overall 
IgG4-Fc. The reduced thermal stability of proteins can potentially lead to increased aggregation 
propensity71, shorter shelf-life72-73, and safety issues72. 
3.4.2.1. Backbone flexibility of WT and W381A IgG4-Fc. 
Changes in protein conformation can potentially accompany in changes in the backbone flexibility 
	 153	
of proteins. Therefore, the backbone flexibilities of WT and W381A were evaluated by HX MS 
analysis. Deuteration controls were prepared with denatured WT and W381A, and display a 
maximum of 100 -110 Da mass increase due to deuterium incorporation. This value can be utilized 
to calculate the fraction of deuteration of native WT and W381A. W381A reaches full deuteration 
(~96 -100%) within 12500 s exposure to D2O, whereas, WT achieves only 87.83 -89.46% 
deuteration even at 62500 s. Therefore, W381A possesses much higher backbone flexibility than 
WT IgG4-Fc. On the other hand, W381A does not reach full deuteration at the initial time point, 
indicating that it is not completely unstructured. These data are consistent with our FTIR analysis 
(Fig. 5), revealing that W381A and WT IgG4-Fc display similar amounts of secondary structure, 
where β-sheet shows the highest abundance (Fig S7).  
3.4.2.2. The effects of N-glycans on thermal stability.  
N-glycans at Asn297 in IgGs are critical for their thermal stability, particularly for the CH2 domain 
of Fc17. Hence, the effects of N-glycans on the thermal stability of WT, S375A, W381A, and 
S375A/W381A IgG4-Fc were examined. PNGase F was utilized to release N-glycans from these 
IgG4-Fc variants, to obtain WT_degly, S375A_degly, W381A_degly, and S375A/W381A_degly 
IgG4-Fc. The DSC thermograms of WT_degly and S375A_degly IgG4-Fc present three transitions. 
For comparison, we fitted also the DSC thermograms of WT and S375A to three transitions, and 
derived Tm1, Tm2 and Tm3 (Table 2). As expected18, the removal of N-glycans reduced thermal 
stability of WT IgG4-Fc. However, the removal of N-glycans did not modify the thermal stability 
of S375A IgG4-Fc, indicating a possible interaction of the O-glycan at Ser375 with the N-glycan at 
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Asn297. W381A, S375A/W381A, and W381A_degly, S375A/W381A_degly (Chart 1 and 2) reveal 
no thermal transitions independent of the presence of N-glycans or O-glycans (Fig. 3 and 4), 
indicating that the Trp381Ala mutation results in the loss of conformation. It must be pointed out 
that PNGase F dependent deglycosylation of Asn297 yields Asp297, introducing a negative charge74 
at residue 297, which may affect protein structure. 
 
3.4.3. The impact of photo-induced conversion of Trp and Tyr on binding kinetics and 
equilibria with FcγRIIIA.  
We evaluated the impact of light-induced conversion of Tyr to Gly on the affinity of IgG4-Fc to 
FcγRIIIA. We also evaluated the W381A mutant instead of W381G as the expression yields of 
W381A were sufficiently high to generate sufficient material for the binding experiments. As both 
W381A and W381G showed no significant thermal transition during DSC experiment, we 
concluded that the W381A mutant was a viable substitute for W381G in the receptor binding 
experiments. FcγRIIIA binds with the lower hinge and hinge-proximal CH2 domain of IgG-Fc in 
a 1:1 stoichiometry75. Interestingly, our BLI sensorgrams could not be fitted with monoexponential 
kinetics (Fig. 10 and Fig. S10). On close inspection of the literature76, we found references77,78 
which did not show simple mono-exponential binding kinetics of IgG to FcγR. This can be 
rationalized in various ways. First, our FcγRIIIA may be heterogeneous, e.g. distinct receptor 
populations at the biosensor surface resulting from immobilization78. In addition, the two N-linked 
glycosylation sites at Asn162 and Asn45 of FcγRIIIA may present distinct glycoforms79-80,81-82. The 
literature shows that the binding between Fc and FcγRIIIa involves carbohydrate-carbohydrate 
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interactions, which require unique glycoforms of both proteins to achieve high affinity73. Second, 
IgG4-Fc is expressed with various glycans at Asn297 (see Table S1)83. The glycosylation at Asn297 
in the CH2 domain has shown not only to affect the affinity of mAbs to FcγRIIIA but also the 
binding kinetics84. Third, the presence of low levels of impurities of IgG4-Fc, e.g., ca. 2% of 
aggregates of mAbs, can affect binding kinetics with FcγRIIIA78. Fourth, the sensorgrams may 
contain elements of non-specific reversible association in IgG4-Fc as a function of increased 
protein concentration. To minimize potential nonspecific binding, a 1 mg/mL BSA additive was 
supplemented to the running buffers and sample solutions. All the above conditions can lead to 
heterogeneous binding, resulting in two or more phases of association events. Thus, to achieve a 
better fit and more accurate results, a two-phase exponential association model was utilized to 
derive the kon and koff values for a slow and a fast phase. Here, we reported values for the fast phase 
based on previous knowledge62 of the specific binding between Fc and FcγRIIIA. Overall, Y300G 
and W381A display up to 10-fold reduced affinity to FcγRIIIA as compared to WT. The reduced 
binding affinity can be due to different reasons. Tyr300 residue is located in the upper CH2 domain 
adjacent to the N-glycosylated site at Asn297, potentially participating in interaction with 
FcγRIIIA85-86. The mutation Trp381Ala causes a loss of conformation of IgG4-Fc, which may 
perturb the potential structural interface, or orientations of the Fc domains, critical for affinity to 
FcγRIIIA87. Y436G presents relative high kon and koff values, which, overall, result in an 8-fold 
increase in KD compared to WT, and thus weaker binding affinity. In addition, Tyr436 is part of a 
common ‘consensus’ sequence of the CH2-CH3 interface to interact with FcRn88, which is crucial 
to protect mAbs from lysosomal degradation and to maintain long serum half-life.  
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3.4.4. O-glycosylation at Ser375 in W381A and W381G IgG4-Fc.  
We initially prepared the mutants W381A and W381G IgG4-Fc to evaluate the effect of Trp side 
chain cleavage on biophysical stability. The biophysical analysis of W381A and W381G IgG4-Fc 
reveals a perturbation of overall thermal stability (Fig. 3 and Fig. S6). Moreover, the expression 
yields of W381G were very low, suggesting that W381G is potentially even less stable than 
W381A89. The lower stability would be consistent with the ca. 15% higher level of O-glycosylation 
at Ser375 in W381G as compared to W381A (Fig. S12). Since W381A was expressed with higher 
yields, it was selected for further production and characterization.  
 
IgG4-Fc variants were produced in the pno1/och1 KO and STT3D added Pichia pastoris yeast 
strain. Several IgG-Fc subtypes, e.g., IgG1-Fc49 and IgG3-Fc90, were previously expressed from 
the same system, showing <10% O-glycosylation. We obtained similar results with IgG4-Fc, 
displaying approximate 8.1% O-glycosylation in WT IgG4-Fc. However, the mutation of Trp381 to 
Ala381 in the CH3 domain of IgG4-Fc leads to a surprising increase of up to 61% O-glycosylation 
at Ser375, which was confirmed by mass spectrometry analysis: (1) the identification of two major 
peaks in the mass spectra of W381A_degly (Fig. S3) is consistent with the presence of N-
deglycosylated and O-glycosylated forms, respectively. Here, the O-glycosylated form is indicated 
by a mass addition of 16291-92; (2) peptide mapping of W381A identifies Ser375 as the major O-
glycosylated site (Fig.2); (3) the O-glycosylated form is removed in S375A/W381A_degly IgG4-
Fc (Fig. S3).  
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O-linked glycosylation at Ser375 does not appear to cause the structural alterations, but occurs more 
easily when the structure of IgG4-Fc is perturbed, e.g., in W381A and W381G. This is particularly 
consistent with the observation of Neubert et al., who mapped the O-mannose glycoproteome in 
Saccharomyces cerevisiae39, where O-linked mannosylation was more favored in unstructured 
regions and β-strands. Alternatively, protein O-mannosyltransferases can participate in protein 
folding quality control as a part of unfolded protein O-mannosylation (UPOM), which may explain 
that W381A and W381G are better substrates for O-mannosylation than the more stable WT, and 
reveal a higher level of O-mannose93.  
 
3.4.5. Photostabiliy of WT, S375A, W381A, and S375A/W381A IgG4-Fc. During photo-
irradiation, the formation of different photo-products can result from distinct reaction pathways. 
For example, the side chain fragmentation of Tyr is induced by electron transfer from Tyr to a 
radical cation, Trp.+, generated by photo-ionization of Trp.16 The yield of the respective photo-
products can therefore, be affected by the mutation of Trp and conformational alterations changing 
the distance between Tyr and Trp.+. As such, photo-products from the side chain fragmentation of 
Tyr reveal a 2.6-13.5 fold reduction of yields in W381A and S375A/W381A (Fig. 7) compared to 
WT and S375A. The higher susceptibility of photo-degradation at Trp313 and Trp417 to photo-
degradation in W381A, S375A/W381A, W381A_degly, and S375A/W381A_degly is likely due 
to the fact that Trp381 is deleted in these mutant leading to preferred light absorption of other Trp 
residues, e.g., Trp313 and Trp417. In parallel, the increased susceptibility of Trp313 and Trp417 to 
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photo-degradation leads to an increase in photo-induced electron transfer to disulfide bonds 
containing Cys321, Cys367, and Cys425, resulting higher vinyl Cys formation from Cys321, Cys367, and 
Cys425. 
 
With regard to the effect of glycans on photostability, O-glycosylation does not significantly affect 
the yield of photoproducts, evident from a comparison of W381A and S375A/W381A. This is 
likely due to the fact that the mutation of Trp to Ala has a more significant impact on photo-
degradation, leading to unfolding, to which O-glycosylation, does not add much. Alternatively, the 
size of O-mannose is small, which does not significantly modify the structure. The presence of N-
glycans, on the other hand, does play a role in the yield of photo-products. Similar observations 
were documented regarding IgG1-Fc8. 
 
3.5. Conclusions 
The present paper elucidates the impact of photo-induced Tyr and Trp side chain fragmentation on 
the physico-chemical stability and receptor binding of IgG4-Fc, and the effect of N- vs O-glycans 
on product formation. Surprisingly, the side chain cleavage of Trp381, represented by W381G and 
W381A, causes a conformational perturbation of both the CH2 and CH3 domains of IgG4-Fc. 
Moreover, W381A and W381G reveal significantly enriched atypical O-glycosylation at Ser375. 
The fragmentation of Tyr side chain results in reduced thermal stability, and decreased receptor 
binding affinity to FcɣRIIIA. These findings help elucidate photo-induced inactivation, 
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fragmentation and physical instability in protein therapeutics. 
 
3.6. Acknowledgements 
We gratefully acknowledge support of H.K. by a Graduate Fellowship from the Genentch 
Foundation.  
 
3.7. Associated content 
Fig. S1. Mass spectrometry analysis of (A) Y300G_degly, Y373G_degly, Y436G_degly and (B) 
Y300G, Y373G, Y436G after reduction with DTT.  
Fig. S2. MS analysis of WT, S375A, W381A, and S375A/W381A IgG4-Fc after chemical 
reduction of disulfides.  
Fig. S3. MS analysis of WT_degly, S375A_degly, W381A_degly, and S375A/W381A_degly 
IgG4-Fc after chemical reduction of disulfides.  
Fig. S4. SDS-PAGE analysis of WT, S375A, W381A, and S375A/W381A, glycosylated proteins 
were run under reducing conditions; deglycosylated proteins were run under nonreducing 
conditions.  
Fig. S5. Chromatogram of proteolytic digest of W381A IgG4-Fc analyzed with HPLC-MS/MS. 
Peak 1 contains the O-linked glycosylated peptide, MTKNQVSLTC(+57)LVKGFYPS375(+162) 
DIAVE (m/z 921.47). Peak 2 contains the nonglycosylated peptide, MTKNQVSLTC(+57)LV 
KGFYPS375DIAVE (m/z 867.45). 
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Fig. S6. Thermal stability of (A) WT, W381G, and W381A, and (B) chemical rescue with indole.  
Fig. S7. Relative percentage of individual secondary structures of WT, S375A, W381A, and 
S375A/W381A, glycosylated and deglycosylated, analyzed by FTIR.  
Fig. S8. Representative DSC thermograms of W381F. The corresponding Tm values are displayed.  
Fig. S9. Dityrosine detection of WT, Y300G, Y373G, Y436G and W381A by exciting photo-
irradiated IgG4-Fc at 320 nm and fluorescence emission scan from 371 – 500 nm. Photo-irradiation 
was performed at λmax =305 nm for 45 min. 
Fig. S10. BLI association of (A) Y373G and FcγRIII A, (B) Y436G and FcγRIII A, (C) W381A 
and FcγRIII A in PBS kinetic buffer (pH 7.4), where the red line corresponds to two-phase 
exponential association fit, and the blue dots correspond to experimental data points.  
Fig. S11. Plot of kobs of the slow phase as a function of concentrations of the IgG4-Fc variants, WT, 
Y373G, and Y300G. The error bars represent the standard error from three independent 
measurements. Y373G and W381A were not shown due to the absence of linear relationship 
between kobs of their slow phase and protein concentrations. 
Fig. S12. The presence of O-linked glycosylation (%) in W381G, W381A, and WT IgG4-Fc 
characterized by HPLC-MS analysis. 
Table S1. Relative abundance (in %) of different glycoforms of Y300G, Y373G, and Y436G IgG4-
Fc.  
Table S2. Theoretical and observed masses of glycosylated WT, S375A, W381A, and 
S375A/W381A, and the N-deglycosylated variants WT_degly, S375A_degly, W381A_degly, and 
S375A/W381A_degly under reducing conditions.  
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Table 1. Melting temperature (Tm) of Y300G, Y373G, and Y436G from DSC and fluorescence. 
Experiments were conducted in triplicate. 
 Tm1 (DSC) Tm2 (DSC) Tm (Fluorescence) 
WT 65.12± 0.1 71.68± 0.1 63.6 ± 0.3 
Y300G 64.6 ± 0.1 71.3 ± 0.1 63.5 ± 0.1 
Y373G 54.9 ± 0.1 60.8 ± 0.04 55.3 ± 0.1 

















Table 2. Melting temperature (Tm) of WT, S375A, WT_degly, and S375A_degly from DSC and 
fluorescence. Experiments were conducted in triplicate. 
 Tm1 (DSC) Tm2 (DSC) Tm3 (DSC) Tm (Fluorescence) 
WT 60.0 ± 0.1 65.9 ± 0.1 71.8 ± 0.4 63.6 ± 0.3 
S375A 62.2 ± 0.1 66.8 ± 0.2 72.7 ± 0.1 63.6 ± 0.2 
WT_degly 54.2 ± 0.7 62.9 ± 0.6 69.9 ± 0.5 62.6 ± 0.4 

















Table 3. Photo-degradation products identified by HPLC-MS/MS through peptide mapping. The 
corresponding modified residue is listed in the “position” column. The mass modification of +57 
or +58 of Cys indicates the alkylation by IAA or IAC, respectively, M(+16) is the formation of 
methionine sulfoxide, C(+55) is the formation of vinyl thiol, W(+16), W(+32), and W(+4) are the 
formation of Trp-OH, NFK, and Kyn, respectively. 
Product Photoproducts Position m/z z 
1 MTKNQVSLTC(+57)LVKGF-NH2 Tyr373 575.61 3 
2 M(+16)TKNQVSLTC(+57)LVKGF-NH2 Tyr373 580.96 3 
3                TQKSLSLSLGK Tyr436 609.30 2 
4 [                TQKSLSLSLGK]+18 Tyr436 618.30 2 
5 TQKSLSLSLGK Tyr436 387.89 3 
6 FLGGPSVFLFPPKPKDTLM(+16)ISRTPE Met252 698.38 4 
7 M(+16)TKNQVSLTC(+57)LVKGFYPSDI
AVE 
Met358 872.76 3 
8  GNVFSC(+57)SVM(+16)HE Met426 641.75 2 
9 YKC(+55)KVSNKGLPSSIE Cys321 569.96 3 
10 MTKNQVSLTC(+55)LVKGFYPSDIAVE Cys367 866.76 3 
11 GNVFSC(+55)SVMHE Cys425 632.75 2 
12 VVSVLTVLHQDW(+16)LNGK Trp313 608.65 3 





































Trp417 613.26 5 
15 VVSVLTVLHQDW(+4)LNGK Trp313 604.65 3 
16 VVSVLTVLHQDW-NH2 Trp313 604.84 2 
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Fig. S1. Mass spectrometry analysis of (A) Y300G_degly, Y373G_degly, Y436G_degly and (B) 



















Fig. S2. MS analysis of WT, S375A, W381A, and S375A/W381A IgG4-Fc after chemical 










Fig. S3. MS analysis of WT_degly, S375A_degly, W381A_degly, and S375A/W381A_degly 















Fig. S4. SDS-PAGE analysis of WT, S375A, W381A, and S375A/W381A, glycosylated proteins 





































Fig. S5. Chromatogram of proteolytic digest of W381A IgG4-Fc analyzed with HPLC-MS/MS. 
Peak 1 contains the O-linked glycosylated peptide, 
MTKNQVSLTC(+57)LVKGFYPS375(+162)DIAVE (m/z 921.47). Peak 2 contains the 







































































Fig. S7. Relative percentage of individual secondary structures of WT, S375A, W381A, and 






































































Fig. S9. Dityrosine detection of WT, Y300G, Y373G, Y436G and W381A by exciting photo-
irradiated IgG4-Fc at 320 nm and fluorescence emission scan from 371 – 500 nm. Photo-irradiation 





































Fig. S10. BLI association of (A) Y373G and FcγRIII A, (B) Y436G and FcγRIII A, (C) W381A 
and FcγRIII A in PBS kinetic buffer (pH 7.4), where the red line corresponds to two-phase 































































































































Fig. S11. Plot of kobs of the slow phase as a function of concentrations of the IgG4-Fc variants, WT, 
Y373G, and Y300G. The error bars represent the standard error from three independent 
measurements. Y373G and W381A were not shown due to the absence of linear relationship 


























Fig. S12. The presence of O-linked glycosylation (%) in W381G, W381A, and WT IgG4-Fc 





































Table S1. Relative abundance (in %) of different glycoforms of Y300G, Y373G, and Y436G IgG4-
Fc.  
 WT Y300G Y373G Y436G 
No glycan 2.89  0.69  2.69  0.77  
Man8 35.61  34.87  52.06  64.48  
Man 9 36.58  21.43  19.40  18.70  
Man10 15.49  5.24  4.24  3.74  
Man11 6.49  14.22  10.06  6.46  
Man12 2.46  13.12  7.17  4.04  
Man13 0.48  2.74  1.20  0.70  
Man14 0.00  2.92  1.58  0.58  
Man15 0.00  3.93  1.37  0.49  




























Table S2. Theoretical and observed masses of glycosylated WT, S375A, W381A, and 
S375A/W381A, and the N-deglycosylated variants WT_degly, S375A_degly, W381A_degly, and 
S375A/W381A_degly under reducing conditions.  
 Theoretical Observed    
WT_degly 25006.24 25004.6    
S375A_degly 24990.24 24987.9    
W381A_degly 24891.11 a24889.6/25051.8    
W381A/S375_
degly 
24875.11 24870.8    
 Theoretical     
 GlcNAc2Man8 GlcNAc2Man9 GlcNAc2Man
10 
GlcNAc2Man11 GlcNAc2Man12 
WT 26707.7 26869.75 27031.81 27193.86 27355.91 
S375A 26691.7 26853.75 27015.81 27177.86 27339.91 
W381A 26592.56 26754.61 26912.66 27078.72 27240.77 
W381A/S375A 26576.56 26738.61 26900.66 27062.72 27224.77 
 Observed     
 GlcNAc2Man8 GlcNAc2Man9 GlcNAc2Man
10 
GlcNAc2Man11 GlcNAc2Man12 
WT 26705.5 26867.5 27029.7 27191.7 27354.3 
S375A 26688.8 26850.9 27012.9 27175.2 27338.1 
W381A 26591.4 26753.5 26915.6 27077.8 27240 
W381A/S375A 26572 26734.1 26896 27058.2 27220.4 
 
aW381A_degly presents two masses, 24889.6 and 25051.8, corresponding to the absence and presence of O-















Chapter 4. Effects of glycan structure on the physicochemical stability, photostability, and 




















1. Introduction.  
Monoclonal antibodies (mAbs), primarily IgGs, represent important therapeutics owing to their 
target specificity and long serum half-life(1-3). Among the four human isotypes of IgG (i.e., IgG1, 
2, 3 and 4), isotypes 1, 2 and 4 have been developed into therapeutic mAbs. IgG3-based mAbs are 
usually not developed due to their susceptibility to proteolysis, the existence of many allotypes, 
and the shorter half-life in vivo(4). The four IgG isotypes are highly conserved with respect to their 
primary residual sequences, presenting more than 90% similarity(5). However, each isotype 
reveals a distinctive profile with regard to biological effector functions and immune complexes(5). 
For example, IgG4 displays no affinity to complement component 1q (C1q) and a low affinity to 
Fc receptors(6). Because of this IgG4 has been preferably selected as an isotype for therapeutic 
mAbs when a host effector function is undesirable or unnecessary. For example, IgG4-based mAbs 
have been selected for immune-checkpoint therapy, blocking the inhibitory interaction between 
programmed death protein-1 (PD-1) on immune cells and the ligand PD-L1 on tumor cells by 
binding to PD-1 on immune cells and allowing an effective immune response to be initiated against 
tumor cells(7). By the end of 2018, 10 IgG4-based mAbs were introduced into the market among 
approximately 80 approved mAbs in the USA and the EU(8, 9). Therefore, IgG4 is an essential 
IgG subclass for the development of effective immunotherapies.  
 
Glycosylation at Asn297 (Eu numbering(10)) is a heterogeneous, conserved, and critical post-
translational modification (PTM) of IgGs. It contributes to their biological function and 
physicochemical stability(11-13). However, glycan structures are difficult to control and can be 
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affected by host cell genotypes, strains, culture conditions, protein sequences, the manufacturing 
process(14) as well as the length of storage(15). Hence, glycosylation at Asn297 is a critical quality 
attribute (CQA) that is required to be strictly defined and controlled(16), (17). Several analytical 
approaches have been developed to qualitatively and quantitatively monitor oligosaccharide 
profiles of mAbs, including fluorescence detection of 2-aminobenzamide (AB) labeled glycans 
and HPLC-MS analysis of released glycans, glycopeptides and glycoproteins(18). Analytical 
results suggest that variations of glycan structures constantly exist among biosimilars and 
reference products(19). Alterations in glycan structures have been shown to affect physico-
chemical properties(11, 12, 20, 21) and biological effector functions(13, 17) of IgG1 or the 
crystallizable fragment of IgG1 (IgG1-Fc), but such knowledge is limited with regard to IgG4.  
 
IgG4-Fc is a dimer, composed of a lower hinge region, and the CH2 and CH3 domains (Scheme 1). 
Although IgG4-Fc presents a structure similar to IgG1-Fc, it reveals several unique properties such 
as the capability of undergoing half-molecule exchange(22). Half-molecule exchange refers to a 
process where an IgG4-Fc dimer dissociates into monomers, and the dissociated monomer 
exchanges with an adjacent monomer to reform a new dimer(23). The capability of IgG4 to 
undergo half-molecule exchange has been investigated by mutagenesis(24) and by a high-
resolution crystal structure of IgG4-Fc(23), where two amino acid modifications were found to be 
essential for such exchange. One is the replacement of Ser228 by Pro228 (Eu numbering(10)) in the 
core-hinge region(22), which enhances the flexibility of the hinge, allowing the formation of inter- 
and intra-chain disulfides. The other is the presence of a bulkier Arg409 instead of a Lys409 in the 
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CH3 domain, which disrupts the essential hydrogen bond interaction between Asn390 in one CH3 
domain and Ser400 in the other CH3 domain, leading to the dissociation of CH3-CH3(24). Many 
IgG4 therapeutics are designed for hinge stabilization via mutating Ser228 to Pro228 to prevent half 
molecule exchange in vivo(25). In addition, the crystal structure of IgG4 presents an altered 
conformation (compared to IgG1) of the CH2 FG loop (residues 325-331), which may explain 
reduced affinity of IgG4-Fc to Fcɣ receptor IIIA (FcɣRIIIA) relative to IgG1-Fc. A variety of 
studies of FcɣRIIIA binding to IgG1 have shown that the interaction is complex, with both 
antibody and receptor glycosylation altering binding(26-31). IgG1 Asn297 glycan structures, e.g., 
the attachment of core fucose, significantly reduce the binding affinity of IgG1 to FcɣRIIIA, and 
this has been attributed to carbohydrate-carbohydrate interactions or entropic effects. FcɣRIIIA 
glycosylation at N162, has also been demonstrated to alter IgG1 binding, with Man5 FcɣRIIIA 
glycoforms exhibiting higher affinity. The affinity of IgG-Fc to FcɣRIIIA is important in eliciting 
antibody-dependent cellular cytotoxicity (ADCC) which can be important in the mechanism of 
action of mAb therapeutics. The purpose of this work was to evaluate the effect of glycan structure 
on the physico-chemical properties, photochemical stability and receptor binding of IgG4-Fc. 
These are critical parameters, which could affect shelf-life and in vivo half-life of IgG4-based 
protein therapeutics. We selected photostability studies as representative for chemical stability 
studies in view of our recent results, demonstrating that the UV exposure of wild-type IgG4-Fc 
leads to the side chain cleavage of specific Tyr residues(32). The mechanism of this reaction 
involves photo-induced electron transfer between Tyr and an intermediate Trp radical cation and 
is controlled by solvent-dependent changes of protein conformation(32). Therefore, we expect 
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differences in the yields of Tyr-derived reaction products depending on the effect of glycan 
structure on the dynamics of IgG4-Fc. In addition, we monitored the photo-induced formation of 
methionine sulfoxide (MetSO) and disulfide cleavage products. 
 
 
Scheme 1. A scheme presentation of three glycosylated IgG4 including HM, Man5, and GlcNAc1, 
where HM was obtained from yeast expression, Man5 (A) and GlcNAc1 (B) were obtained from 














Previous studies reported the affinity between FcɣRIIIA and human serum-derived IgG4 with an 
equilibrium dissociation constant of 4-5 µM, where IgG4 potentially contained a mixture of various 
glycoforms(6). However, the affinity of specific glycoforms of IgG4 to FcgIIIA is unknown. 
Considering that the micro-heterogeneity of Asn297 glycans may impact the binding affinity of the 
Fc domain to FcɣRIIIA, we prepared three well-defined glycosylated and one non-glycosylated 
IgG4-Fc. The designed IgG4-Fc variants include GlcNAc2Mn(8+n) (n =0-4), referred to as high 
mannose (HM); GlcNAc2Man5, referred to as Man5; GlcNAc1 and the N297Q mutant, as displayed 
in Scheme 1. Binding affinities to FcγRIIIA of the four IgG4-Fc were evaluated and correlated 
with physico-chemical properties.  
 
2. Materials and methods. Yeast extract, peptone, and agar were purchased from Becton 
Dickinson and Company (Franklin Lakes, NJ). Yeast nitrogen base (YNB) was bought from 
Sunrise Biosciences (San Diego, CA). Zeocin was provided by Invitrogen (Carlsbad, CA). Rmp 
protein A sepharoseTM fast flow, phenyl sepharoseTM high performance and XK 26 empty columns 
were obtained from GE Healthcare Bio-Sciences (Uppsala, Sweden). Endo H was provided by 
NEB Biolab (Ipswich, MA). Dextrose, sodium chloride, methanol, glycerol, ammonium hydroxide, 
phosphoric acid, and sodium phosphate were obtained from Fisher (Fair Lawn, NJ). Biotin, citric 
acid, ammonium bicarbonate, dithiothreitol (DTT), and iodoacetamide (IAA) were obtained from 
Sigma-Aldrich (Saint Louis, MO). 0.1% formic acid in H2O and 0.1% formic acid in acetonitrile 
were provided by Optima Fisher Chemical (Fair Lawn, NJ).  
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2.1 Expression of wild-type IgG4-Fc.  For the expression of wild-type IgG4-Fc, we followed 
an approach described by Okbazghi et al(33, 34). Briefly, the gene of IgG4-Fc-cDNA was 
transferred to pno1/och1/bmt 1/bmt 2 deleted and STT3D added Pichia pastoris yeast strain 
through electroporation(34). The successfully transformed yeast colonies were screened on a yeast 
extract-peptone-dextrose (YPD, 1% yeast extract, 2% peptone, 2% dextrose and 1.5% agar) plate 
containing 100 µg/mL zeocin. A selected single colony was then inoculated in a 2.5 mL YPD 
culture media containing 100 µg/mL zeocin, and shaken at 27 °C for 72 hr. The 2.5 mL YPD cell 
culture was transferred to a 250 mL YPD medium containing 100 µg/mL zeocin, and shaken at 
27 °C for ca. 72 hr before transfer to an NBS BioFlo 415 fermenter (Eppendorf, Enfield, CT). The 
fermenter was prepared in the following way: initially, 7 L of a media base composed of 1% yeast 
extract, 2% peptone, and 2% glycerol with anti-foam were prepared and sterilized. After the media 
was cooled, the temperature was set to 30 °C., and 0.34% of yeast nitrogen base, 1% ammonium 
sulfate, and 4 x10-5 % biotin were filter sterilized and added to the fermenter. The pH of the medium 
was adjusted to 6 and maintained during fermentation by addition of concentrated ammonium 
hydroxide. Finally, the 250 mL yeast cell culture was added to the fermenter. The yeast cells were 
allowed to grow until the batch glycerol was consumed, followed by an additional addition of 300 
mL of glycerol. Once the added glycerol was also consumed, methanol was added by peristaltic 
pump to induce the production of IgG4-Fc, initially at a rate of 1% (v/v) per 24 hr and increasing 
to approximately 4% (v/v) once the culture was acclimated to metabolize methanol. For induction, 
the cells were grown at 25 °C for approximately 3 days prior to harvest. Protein A-purified IgG4-
Fc yielded non-glycosylated, mono-glycosylated, and di-glycosylated IgG4-Fc with a yield of ca. 
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150 mg/L, which is sufficient for analytical characterization. Therefore, in total, one batch was 
prepared. 
 
2.2 Purification of IgG4-Fc with protein A affinity chromatography. Yeast cells harvested from 
the fermentation batch were centrifuged at 6,693 g for 20 min on an Avanti J-25I centrifuge 
(Beckman Coulter, Palo Alto, CA) with a JLA-10500 rotor at 4°C. After centrifugation, the 
supernatant was combined and filtered with five layers of 90 mm Whatman type 1 filter pads, 
where the flow-through was collected. A volume of approximate 100 mL of Sepharose Fast Flow 
protein A (GE Healthcare, Uppsala, Sweden) was packed into a XK50/20 column container (GE 
Healthcare). The column was equilibrated with 10 column volumes of 20 mM sodium phosphate, 
pH 7, followed by loading the filtered yeast culture supernatant to allow IgG4-Fc to bind. Non-
specific binders were washed out with high salt wash buffer, containing 500 mM NaCl in 20 mM 
sodium phosphate, pH 7.0. IgG4-Fc was eluted with 50 mM citric acid, pH 3.0, and immediately 
neutralized with Tris-HCl, pH 9.0. The eluted IgG4-Fc was dialyzed overnight in 20 mM sodium 
phosphate, pH 7.0, at 4°C prior to further purification.  
 
2.3 Purification of HM IgG4-Fc with hydrophobic interaction chromatography (HIC). 
Protein A-purified IgG4-Fc contained di-, mono-, and non-glycosylated IgG4-Fc, where the major 
glycosylation form was HM, GlcNAc2Man(8+n) (n=0-4) (Fig. 1). To obtain a more homogeneous 
protein solution, a second purification step utilizing HIC chromatography was applied to remove 
mono- and non-glycosylated IgG4-Fc and potential aggregates. Briefly, a volume of 75 mL phenyl 
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sepharoseTM high-performance resin was packed into an XK26 column and operated by an ÄKTA 
micro system controlled by the Unicorn 5.20 software (Amersham Biosciences, Piscataway, NJ). 
Initially, the packed column was washed with 8 column volumes (CV) of distilled water, followed 
by equilibrating with 9 CV of mobile phase A (1 M ammonium sulfate in 20 mM sodium phosphate, 
pH 7.0). An IgG4-Fc solution was prepared by mixing with 1 M ammonium sulfate in 20 mM 
sodium phosphate, pH 7.0, and loaded onto the HIC column through an autosampler loop 
controlled by a MINIPULS 2 pump (Gilson, Lewis Center, OH) loading at ca. 2 mL/min. After 
loading, the sample loop was washed with 50 mL mobile phase A to wash off the residual IgG4-
Fc. To elute different patterns of glycosylated IgG4-Fc, a linear gradient was applied ranging from 
0% to 33% of mobile phase B (20 mM sodium phosphate, pH 7.0) for 288 mL, from 33% to 55% 
of mobile phase B for 282 mL, followed by a constant level of mobile phase B at 55% for 750 mL. 
Di-glycosylated IgG4-Fc eluted in the early fractions, and was collected for future use. The eluates 
were monitored by UV absorption at 220 nm. All the aqueous solutions were filtered with a 0.22 
µm filter prior to loading onto the column.  
 
2.4 Expression and purification of B.t. α-1,2-mannosidase. E. coli cells containing the His-B.t. 
α-1,2-mannosidase-cDNA(35, 36) were inoculated into 6 mL LB media, containing 50 µg/mL 
kanamycin, and shaken at 37°C for 12 hr. The 6 mL cell culture was then transferred to 1 L LB 
medium, containing 50 µg/mL kanamycin in a baffled flask and shaken at 37°C. After 12 hr, the 
cells were induced with 0.2 mM isopropyl β-D-1-thiogalactopyranoside (IPTG), and shaken for 
an additional 12 hr for enzyme production. The cells were harvested by centrifugation at 6,693 g 
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for 30 min on an Avanti J-25I centrifuge (Beckman Coulter, Brea, CA) with a JLA-10500 rotor at 
4°C. The pellets were collected and suspended in 30 mL of 50 mM sodium phosphate containing 
5 mM β-mercaptoethanol, pH 7.5, and then sonicated on ice. The cell lysate was then centrifuged 
at 15,000 rpm for 30 min, where the supernatant was collected and filtered, followed by loading 
onto a Ni2+-NTA-agarose column. The column (ca. 5 mL) was initially equilibrated with 50 mM 
sodium phosphate, pH 7.5, and 5 mM β-mercaptoethanol for 10 CV, followed by loading of the 
supernatant. The column was washed with 50 mM sodium phosphate, pH 7.5, and eluted with 50 
mM sodium phosphate, pH 7.5, containing 250 mM imidazole. The enzyme was dialyzed 
overnight against 20 mM MES buffer, pH 6.6, at 4 °C, followed by the addition of a final content 
at 50% glycerol, to store the enzyme in 50% glycerol, 10 mM MES, pH 6.6 at -20 °C.  
 
2.5 In vitro enzymatic synthesis of Man5 IgG4-Fc. Di-glycosylated Man5 IgG4-Fc were obtained 
by truncating HM IgG4-Fc through in vitro enzymatic remodeling with α-1,2-mannosidase, 
respectively(13). To obtain Man5 IgG4-Fc, 2 mL HM IgG4-Fc at 2 mg/mL were mixed with 8 mL 
solution containing 5 mM CaCl2, 150 mM NaCl, 10 mM MES, pH 6.6, and α-mannose IA at an 
enzyme:protein ratio of 1:8 (w:w). The mixture was placed in a dialysis bag, and kept in a 2 L 
dialysis bottle containing the reaction buffer. The reaction was conducted at room temperature, 
covered with aluminum foil, at a constant moderate stir rate. The dialysis buffer was exchanged 
once every 24 hr for 4 days. The expected and observed masses for Man5 IgG4-Fc under reducing 
conditions are 26221.76 Da and 26220.2 Da, respectively (Fig. 1A). 
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2.6 In vitro enzymatic synthesis of GlcNAc1 IgG4-Fc. To obtain GlcNAc1 IgG4-Fc, 8 mg of HM 
IgG4-Fc in a volume of 31 mL 20 mM sodium phosphate, pH 7.1, were digested with 5 µL Endo 
H, and incubated at room temperature for approximate 18 hr. The completeness of the enzymatic 
reaction was monitored by HPLC-MS analysis. The enzymes, Endo H and B.t. α-1,2-mannosidase, 
were removed using protein A affinity chromatography, respectively. The expected and observed 
masses for GlcNAc1 IgG4-Fc under reducing conditions are 25207.88 Da and 25207.7 Da, 
respectively (Fig. 1A). 
 
2.7 Mutagenesis, production and purification of N297Q IgG4-Fc. A forward primer, 5’-
CGGGAGGAGCAGTTCCAGAGCACGTACCGTGTG-3’, and a reversed primer, 3’-
GCCCTCCT CG TCAAGGTCTCGTGCATGGCACAC-5’, were designed to produce the non-
glycosylated N297Q IgG4-Fc. The site-directed mutation was achieved with a QuikChange 
Lightening Site-Directed Mutagenesis Kit (Agilent Technologies, Inc., Santa Clara, CA). The 
mutated N297Q IgG4-Fc cDNA–transformed colonies were screened with low salt broth (LB) 
plate (1% tryptone, 0.5% NaCl, 0.5% yeast extract, and 1.5% agar) containing 25 µg/mL zeocin, 
inoculated in 6 mL LB media, and grown at 37 °C for 12 hr with shaking. The plasmids were then 
extracted with a miniprep kit (QIAGEN, Valencia, CA), sequenced by the University of California 
Berkeley DNA Sequencing Facility (Berkeley, CA) with 100% accuracy, and linearized with the 
SacI-HF (NEB Biolab, Ipswich, MA). The linearized plasmids were then transferred to an 
och1/pno1/bmt1/bmt2 deleted and STT3D added Pichia pastoris yeast strain. The successfully 
N297Q-IgG4-Fc cDNA-transformed yeast colony, selected by tolerance to 100 µg/mL zeocin 
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containing YPD plate, was inoculated in a 2 mL YPD culture with 100 µg/mL zeocin and grown 
at 27 °C for 72 hr with shaking, followed by transfer to a 50-mL flask containing 100 µg/mL zeocin, 
and grown at 27 °C for 72 hr with shaking. The 50 mL yeast cells were then scaled up to a 1 L 
spinner flask, containing buffered glycerol-complex media(37) (1% yeast extract, 2% peptone, 2% 
glycerol, 0.34% of yeast nitrogen base and 1% ammonium sulfate, 4 x10-5% biotin, and 100 mM 
potassium phosphate, pH 6.0), with a constant flow of air and stirring, followed by growth at room 
temperature. After 72 hr, the expression of N297Q IgG4-Fc was induced by the addition of 1% 
(v/v) MeOH every 24 hr for three times before harvesting the cells. N297Q IgG4-Fc was purified 
in the same manner as WT IgG4-Fc. 
 
2.8 Characterization of IgG4-Fc with intact protein HPLC-MS and sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE). The initial characterization of the four 
glycoforms of IgG4-Fc was evaluated by LC-MS analysis of the intact protein under reducing 
conditions. A volume of 90 µL of 0.22 mg/mL IgG4-Fc protein solution, after reduction with 10 
mM DTT for 5 min at room temperature, was loaded onto a C4 column (50 mm, 4.6 mm i.d.; 300-
Å pore size, 5 µm particle size, Vydac 214 MS, Grace, Deerfield, IL), coupled to an Agilent 1200 
series LC system (Agilent Technologies, Santa Clara, CA). The analytes were eluted by a linear 
gradient, changing mobile phase B (99.9% acetonitrile, 0.08% formic acid, and 0.02% 
trifluoroacetic acid) from 5 to 90% within 7 min.  Mobile phase A was 99.9% H2O, 0.08 % formic 
acid, and 0.02 % trifluoroacetic acid. The IgG4-Fc was ionized in an electrospray ionization (ESI) 
source, and analyzed in the positive mode by an Agilent 6520 Quadrupole Time-of- Flight mass 
	 201	
spectrometer (Agilent Technologies, Santa Clara, CA). A scan rate of 1 scan/second and a 
mass/charge (m/z) range of m/z 300 to m/z 3000 were applied. The acquired raw file was extracted 
and deconvoluted by the Agilent MassHunter Qualitative Analysis software to obtain the 
molecular weight and relative intensities of different IgG4-Fc species (Fig. 1A).  
  
SDS-PAGE analysis was conducted under reducing and non-reducing conditions. For non-
reducing conditions, 20 µL of 0.2 mg/mL IgG4-Fc in 20 mM sodium phosphate were mixed with 
Laemmli sample buffer (containing 20-35% of glycerol and 1-2.5% of SDS, BIO-RAD, Richmond, 
CA) at a 1:1 (v:v) ratio, followed by loading onto a 4% -20% gradient PAGE gel (Mini-PROTEAN 
TGXTM Gels, BIO-RAD, Richmond, CA). For reducing conditions, an additional 1.5 µL of 2-
mercaptoethanol (14.3 M) were added to the protein solution, followed by boiling for 5 min to 
achieve full reduction. The gel was run at 200 volts until the front dye reached the bottom. A 
typical stain with 0.25% Coomassie Brilliant Blue and destain with 30% methanol, 10% acetic 
acid, 60% water was applied until the bands became clear (Fig. 1B).  
 
2.9 Peptide mapping. Aliquots of 500 µL at 0.22 mg/mL of photo-irradiated and controlled IgG4-
Fc were denatured with 3 M GdnHCl, reduced with 5 mM DTT, and alkylated with 20 mM IAA in 
50 mM NH4HCO3. The reduction and alkylation was conducted at 37 °C for 1 hr, respectively, in 
the presence of GdnHCl. Excess amounts of reducing and alkylating agents were removed with 
Amicon Utra Centrifugal Filter Units with 10 kDa cutoff by centrifugation at 16,900 g for 10 min. 
The protein solution was collected by reverse flip of the filter and centrifugation at 300 g for 4 min. 
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Peptides were obtained by digestion with GluC (Promega Corporation, Madison, WI) at a w:w 
ratio of 10:1 (protein:enzyme) at 37 °C for 6 hr. The obtained peptides were analyzed by HPLC-
MS/MS.  
 
2.10 HPLC-MS/MS analysis. An aliquot of 4 µL of GluC-digested IgG4-Fc was injected onto a 
nanoAcquity ultra performance liquid chromatography (UPLC) system (Waters Corporation, 
Milford, MA) coupled to a Xevo-G2 mass spectrometer (Waters Cooperation, Milford, MA), 
equipped with an electrospray ionization source (ESI). The injected peptides were initially loaded 
onto a C18 trap column (nanoACQUITY UPLC 2G-V/M Trap 5 µm Symmetry C18 180 µm x 
20mm, Waters, Milford, MA), and desalted for 3 min isocratically with 97% of mobile phase A 
(0.1% formic acid in water) and 3% of mobile phase B (0.1% formic acid in acetonitrile) at a flow 
rate of 4 µL/min. The peptides were eluted to and fractionated on an analytical C18 column 
(ACQUITY UPLC Peptide CSH C18 NANOACQUITY column 10K psi, 1.7 µm, 75 µm x 250 
mm, Waters, Milford, MA) with a linear gradient of mobile phase B changing from 3% to 35% 
within 50 minutes at a flow rate of 300 nL/min, followed by a linear gradient changing mobile 
phase B from 35% to 95% between 50 and 70 min. The column was susequently washed with 95% 
mobile phase B for 10 min before re-equilibration with 97% of mobile phase A. The analytes were 
ionized by ESI, and analyzed in the positive mode with an m/z range of 200-2000 at a scan rate of 
1 scan/second. The fragment ions were collected in the MSE mode after collision-induced 
dissociation (CID).  
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2.11 Photo-degradation. Photoirradiation was conducted in a UV irradiator (RayonetÒ, The 
Southern New England Ultraviolet Company, Branford, CT), equipped with 4 lamps (RayonetÒ, 
catalog# RPR-3000A) emitting continuous wavelengths between 265 nm and 340 nm, with a 
maximum emission at λmax = 305 nm. We used the ferrioxalate actinometer(38, 39) to quantify the 
photon flux to 1.87x10-8 Eistein/s. Aliquots of 500 µL of IgG4-Fc (HM, Man5, GlcNAc1, and 
N297Q at 0.22 mg/mL, pH 7.1) in 20 mM sodium phosphate were placed in Pyrex tubes, and 
capped with rubber stoppers. Pyrex tubes have a wavelength cutoff of 295 nm. The 
photoirradiation was conducted for 30 min at RT. These photo-irradiation conditions ensured that 
our samples were exposed to light intensities of < 20 Whr/m2, i.e., <10% of the minimum light 
exposure (200 Whr/m2) advised by the ICH Q1B guideline for UV photostability testing(40). 
Control samples were placed in the dark at RT. Two independent experiments were conducted.  
 
2.12 Differential scanning calorimetry (DSC). The thermal stability of the four IgG4-Fc 
glycoforms was evaluated using a MicroCal VP-capillary calorimeter (Malvern, UK). A volume 
of 400 µL of 0.22 mg/mL IgG4-Fc was placed in a 96-well plate at 5 °C, sealed with a plastic cover. 
Thermograms were obtained within a temperature of 10°C-90°C at a scan rate of 1°C/min with a 
filtering period of 16 s. The built-in Origin software (Origin Lab, Malvern, UK) was utilized for 
the analysis of the raw thermograms after the processing of buffer subtraction, baseline correction 
and concentration normalization. Tm values were then derived from the processed thermograms by 
a fit to a non-two-state equilibrium model(41).  
 
	 204	
2.13 Intrinsic fluorescence. The intrinsic fluorescence of the four IgG4-Fc glycoforms was 
measured by excitation with a dye laser emitting from 280 nm to 300 nm, a temperature-controlled 
fluorescence plate reader, and a charge coupled device detector (Fluorescence Innovations, Inc., 
Minneapolis, MN). The fluorescence was examined within a temperature range between 10°C and 
90°C at an increment rate of 2.5 °C/step. A volume of 20 µL containing 0.22 mg/mL IgG4-Fc was 
applied to a 384 well plate, followed by loading 2 µL silicon oil on top of the protein solution to 
minimize sample evaporation. The excitation was conducted at 295 nm, and the emission spectra 
were collected between 300 nm and 400 nm. The fluorescence center of mass, defined as moment, 
was calculated as follows, using the ThermoSpec software (Fluorescence Innovations, Inc.): 
Moment = E F FGF
E F GF
 
where x is the wavelength, and I(x) is the intensity. The fluorescence moment was plotted as a 
function of temperature, and Tm values were derived from the 1st derivative of the plot.  
 
2.14 Biolayer interferometry (BLI) binding assays. Binding affinities of the four IgG4-Fc to 
FcγRIIIA were evaluated by BLI using a BLItz system (ForteBio, Menlo Park, CA) via 
immobilizing biotinylated FcγRIIIA to a streptavidin tip (SA; ForteBio, Menlo Park, CA). The 
biotinylated FcɣRIIIA (Val158) was prepared as described(13). IgG4-Fc was dialyzed into 2 L PBS 
buffer (39.3 mM Na2HPO4, 150 mM NaCl, and 10.65 mM NaH2PO4, pH 7.4) at 4 °C. The dialysis 
buffer was exchanged once after 12 hr. PBS kinetic buffer, containing 1 mg/mL BSA (VWR 
Chemicals, Solon, Ohio) in PBS, was prepared. After dialysis, IgG4-Fc was mixed with 10 mg/mL 
BSA (prepared in PBS buffer) at a ratio of 9:1 (v:v) to obtain a protein mixture in 1 mg/mL BSA 
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in PBS buffer, pH 7.4, to minimize non-specific binding. A series of five concentrations were 
applied for each IgG4-Fc glycoforms. For HM, a series of 0.2 µM, 0.4 µM, 0.8 µM, 1.6 µM, and 
3.2 µM was applied. For Man5, a series of 0.0478 µM, 0.0958	µM, 0.192	µM, 0.383 µM, and 0.766	
µM was applied. For GlcNAc1, a series of 2.7 µM, 3.28 µM, 5.4 µM, 6.57 µM and 13.14 µM was 
applied. For N297Q, two concentrations, 11.35 µM and 16.27 µM, were applied.  
 
The SA tip was prepared by hydration in PBS for 10 min, followed by hydration in PBS kinetic 
buffer for 30 min. The SA tip was then loaded onto the BLItz system. For FcγRIIIA loading, a 30 
s of baseline was first established with 250 µL of PBS kinetic buffer. In the 3-min receptor loading 
step, 0.02 µM of FcγRIIIA in PBS kinetic buffer was loaded until the response level reaches 0.4 
Δnm. BLI measures the interaction of proteins at the surface of the SA tips (equipped with 
biosensors), which results in a shift of light wavelength (Δnm), referred to as light interference. 
After the response level reached Δnm= 0.4, the FcγRIIIA solution was exchanged with a PBS 
kinetic buffer. In the 3-min dissociation step, the tips were dipped into PBS kinetic buffer. For 
collection of a blank, tips were dipped into 250 µL PBS kinetic buffer in all three binding steps, 
including 30 s of baseline collection, 180 s of association and 180 s of dissociation. For sample 
analysis, in the 30-s baseline step, tips were dipped into PBS kinetic buffer, then in the 3-min 
association step the sample was loaded at various concentrations, and finally the tips were dipped 
into PBS kinetic buffer in the 3-min dissociation step. For each IgG4-Fc variant, the samples were 
loaded from the lowest to the highest concentrations. Between each sample run, a regeneration 
step was applied through washing with 1 mM NaOH for 30 s, followed by washing with PBS 
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kinetic buffer for 2 min. A minimum of two independent replicates were conducted. The tip was 
replaced between each replicate.  
 
The association sensorgrams of IgG4-Fc and FcγRIIIA cannot be fit by mono-exponential 
kinetics(42-45) (Fig. S1). Instead, a model based on two separate association equilibria (Reactions 
1 and 2), a fast and a slow one, led to excellent kinetic fits. Here, L1 and L2 represent two variants 
within a heterogeneous population of FcγRIIIA(46, 47), P represents IgG4-Fc, k1 and k2 represent 
the kon values for Reactions 1 and 2, respectively, and k-1 and k-2 represent the koff values for 




Kinetically, the reactions are of pseudo first order due to the excess quantity of P (IgG4-Fc). The 
following equations were used for the kinetic fits.  
[L1P] + [L2P] = [L1P]∞(1-exp(-(k1[P0]+ k-1)t) + [L2P]∞(1-exp(-(k2[P0]+ k-2)t) (1) 
y = A(1-exp(-Bx)) + C(1-exp(-Dx)) (2) 
where in equation 1, [L1P] and [L2P] are the concentrations of complex L1P and L2P at time t as 
dependent variables, respectively. [P0] is the initial and constant concentration of P, based on [P] 
»[L]. [L1P]∞ and [L2P]∞ are the concentrations of L1P and L2P at infinite reaction time. A two-
exponential association fit was applied using XL fit analysis (IDBS, Boston, MA) as displayed in 
equation 2, where A =[L1P]∞; B = k1[P0]+k-1; C=[L2P]∞; D = k2[P0]+k-2. The values for B and D 
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were constrained to be  ≥ 0. The fitting parameters B and D correspond to kobs of the fast and the 
slow phase, respectively.  Linear plots of kobs as a function of the concentration of [P0] were 
obtained, where the slopes represent kon (M-1s-1) (k1 or k2), and the intercepts represents koff (s-1) 
(k-1 or k-2). The kon and koff values derived from the fast phase are consistent with previously 
reported binding affinities between Fc and FcγRIII(5, 6, 13). Hence, in the present work, we focus 
mainly on the kinetic parameters derived from the fast phase. The kon and koff  from the slow phase 
were derived for HM and Man5 IgG4-Fc.  
 
3. Results. The physicochemical stability of the four IgG4-Fc variants (0.22 mg/mL) was analyzed 
in 20 mM sodium phosphate, pH 7.1, while binding assays were performed in PBS, pH 7.4.  
3.1 Initial characterization of HM, Man5, GlcNAc1, and N297Q IgG4-Fc. HM, Man5 and 
GlcNAc1-IgG4-Fc were derived from the same batch of a 10 L-fermenter production. N297Q was 
expressed in 1L-scale spinner flasks. To ensure that the three glycosylated IgG4-Fc variants and 
the non-glycosylated IgG4-Fc were of adequate quality, an initial characterization with HPLC-MS 
and SDS-PAGE analysis was performed (Fig. 1). In the reducing gel (Fig. 1B, right panel), single 
bands of HM, Man5, GlcNAc1, and N297Q were observed, migrating between 25 kD and 37 kD, 
indicating that the four IgG4-Fc variants were obtained with good purity. In the non-reducing gel 
(Fig. 1B, left panel), HM displays two bands, and a reduced mobility compared to Man5, GlcNAc1 
and N297Q. The differential mobility in both the reducing and non-reducing gels results from the 
differences of glycan mass and branching associated with each IgG4-Fc form. The two bands, 
predominantly observed for HM in the non-reducing gel, are consistent with both intra- and inter-
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chain disulfide bonds in the hinge region, where intra-chain disulfide band formation leads to 
dissociation of an IgG4-Fc dimer. The intra- and inter-chain disulfides were quantified by 
densitometry analysis with Image J (National Institutes of Health, Washington D.C., US). Here, 
inter-chain disulfides account for 50.6% for HM, 70.5% for Man5, 67.4% for GlcNAc1, and 80.3% 
for N297Q IgG4-Fc. In turn, intra-chain disulfides are present at 49.4% for HM, 29.5% for Man5, 
32.6% for GlcNAc1 and 19.7% for N297Q IgG4-Fc.  
 
Intact protein HPLC-MS was applied to analyze the homogeneity of the glycoforms of HM, Man5 
and GlcNAc1 IgG4-Fc (Fig. 1A). The signal intensities of glycosylated and nonglycosylated forms 
were recorded utilizing MassHunter Qualitative Analysis. The homogeneity of HM was calculated 
as the sum of intensity of Man8 to Man12 forms divided by the sum of intensity of nonglycosylated 
and Man8 to Man12 forms. The homogeneity of GlcNAc1 was calculated as the intensity of 
GlcNAc1 form divided by the sum of nonglycosylated and GlcNAc1 forms. The homogeneity of 
Man5 was calculated as the intensity of Man5 form divided by the sum of intensity of 
nonglycosylated and Man5 to Man9 forms. HM, GlcNAc1 and Man5 presented a homogeneity of 
97.1%, 96.4%, and 86.7%, respectively. N297Q was obtained through site-directed mutation and 






















Fig. 1. Initial characterization of intact GlcNAc2Man(8+n) (n =0-4), GlcNAc2Man5, GlcNAc1, and 
N297Q IgG4-Fc with (A) MS under reducing conditions after treatment with DTT and (B) SDS-
PAGE under non-reducing (left) and reducing conditions (right).  
 
3.2 DSC. The overall conformational stability of the four IgG4-Fc glycoforms was evaluated by 
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DSC using a temperature ramp from 10 to 90°C with 1°C increments (Fig. 2). All of the four IgG4-
Fc variants display two thermal transitions, corresponding to the unfolding of the CH2 and CH3 
domains, respectively. Melting temperatures of the transitions, represented as Tm1 and Tm2, were 
derived and are listed in Table 1. Overall, the thermal stability of HM, Man5, and GlcNAc1 does 
not vary significantly, where Tm1 and Tm2 values show only small differences within 1°C. On the 
other hand, N297Q IgG4-Fc shows a reduction of approximate 3°C for Tm1 as compared to the 




























Fig. 2. Thermograms of HM, Man5, GlcNAc1, N297Q examined by DSC from 10°C to 90°C. 
Corresponding Tm values are displayed in Table 1, where Tm1 represents the melting temperature 
of the CH2 domain, and Tm2 represents the melting temperature of the CH3 domain.  
 
3.3. Intrinsic fluorescence. The tertiary structures of the four IgG4-Fc variants were evaluated by 
intrinsic fluorescence spectroscopy through excitation at 295 nm, and emission measurements 
between 300 nm and 400 nm. The fluorescence emission spectra of the four IgG4-Fc recorded at 
25°C (Fig. 3A) reveal a maximum fluorescence intensity at similar wavelengths, between 337 and 
340 nm. This suggests, that the four IgG4-Fc variants present similar tertiary structure. A 
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temperature ramp from 10 to 90 °C was applied to evaluate the thermal stability of the four IgG4-
Fc variants, and the fluorescence moment plotted as a function of temperature (Fig. 3B). The 
respective transition values Tm were derived and are listed in Table 1. These data suggest the 




































Fig. 3. Intrinsic fluorescence of HM, Man5, GlcNAc, and N297Q of IgG4-Fc, where (A) is the 
normalized fluorescence intensity (%) as a function of wavelength, (B) is fluorescence moment 
(nm) as a function of temperature (°C). Three independent experiments were performed.  
 
3.4 Photostability. The photostability of the four IgG4-Fc variants was evaluated by photo-
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irradiation at λmax = 305 nm for 30 min. The conversion of native peptides (%) into eleven photo-
products was quantified, and relative yields of the photoproducts are displayed in Fig. 4. These 
products include five peptide backbone cleavage products resulting from photo-induced Tyr side 
chain fragmentation(32), three Met sulfoxide products (MetSO), and three vinyl Cys products. 
Detailed information on the nature of the photoproducts is provided in Table 2.  
3.4.1 Formation of Tyr side chain fragmentation products. Two Tyr residues in IgG4-Fc, Tyr373 
and Tyr436, were monitored to quantify photo-induced tyrosine side chain fragmentation. The 
mechanism of such Tyr fragmentation was documented in a previous publication(32). In the 
presence of O2, the major degradation products are peptide backbone cleavage products (Table 2), 
including product 1 from Tyr373, and products 3, 4 and 5 from Tyr436. Product 2 (from Tyr373) is a 
secondary oxidation product, derived from Met oxidation of product 1. Products 1-5 were formed 
with higher relative yields in GlcNAc1 and N297Q IgG4-Fc, presenting more than 1.5- and 2-fold 
increase over the yields obtained from HM and Man5 IgG4-Fc, respectively. It appears, that the 
size of the glycans inversely correlates with the relative yields of products 1-5 (Fig. 4A and 4B).  
3.4.2 Formation of MetSO. IgG4-Fc contains three Met residues, Met252, Met358, and Met426. 
Their corresponding oxidation products, referred to as products 6, 7 and 8 (Fig. 4C), show an 
increase of yields in the following order: MetSO252> MetSO426> MetSO358. This trend is similar 
to observed trends for peroxide-treated IgG1 and photo-oxidized IgG2(48). The glycan structure 
does not significantly affect the yields of MetSO (products 6-8, Fig. 4C). 
3.4.3 Formation of Vinyl Cys Three Cys residues in IgG4-Fc, Cys321, Cys367, and Cys425, were 
monitored to quantify the yield of vinyl Cys formation. Their corresponding products are referred 
	 215	
to as products 9, 10, and 11 (Fig. 4D). Interestingly, their relative yields follow an opposite trend 
as compared to the yields of Tyr derived products, where HM shows the most efficient formation 
of vinyl Cys. The other IgG4-Fc variants, Man5, GlcNAc1, and N297Q, show approximate half the 
yields as compared to HM IgG4-Fc.  
 
 
Fig. 4. Conversion of native peptides resulting from Tyr (A and B), Met (C) and Cys (D) photo-
degradation. The photoirradiation was conducted at λmax= 305 nm for 30 min. Detailed peptide 
sequences information is presented in Table 2. Product yields from the four IgG4-Fc: HM, Man5, 




3.5 Binding of IgG4-Fc variants to FcγRIIIA. The effect of glycan structure at Asn297 in IgG4-
Fc on binding to FcγRIIIA(Val158) was evaluated using biolayer interferometry on a BLItz system. 
The equilibrium binding for HM, Man5, GlcNAc1, and N297Q IgG4-Fc is displayed in Fig. 5. The 
sensorgrams for the association between IgG4-Fc and FcγRIIIA are displayed in Fig. 6. All binding 
curves were well fit to bi-exponential kinetics, indicative of at least two separate association 
equilibria, potentially reflecting the glycan heterogeneity of FcγRIIIA (28, 29, 42, 45). For 
comparison, also the surface plasmon resonance data by Bruhns et al. (6) suggest more than one 
process in the interaction of FcgIIIA(Val158) with full length IgG4. In the two-exponential 
association model used for the kinetic fits (y = A(1-exp(-Bx)) + C(1-exp(-Dx))), B = kobs,1 = 
k1[P0]+ k-1 and  D = kobs, 2 = k2[P0]+k-2, as described in Section 2.13. Here, k1 and k2 represent 
the kon values for Reactions 1 and 2, respectively, and k-1 and k-2 represent the koff values for 
Reactions 1 and 2, respectively. This two-exponential association model leads to good quality 
curve fits (Fig. 6, in red) for HM, Man5, and GlcNAc1 IgG4-Fc (Fig. 6, experimental data in blue). 
No measurable binding to FcRgIIIA was observed for the non-glycosylated variant N297Q IgG4-
Fc (Fig. 5 and Fig. 6D). The values for kobs were plotted as a function of the concentration [P0], 
from where kon (M-1s-1) was derived from the slope, and the koff (s-1) was derived from the intercept. 
The plots for the fast phase are shown in Fig. 5, while the plots for the slow phase are shown in 
Fig. S2 (for the slow phase, linear plots were only obtained for HM and Man5 IgG4-Fc). The fitting 
parameters for the fast phase correspond more closely to the affinity between IgG4 and FcγRIIIA 
(6), and, therefore, we primarily compared the IgG4-Fc variants based on the kinetic parameters 
for the fast phase. Equilibrium dissociation KD constants were calculated as the ratio of koff over 
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kon. All values for kon, koff, and KD for HM, Man5, and GlcNAc1 IgG4-Fc are summarized in Table 
3.  
 
Man5 IgG4-Fc reveals a two-fold increase of kon compared to HM IgG4-Fc, resulting in a ca. two-
fold reduction of KD. The lower KD of Man5 indicates a ca. two-fold higher affinity to FcγRIIIA 
over HM IgG4-Fc. For GlcNAc1, kon reveals a 2- to 4-fold reduction compared to HM and Man5, 
while koff shows a 7.7-fold increase over HM and Man5 IgG4-Fc. Hence, GlcNAc1 presents a 14.7-
fold reduction of binding affinity to FcγRIIIA as compared to HM and Man5. For N297Q IgG4-Fc, 
the binding response merely reached Δnm = 0.03 at concentrations [P0] of 11.35 µM and 16.27 µM 
(Fig. 5 and 6). In addition, no reasonable curve fits were obtained, indicating no significant binding 





Fig. 5. Equilibrium dissociation constant, KD, obtained with non-linear regression, using equation equivalent to 
the Langmuir isotherm. Respective KD constants are displayed. Not applicable (NA) of N297Q indicates there 

















































































KD (HM) = 0.39 µM KD (Man5) = 0.54 µM
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Fig. 6. BLI sensorgrams of (A) HM (B) Man5 (C) GlcNAc1, and (D) N297Q IgG4-Fc, where the red line is curve 

















































































































































































































































4. Discussion.  
The aim of this work was to evaluate the effect of glycan structure (HM, Man5, GlcNAc1 and non-
glycosylated) at Asn297 IgG4-Fc on the physicochemical stability (pH 7.1, 20 mM sodium 
phosphate, 0.22 mg/mL), photostability, and receptor binding. The four IgG4-Fc variants were 
initially characterized by HPLC-MS, indicating that the glycoforms display > 95% (HM and 
GlcNAc1), 86% (Man5), and 100% (N297Q) homogeneity.  
 
The nature of these glycans was previously shown to affect IgG1-Fc conformation, which is 
essential for mAb stability, safety and efficacy (11). A similar effect of glycans was observed here 
on the thermal stability of IgG4-Fc. Based on the values for Tm1 derived by DSC, HM, Man5 and 
GlcNAc1 IgG4-Fc display similar thermal stability, while N297Q IgG4-Fc shows lower thermal 
stability (Table 1). The Tm1 value, corresponding to the melting temperature of the CH2 domain, 
is a measure of conformational stability, involving the unfolding of CH2 domains, CH2 glycan 
contacts, and CH2/CH3 inter-domain interactions (49). The decreased Tm1 value of N297Q can, 
therefore, be attributed to the lack of a glycan, which prevents glycan-glycan or glycan-protein 
interactions (50). For all four IgG4-Fc variants, more than two thermal transitions were observed 
by DSC (Fig. 1). Interestingly, a previous report showed that homogeneous G0 and G2 glycoforms 
of IgG4-Fc reveal only one thermal transition with a melting temperature of 64°C(51). It was also 
reported that deglycosylated IgG4-Fc reveals two transitions, where Tm1= 60 °C, and Tm2= 
68 °C(51). In this work, the DSC thermograms of IgG4-Fc with different truncated glycans present 
a similar phenomenon: two thermal transitions are resolved better for the smaller sized glycans 
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(Fig. 1). All four IgG4-Fc variants reveal a 10°C reduction of Tm2 as compared to IgG1-Fc, where 
the Tm2 of IgG4-Fc is approximately 70°C while the Tm2 of IgG1-Fc is approximately 78 -80°C, 
reported elsewhere(11). This difference can be attributed to the weakened hydrophobic interactions 
between the CH3 domains in IgG4-Fc homodimers compared to IgG1-Fc (22, 24).  
 
During the process of pharmaceutical development, light exposure needs to be strictly controlled, 
due to the fact that mAb-based therapeutics are prone to photo-degradation(52, 53) (54, 55). Upon 
exposure to UV light, photo-sensitive amino acids (Tyr, Trp, Cys, cystine, and Phe) can directly 
absorb light leading to several pathways of photo-transformation(52). Upon exposure to visible 
light, proteins are potentially damaged by reactive oxygen species(54, 56). Here, we investigated 
the effects of glycan structure on IgG4-Fc photo-stability during photo-irradiation at λmax =305 nm 
(between 295 nm and 340 nm). The relative yields of photo-degradation products resulting from 
Tyr (Tyr373 and Tyr436), Met (Met252, Met358, and Met426), and Cys (Cys321, Cys367, and Cys425) were 
quantified. 
 
We previously discovered and characterized a photo-induced Tyr side chain fragmentation, 
initiated by electron transfer from Tyr to an intermediary Trp radical cation (Trp+.)(32). The 
distance between Tyr and Trp can affect the efficiency of photo-induced Tyr side chain 
fragmentation(32). Products 1-5, resulting from photo-induced Tyr side chain fragmentation reveal 
relatively higher yields in IgG4-Fc with smaller sizes of Asn297 glycans (e.g., in N297Q and 
GlcNAc1). The smaller size glycans may allow for a more dynamic protein conformation (57) 
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resulting a closer approach between Tyr and Trp+.. 
 
FcγRIIIA is the most important Fc receptor for natural killer cells since it is the only one present 
for ca. 80% of people(58, 59). In addition, binding affinities between IgGs and FcγRIIIA depend 
on the patterns of Asn297 glycans in IgGs (27, 60). Therefore, FcγRIIIA was selected in the present 
work. We utilized biotinylated FcγRIIIA (Val158) and streptavidin (SA) to immobilize FcγRIIIA on 
SA biosensor tips(13), to measure its affinities to the IgG4-Fc variants. The association rate of 
Man5 IgG4-Fc (2.60 x 105 M-1s-1) reveals a somewhat higher kon value compared to HM (1.24 x 
105 M-1s-1), and both present rather similar koff values. The truncated GlcNAc1 glycoform revealed 
an approximate two-fold reduction of kon, and a seven-fold increase of koff, as compared to Man5 
and HM. N297Q does not reveal any significant binding to FcgRIIIA at the highest concentration 
tested (16 µM). The reduction of N297 glycan size in IgG4-Fc has a smaller effect on kon but a 
larger effect on koff. The effect of glycan nature on IgG4-Fc affinities to FcγRIIIA is similar to that 
reported for similar glycoforms of IgG1-Fc in that both HM and Man5 glycoforms bind tightly, the 
GlcNAc1 glycoform retains weak affinity, and the non-glycosylated IgG4-Fc mutant does not show 
significant affinity (13).   
 
The equilibrium constant (KD) between a serum-derived IgG4 and FcγRIIIA was reported to be ca. 
4 µM (6). This KD value was obtained via analysis of the binding response at equilibrium as a 
function of protein concentration, where the corresponding steady-state KD can be derived (6). For 
comparison, we applied a similar analysis of our data, rendering steady-state KD values of 0.39 
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µM, 0.54 µM, and 25.76 µM for HM, Man5 and GlcNAc1, respectively (Fig. S3). The KD of HM 
and Man5 IgG4-Fc reveal a 10- and 8-fold reduction as compared to the serum-derived IgG4, 
suggesting an 8-10-fold increase of the affinities to FcγRIIIA. These increased affinities of our 
IgG4-Fc glycoforms can be rationalized by the absence of fucose in the high mannose glycoforms 
tested in this study and the likelihood of high levels of core-linked fucose in serum derived IgG4 
(60-62). As mentioned previously, fucosylation of IgG1-Fc and differential glycosylation of N162 
of FcγRIIIA has proven to modulate the interactions between the two proteins (60-62). Given that 
the dissociation constants measured in this study for HM and Man5 IgG4-Fc, 0.39 and 0.54 µM 
respectively, are similar to dissociation constants that have been measured for fucosylated IgG1 
Fc glycoforms (ranging from 0.095-0.5 µM)(6, 27) high mannose IgG4 glycoforms may elicit 
ADCC similar to fucosylated IgG1. Based on this, in addition to monitoring levels of afucosylated 
IgG4 (63), it would be prudent to monitor levels of high mannose IgG4 glycoforms as well for 
IgG4 based mAb therapeutics. 
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Table 1. Tm values of HM, Man5, GlcNAc1, and N297Q IgG4-Fc from DSC and intrinsic 
fluorescence analysis. The average Tm and the range from two independent measurements are 
presented. 
  
 Tm1 (°C) (DSC) Tm2 (°C) (DSC) Tm (°C) (Fluorescence) 
HM 64.5 ± 0.0071	 71.7 ± 0.11 61.97 ± 0.14 
Man5 65.3 ± 0.25 71.3 ± 0.099 62.69 ± 0.16 
GlcNAc1 64.6 ± 0.014 70.8 ± 0.078 61.24 ± 0.23 















Table 2. A list of eleven photoproducts were identified and quantified from photoirradiation of HM, 
Man5, GlcNAc1, and N297Q IgG4-Fc at λmax = 305 nm for 30 min. Corresponding product 
sequences and modified residues are listed.   






Product Photoproducts Position m/z z 
1 MTKNQVSLTC(+57)LVKGF-NH2 Tyr373 575.61 3 
2 M(+16)TKNQVSLTC(+57)LVKGF-NH2 Tyr373 580.96 3 
3         TQKSLSLSLGK Tyr436 609.30 2 
4 [         TQKSLSLSLGK]+18 Tyr436 618.30 2 
5 TQKSLSLSLGK Tyr436 387.89 3 
6 FLGGPSVFLFPPKPKDTLM(+16)ISRTPE Met252 698.38 4 
7 M(+16)TKNQVSLTC(+57)LVKGFYPSDI
AVE 
Met358 872.76 3 
8  GNVFSC(+57)SVM(+16)HE Met426 641.75 2 
9 YKC(+55)KVSNKGLPSSIE a Cys321 569.96 3 
10 MTKNQVSLTC(+55)LVKGFYPSDIAVE Cys367 866.76 3 
11 GNVFSC(+55)SVMHE Cys425 632.75 2 
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Table 3. Binding parameters, kon, koff and KD of HM, Man5, GlcNAc1, and N297Q IgG4-Fc, 
representative of binding affinities to FcγRIIIA. kon, koff and KD (kinetic) were obtained from 
kinetic binding analysis. KD (kinetic) was obtained from the ratio of koff to kon. KD (equilibrium) 
was obtained from equilibrium binding analysis with non-linear regression fit. These data are 
averaged from 2 or 3 independent measurements. 




HM (1.24±0.3) x105   0.207 ± 0.052	 1.66 0.39 
Man5 (2.60±0.9) x105 0.177 ± 0.035 0.68 0.54 
GlcNAc1 (6.30±3) x104 1.546 ± 0.238 24.52 25.76 


















Fig. S1. Binding analysis of IgG4-Fc glycoforms and FcγRIIIA. Fitted curve is displayed in black 
with corresponding glycoform structure (A) HM-IgG4-Fc (B) Man5-IgG4-Fc (C) GlcNAc1 IgG4-














Fig. S2. Plots of kobs of the slow phase as a function of [P0] for HM and Man5 IgG4-Fc. The error 
bars represent the standard error from two or three independent measurements. GlcNAc1 IgG4-Fc 
is not displayed due to the lack of linear relationship between kobs and protein concentration. 

























































Antibody-drug conjugates (ADCs) are rapidly evolving due to their high potency and specificity. 
So far, two ADCs have been marketed in the US and approximately 60 ADCs are in the clinical 
development1. ADCs refer to the chemical conjugation of a humanized antibody to small cytotoxic 
molecules (e.g., antimitotic agents) through a chemical linker. Thus, ADCs combine the specificity 
of an antibody for its target antigen and the potency of a small molecule drug2. In ADCs, the 
antibody reacts as a cell-targeting molecule and its conjugation with cytotoxic drugs, enabling the 
selective delivery of the toxic agents, leading to death of the targeted cells.  
 
The selection of the linker chemistry is critical for the successful development of ADCs. An 
optimal linker needs to meet the potential criteria as follows1. First, the linker needs to present 
sufficient stability before reaching target cells. Second, the linker is readily to be cleaved after 
endocytosis. Third, the linker should not induce instability of the conjugated molecule. 
Conjugation is typically achieved via two major methods, e.g., chemical and enzymatic 
conjugation, where chemical conjugation potentially involves coupling with Lys amine or Cys 
thiol. Overall, Cys-based conjugation is superior to Lys attributed to Cys low abundance in proteins, 
leading to more controlled drug-to-antibody ratio (DAR)3, reduced heterogeneity, high efficacy 
and improved therapeutic window4. The most common approach of Cys coupling is to utilize 
maleimide-based conjugation, e.g., in brentuximab vedotin, an FDA approved ADC5, where such 
process requires reduction and re-oxidation of disulfides. These processes normally introduce 
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difficulties to control the extent of the reactions and lead to undesired polymerization6. For 
example, the partial reduction process may result in the loss of the light chain, imparing binding 
affinity of mAbs to antigens, and additionally lead to reduced stability7. Therefore, in this work, a 
specific chemical modification at the N-terminal Cys of an IgG4-Fc was investigated via reaction 
with acetonitrile, which results in a cyclic product at the N-terminus of the IgG4-Fc. An Fc domain 
was utilized due to its simplicity for deriving reactions, as compared to a full IgG. Conjugation to 
an Fc fragment prolongs the half-life of the conjugated molecule8, and potentially improves 
solubility and stability of the partner molecule in vivo and in vitro9. The IgG4-Fc was expressed 
from yeast strain Pichia pastoris, presenting predominantly high mannose (HM) glycoforms at 
Asn297 containing GlcNAc2Man(8+n) (n = 0-4). 
 
5.2 Experimental section. 
5.2.1 Materials. 
GluC was purchased from Promega Corporation (Madison, WI). Iodoacetamide (IAA), iodoacetic 
acid (IAC), ammonium bicarbonate, tris (2-carboxyethyl)phosphine hydrochloride (TCEP), 4-
cyano-1-butyn (HCCCH2CH2CN) and guanidine hydrochloride (GdnHCl) were bought from 
Sigma-Aldrich (Saint Louis, MO). Bis(2-mercaptoethyl)sulfone (BMS) was purchased from EMD 
Millipore Corp. (Billerica, MA). Acetonitrile (CH3CN) was bought from Fisher (Fair Lawn, NJ). 




5.2.2 Reaction of acetonitrile with intact WT IgG4-Fc under reducing conditions. 
An aliquot of 150 µL of IgG4-Fc (0.2 mg/mL) in 20 mM sodium phosphate, pH 7.0, was mixed 
with 8 µL of 100 mM BMS (dissolved in CH3CN). 100 mM BMS was prepared by dissolving 93.1 
mg of BMS in 5 mL of CH3CN. The mixture was incubated at 37°C for different time points: 1 hr, 
2 hr, 3 hr, 6 hr, 12 hr, and 24 hr. At each time point, the reaction mixtures were collected and stored 
at -80°C for future analysis. 
 
5.2.3 Reaction of 4-cyano-1-butyne (HCCCH2CH2CN) and intact N297Q IgG4-Fc under 
reducing conditions. 
An aliquot of 150 µL of N297Q IgG4-Fc (0.2 mg/mL) in 20 mM sodium phosphate, pH 7.0, was 
mixed with 4 µL of 200 mM tris (2-carboxyethyl)phosphine hydrochloride (TCEP) and 8 uL of 
HCCCH2CH2CN. 200 mM TCEP was prepared by dissolving 57.3 mg of TCEP in 1 mL of sodium 
phosphate, pH 7.0. The mixture was incubated at 37°C for 90 min, followed by analyzed with 
HPLC-MS.  
 
5.2.4 HPLC-MS of intact IgG4-Fc 
Wild type and nonglycoform N297Q IgG4-Fc were prepared in the same manner as described in 
Sections 2.2.2 and 2.2.4 in Chapter 2. The reaction mixtures of IgG4-Fc (0.2 mg/mL in 20 mM 
sodium phosphate, pH 7.5) and acetonitrile in the presence of reducing agents were collected at 
different time points and analyzed on an HPLC-MS system. Aliquots of 95 µL of the reaction 
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mixtures were injected onto a C4 column (50 mm, 4.6 mm i.d.; 300-Å pore size, 5 um particle size, 
Vydac 214 MS, Grace, Deerfield, IL) operated by an HPLC system coupled with ESI-MS. The 
analysis was performed in the same way as described Section 3.2.5 in Chapter 3.  
 
5.2.5 Peptide mapping of IgG4-Fc.  
An aliquot of 250 µL IgG4-Fc in 20 mM sodium phosphate (pH 7.0) was denatured and reduced 
by addition of 250 µL 6 M GdnHCl and 25 µL of 100 mM BMS, followed by incubation at 37°C 
for 1 hr. 6 M GdnHCl was prepared by dissolving 5.73 g in 10 mL of 50 mM ammonium 
bicarbonate. 100 mM BMS was prepared by dissolving 93.1 mg of BMS in 5 mL of CH3CN or 
CD3CN. After reduction, 41.6 µL of 500 mM IAA (in NH4HCO3) were added, and the protein 
solution was incubated at 37°C for 1hr. Excess quantities of GdnHCl, BMS and IAA were 
exchanged to 5 mM NH4HCO3 through a 10 kDa filter unit (Amicon, Ultra Centrifugal Filter, 
County Cork, Ireland) via centrifugation at 16,900 g for 15 min at 4°C. The protein solution was 
reverse-flip collected via centrifugation at 300g for 4 min at 4°C. The collected IgG4-Fc (ca. 50 
µg) was digested with 5 µg of GluC for 6 hr. GluC was prepared by dissolving in 5 mM NH4HCO3 
at 0.2 mg/mL. Two shots of GluC were applied, with 12.5 µL in each shot, and added at 0 hr and 
3 hr, respectively. The GluC-digested peptides were analysed by HPLC-MS/MS. 
 




5.3.1 Identification of an N-terminal peptide derivative resulting from reaction with 
acetonitrile.  
IgG4-Fc was reduced with BMS (dissolved in acetonitrile), alkylated with IAA, digested with 
GluC, and analyzed by HPLC-MS/MS. A new peak with an m/z value of 884.34 (z=1) was 
observed. The MS/MS spectrum of this peak is displayed in Fig. 1, bottom. The presence of a 
series of b ions, including b2, b3, b4 and b6, indicates that the N-terminal Cys reveals a mass 
addition of 24 Da. Overall, the peak was identified as an N-terminal peptide derivative with the 
following sequence: C225(+24)PSC228(+57)PAPE, where +24 indicates that Cys225 is modified, +57 
indicates that Cys228 is alkylated by IAA. The product is proposed to result from the reaction of 
the N-terminal Cys with acetonitrile, which was utilized to dissolve the reducing agent, BMS. 
Therefore, a deuterium-labeled acetonitrile (CD3CN) was subsequently applied. The MS/MS 
spectrum of the product from CD3CN corresponds to C225(+27)PSC228(+57)PAPE, indicating that 
the product results from reaction with acetonitrile, and that the three hydrogens in acetonitrile are 
all incorporated in the product at the N-terminal Cys residue, revealed by the mass addition of 27 
Da at Cys225. 
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Fig. 1. MS/MS identification of N-terminal cyclic product, top: C(+27)PSC(+57)PAPE, formed in 













5.3.2 Characterization of reaction of intact IgG4-Fc with acetonitrile: identification of 
reaction intermediates, products and effect of incubation time 
To further characterize the reaction of IgG4-Fc and acetonitrile, 150 µL HM IgG4-Fc (0.2 mg/mL, 
pH 7.1) was incubated with 8 µL acetonitrile under reducing conditions at 37°C for different times, 
e.g., 1 hr, 2 hr, 3 hr, 6 hr, 12 hr, and 24 hr. At each time point, the solution was collected and 
subsequently analyzed by HPLC-MS, where the de-convoluted mass spectra are shown in Fig. 2. 
The top two abundant species of IgG4-Fc, GlcNAc2Man8 IgG4-Fc (theoretical mass: 26708.6 Da) 
and GlcNAc2Man9 IgG4-Fc (theoretical mass: 26870.16 Da) were monitored for potential 
chemical modifications, displayed in Fig. 2. After 1 hr incubation, two new peaks were observed, 
derived from native GlcNAc2Man8 IgG4-Fc (experimental mass: 26708.2 Da) (Fig. 2A), revealing 
the mass addition of 24 Da and 41 Da, referred to as peak 1 and peak 2, respectively. The mass of 
peak 1 is consistent with the modification at N-terminal Cys225, as described in Section 5.3.1. We 
propose that peak 2 corresponds to a potential intermediate. A reaction scheme will be discussed 
in Section 5.4.1. Meanwhile, similar products were observed for GlcNAc2Man9 IgG4-Fc, referred 
to as peak 1’ and peak 2’ (Fig. 2A). Approximately 30% of non-modified IgG4-Fc is present after 
1 hr incubation (Fig. 2A). After 2 hr (Fig. 2B) and 3 hr (Fig. 2C) incubation, the quantity of native 
proteins decreased significantly, yielding higher intensities of peak 1, 2, 1’ and 2’ (Fig. 2B). It 
needs to be noted that there is not much of an effect of incubation time on the relative difference 
in intensities between peak 1 and peak 2, or peak 1’ and peak 2’. When the incubation time was 
longer than 12 hr, more peaks are observed, referred to as peaks 3, 4, 3’, and 4’ in Fig. 2E and 2F. 
We propose that these correspond to the products resulting from side reactions occurring during 
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elongated incubation time. A proposed mechanism is discussed in Section 5.4.2. 
  
Fig. 2. Characterization of reaction of CH3CN and WT IgG4-Fc in the presence of 5 mM BMS 
after incubation at (A) 1 hr (B) 2 hr (C) 3 hr (D) 6 hr (E)12 hr, and (F) 24 hr at 37°C. Theoretical 
mass of IgG4-Fc-GlcNAc2Man8 is 26708.06 Da, observed mass of IgG4-Fc-GlcNAc2Man8 is 
26708.02 Da, theoretical mass of IgG4-Fc-GlcNAc2Man9 is 26870.16 Da, observed mass of IgG4-
Fc-GlcNAc2Man9 is 26870.5 Da. Corresponding GlcNAc2Man8-IgG4-Fc and GlcNAc2Man9-
IgG4-Fc species are labeled in Fig. 2A. The labeled Peak 1, 2, 3, 4, 1’, 2’, 3’, and 4’ represent the 
IgG4-Fc species derived from reaction with acetonitrile.  
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5.3.3 Characterization of the reaction of IgG4-Fc with 4-cyano-1-butyne.  
We designed to utilize the reactions between N-terminal Cys of IgG4-Fc and acetonitrile as 
potential linker chemistry for molecules of interests to proteins 4-cyano-1-butyne was selected, 
because of the presence of two functional groups, a terminal nitrile and alkyne, where the nitrile 
can selectively react with the N-terminal Cys of a protein and the alkyne can react with azide in a 
process known as “click” reaction10. Additionally, we incorporated two methyl groups between the 
two functional groups to allow increased flexibility.  
 
To characterize the reaction of IgG4-Fc and 4-cyano-1-butyne, 150 µL of nonglycosylated N297Q 
IgG4-Fc (0.2 mg/mL, pH 7.1) was incubated with 8 µL of 4-cyano-1-butyn at 37°C for 90 min, 
followed by analysis with HPLC-MS. Unexpectedly, the presence of alkyne induces 
polymerization of N297Q IgG4-Fc (Fig. 3), under reducing (Fig. 3B) and non-reducing (Fig. 3C) 
conditions. In particular, under reducing conditions, there is a new peak presenting a mass value 
of 25313 Da, indicating the potential reaction of 4-cyano-1-butyne with the free thiol (RSH). In 
the absence of the reducing agent, TCEP, a series of potential protein polymerization products were 
observed as well (Fig. 3C), suggesting that other functional groups of N297Q can potentially react 





















Fig. 3. Characterization of reaction of (A) N297Q IgG4-Fc and TCEP at 37°C for 90 min, pH 7.0 
(B) N297Q, HCCCH2CH2CN and TCEP at 37°C for 90 min, pH 7.0; (C) N297Q and 









5.4.1 Proposed mechanism of N-terminal Cys of IgG4-Fc with acetonitrile.  
A chemical modification at the N-terminal Cys of IgG4-Fc was observed, likely resulting from the 
presence of a co-solvent (CH3CN) during the process of reduction. Particularly, we examined the 
role of acetonitrile with a deuterium-labeled acetonitrile (CD3CN), where the modification at the 
N-terminal Cys presented an additional mass of 3 Da (Fig. 1). Based on these observations, we 
propose the mechanism displayed in Scheme 1. Under reducing conditions, the thiol group (RSH) 
attacks the nitrile carbon and forms a thioether intermediate A, where the nitrile carbon can be 
subsequently attacked by the N-terminal primary amine, forming cyclic intermediate B. 
Intermediates A and B present same mass (Fig.2, peak 2 and/or peak 2’), and the mass 
corresponding to intermediates A and B is detected by HPLC-MS (Fig. 2). The primary amine 
formed on the 5-membered ring eliminates ammonia, resulting in the cyclic product with a mass 
addition of +24 Da (Fig.2, peak 1 and/or peak 1’). The cyclic product was observed with a mass 
addition of +27 Da during reaction with CD3CN, confirming that the methyl group from 
acetonitrile is incorporated (Fig. 1). 
 
We further investigated the effects of incubation time on the yields of the product (Fig. 2), where 
the duration of 3 hr reveals potentially the optimal incubation time, due to the fact that the native 
IgG4-Fc was predominantly reacted. A longer incubation, on the other hand, results in increased 









and 4’ in Fig. 2E and 2F. We propose that this results from the reaction of other Cys residues with 
acetonitrile (Scheme 2), considering that the protein:CH3CN ratio is 1:2.5x105 
(concentration:concentration). The major products reveal the addition of acetonitrile to other Cys 
residues, e.g., peak 3 derived from peak 1, peak 4 derived from peak 2. These observations indicate 
that the other Cys residues in IgG4-Fc react at a significant slower rate with acetonitrile, as 
compared to the N-terminal Cys. These side reactions can be potentially minimized through 
dialysis of the excess quantity of CH3CN and shortened reaction time.  
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Peptide mapping refers to selective fragmentation of a protein into well-defined peptides using 
suitable enzymes or chemicals1. Through peptide mapping of a protein product, primary structures 
and corresponding covalent modifications (e.g., site-specific glycosylation, oxidation, and amino 
acid substitution) can be identified. A typical peptide mapping contains a denaturation step to 
unfold the protein to be accessible for the following reduction and alkylation2. The reduction step 
serves to break covalently linked disulfide bonds, and the alkylation step serves to protect reduced 
thiol with alkylating agents, due to the fact that the reduced thiol (RSH) is highly reactive3. Typical 
reducing agents are dithiothreitol (DTT) and bis(2-mercaptoehyl)sulfone (BMS), and typical 
alkylating agents are iodoacetic amide (IAA), iodoacetic acid (IAC), and N-ethylmaleimide 
(NEM)4. After denaturation, reduction and alkylation, proteins are accessible for enzymatic or 
chemical treatment. Peptide map is a powerful and universal analytical technique to characterize 
primary structures of proteins. Hence, the International Council for Harmonization (ICH) Q6B 
guideline recommends the utilization of peptide mapping for structural characterization and 
confirmation of biotherapeutics5.  
 
Sufficient quantities of denaturing, reducing and alkylating agents are introduced during peptide 
mapping to ensure the completion of each step. The subsequent depletion of these components is 
necessary for reducing side reactions6, minimizing matrix effects (generating good signals in 
analytical detection)7, and sustaining an efficient enzymatic digestion. Enzymes are recommended 
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to be in a buffer system, where they maintain their optimal activity8. Ultra-centrifugal filters, spin 
column, and dialysis are the common approaches to remove the salts. Among these, centrifugal 
filter device represents a relatively convenient and efficient tool, and has been extensively utilized9. 
In the present work, we observed a hydrolysis reaction between Cys425 and Ser426 (Eu numbering10) 
in an IgG4-Fc during peptide mapping, where the hydrolysis products were identified by HPLC-
MS/MS. Notably, the measured relative yields of the hydrolysis products are dependent on the 
steps selected for sample preparation, e.g., the usage of distinct alkylating agents and filtration 
devices. 
 
6.2 Materials and Methods 
6.2.1 Materials. Sodium phosphate, guandine hydrochloride (GdnHCl), IAA, IAC, ammonium 
bicarbonate, and Trypsin/LysC were purchased from the same sources as described in Chapter 
2.2.1. 18O-labeled water (95–98% atom pure 18O) was purchased from Cambridge Isotope 
Laboratories, Inc. (Andover, MA).  
 
6.2.2 Peptide mapping of IgG4-Fc. An aliquot of 500 µL IgG4-Fc (0.22 mg/mL, pH 7.1) in 20 
mM sodium phosphate was mixed with 500 µL of 6 M GdnHCl, 5 µL of 1 M DTT, and incubated 
at 37°C for 1 hr. IgG4-Fc was alkylated by the addition of 20 µL 1 M IAA, and incubated at 37°C 
for 1 hr. The excess quantity of denaturing, reducing and alkylating agents was filtered with a 10 
kDa filter unit (Amicon Ultra Centrifugal Filter, County Cork, Ireland), and exchanged with 300 
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µL of 5 mM ammonium bicarbonate twice via centrifugation at 16,900 g. For the last 
centrifugation step, the protein solution was concentrated to approximately 200 µL. The protein 
solution was collected by reverse-flip of the filters, and centrifuged at 300g for 4 min. The stock 
solutions of GdnHCl, DTT, and IAA were prepared in 50 mM ammonium bicarbonate. Collected 
protein was digested with trypsin/LysC at a protein:enzyme ratio of 30:1 (w:w). 20 µg of 
trypsin/LysC was dissolved in 100 µL of 5 mM ammonium bicarbonate, where 16.6 µL of 
trypsin/LysC solution were added to the protein solution. The digestion was performed at 37°C for 
6 hr prior to analysis by HPLC-MS/MS. 
 
6.2.3 HPLC-MS analysis. A similar approach was described in Section 3.2.8. 
 
6.3 Results 
6.3.1 Identification of hydrolysis products.  
IgG4-Fc was denatured with GdnHCl, reduced with DTT, alkylated with IAA, and digested with 
trypsin/LysC, followed by analysis with HPLC-MS. Two hydrolysis products, WQEGNVFSC(+57) 
and SVMHEALHNHYTQK, were observed, originating from the tryptic peptide 
WQEGNVFSC(+57)SVMHEALHNHYTQK, where +57 indicates that Cys has been chemically 
alkylated by IAA. The collision-induced dissociation (CID) MS/MS spectra of 
WQEGNVFSC(+57) (m/z =563.7, z=2) are displayed in Fig.1. The presence of y3, y7, and b7 ions 
identifies the peptide as a hydrolysis product with the C-terminal sequence SC(+57). The CID 
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MS/MS spectra of SVMHEALHNHYTQK (m/z=424.4, z=4) are displayed in Fig. 2. The 
identification of the b7 ion, and a series of the y ions (e.g., y3, y4, y7, y10, y11, and y12 ions) 










































6.3.2 The origin of oxygen in hydrolysis products.  
Two fragment products, WQEGNVFSC(+57) and SVMHEALHNHYTQK, were observed 
originating from the tryptic peptide WQEGNVFSC(+57)SVMHEALHNHYTQK. A carboxylic 
acid was formed at the C-terminus of WQEGNVFSC(+57), indicating the incorporation of one 
oxygen. Hence, we investigated the origin of the oxygen utilizing 18O-labeled water during tryptic 
digestion. Aliquots of IgG4-Fc were denatured, reduced and alkylated as described in Section 6.2.2 
in H216O prior to tryptic digestion. The excess denaturing, reducing and alkylating agents were 
exchanged into 5 mM ammonium bicarbonate in H218O using 10 kDa Amicon Ultracentrifuge 
filters. The digestion was performed in 5 mM ammonium bicarbonate in H218O with trypsin/LysC 
for 8 hrs at 37°C, followed by analysis with HPLC-MS. The incorporation of 18O was monitored 
for the two products, WQEGNVFSC(+57) and SVMHEALHNHYTQK, displayed in Fig. 3 and 4, 
respectively. WQEGNVFSC(+57) reveals the incorporation of one 18O indicated by the mass 
addition of 2 Da. SVMHEALHNHYTQK reveals the incorporation of one and two oxygens, 
respectively, indicated by the mass additions of 2 Da and 4 Da, respectively.  
 
Prior to digestion, IgG4-Fc was buffer-exchanged to 18O-labeled water through filtration, 
indicating the presence residual H216O. Therefore, the highest mass shift of each product is taken 
into consideration. The mass shift in product WQEGNVFSC(+57) corresponds to a hydrolysis 




Fig. 3. Incorporation of 18O in peptides WQEGNVFSC(+57) due to hydrolysis from 
WQEGNVFSC(+57)SVMHEALHNHYTQK. Spectra displayed in front correspond to digestion 





















Fig. 4. Incorporation of 18O in peptides SVMHEALHNHYTQK due to digestion. Spectra 
displayed in front correspond to digestion performed in H216O, spectra displayed in bottom 
indicates digestion performed in H218O. 
 
6.3.3 The effects of the usage of Amicon filter on the quantity of products.  
Prior to enzymatic digestion, a filtration step was introduced in the sample preparation as described 
in section 6.2.2. We, therefore, evaluated the potential role of this step on the relative quantity of 
the hydrolysis products. The quantification of each peptide was obtained by extracting the intensity 
of each peak using MassLynx (Waters Inc., Milford, CA). The relative hydrolysis products are 
quantified by the means of taking the ratio of the quantity of the product to the total ion count of 
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    Equation 1 
Interestingly, the introduction of the filtration step results in a 1000- to 2000- fold enrichment of 
















Fig. 5. The yields of hydrolysis products (%) formed during peptide map of IgG4-Fc after 
denaturation with GdnHCl, reduction with DTT and alkylation with IAA, with or without filtration, 





In this chapter, a hydrolysis reaction was observed between Cys425 and Ser426 in an IgG4-Fc during 
the process of peptide mapping. Two hydrolysis fragments, WQEGNVSC(+57) and 
SVMHEALHNHYTQK, were identified by HPLC-MS/MS (Fig. 1 and Fig. 2) originating from 
the native peptide, WQEGNVSC(+57)SVMHEALHNHYTQK. To rule out the potential effects of 
digestion from Trypsin/LysC leading to the formation of these products, digestion was performed 
in 18O-labeled H2O. As displayed in Fig. 3, WQEGNVFSC(+57) (m/z 563.71, z=2) reveals the 
presence of no mass shift and an additional mass of 2 Da, indicating there is 0 to 1 18O 
incorporation. On the other hand, SVMHEALHNHYTQK (m/z 424.4, z =4) reveals the presence 
of no mass shift, an additional mass of 2 Da and 4 Da, indicating there is 0, 1 and 2 18O 
incorporation. We prepared the digestion solution in H218O with Amicon filtration via exchange 
H216O to H218O through centrifugation, suggesting that residual amounts of H216O were present 
during trypsin/LysC digestion, which explains the additional presence of no mass shift in products 
1 and 2. We conclude the +2 Da mass addition of WQEGNVFSC(+57) is due to the hydrolysis 
from the parent peptide, with one oxygen from H218O incorporated at the C-terminus of the peptide. 
The +2 Da and +4 Da mass additions for the other hydrolysis product, SVMHEALHNHYTQK, 
are due to trypsin/LysC digestion. Therefore, these observations confirm that the two fragments 
originated from hydrolysis. It needs to be noted that the hydrolysis reaction can occur during the 
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process of reduction, alkylation and digestion. 
 
The yields of the hydrolysis products are higher when IAA was used as the alkylating agent as 
compared to IAC (Fig. 6). The proposed mechanisms are displayed in Scheme 1 (with IAA) and 
Scheme 2 (with IAC), respectively, involving the side chain (OH group) of Ser426 adding to the 
neighboring N-terminal peptide bond, resulting in the fragmentation of the backbone at Cys425-
Ser426. In addition, our rationale that alkylation of Cys with IAA results in higher yields is due to 
inductive effects of the amide group of IAA, as compared to IAC, facilitating the addition of OH 






































































Fig. 6. The yields of hydrolysis products (%) formed during peptide map of IgG4-Fc after 
denaturation with GdnHCl, reduction with DTT and alkylation with IAA and IAC, respectively, 
where product 1 corresponds to WQEGNVSC(+57), and product 2 corresponds to 
SVMHEALHNHYTQK. No filtration step was applied.  
 
Moreover, we observed the utilization of Amicon filters played significant roles in the quantity of 
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the fragmentation products (Fig. 5), where the application of filter step enriched the fragmentation 
products. Our rationale for this observation is that a filtration step potentially enriches the shorter 
protein resulted from the hydrolysis, where the relatively long unfolded proteins may preferably 
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Scheme 1. Proposed mechanism for hydrolysis between Cys425 and Ser426 in an IgG4-Fc, where 





















Scheme 2. Proposed mechanism for hydrolysis between Cys425 and Ser426 in an IgG4-Fc, where 





































7.1 Summary and conclusions  
IgG mAbs are glycoproteins that have emerged as powerful and promising protein therapeutics. 
IgGs are marginally stable1 and sensitive to intrinsic (e.g., glycosylation, primary sequences) and 
extrinsic factors (e.g., light, temperature)2. Photodegradation in IgGs alters their primary structures, 
associated with chemical and physical instability3. More recent studies have recognized an 
additional, critical role of light-induced oxidative, chemical protein modifications for 
immunogenicity4-6. Importantly, when Boll et al.7 analyzed immunogenic samples of an oxidized 
monoclonal antibody (mAb) for common oxidation products of Met and Trp, they concluded that 
these did not contribute significantly to immunogenicity. Hence, the initial aim of the thesis was 
to identify photo-induced chemical modifications other than conventional oxidation products, 
using IgG4-Fc as a model protein. Furthermore, we elucidated the consequences of these chemical 
modifications on the quality and function of IgG4-Fc, in combination with the effects of 
glycosylation. During the method development processes, the reaction of N-terminal Cys of IgG4-
Fc with acetonitrile under reducing conditions was observed and investigated. These reactions can 
likely be utilized as linker chemistry in molecules of interest to proteins. In addition, an 
ultrafiltration device was observed to bias towards the detection of two hydrolysis products from 
peptide backbone cleavage between Cys425 and Ser426.     
Chapter 2 details a mechanism for the photolytic Tyr side chain fragmentation at Tyr300, Tyr373 
and Tyr436 in IgG4-Fc upon irradiation at UVC light at λ = 254 nm and UVB light with λmax = 305 
nm. Tyr side chain fragmentation yielded either Gly or various backbone cleavage products, 
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including glyoxal amide derivatives. A mechanism is proposed involving intermediate Tyr radical 
cation formation, either through direct light absorption of Tyr or through electron transfer to an 
initial Trp radical cation, followed by elimination of quinone methide. To our knowledge, this is 
the first observation of a photo-induced Tyr side chain reaction in a protein.  
Chapter 3 elucidates the impact of photo-induced side chain fragmentation at Tyr300, Tyr373, Tyr436 
and Trp381 on physicochemical stability and receptor binding of IgG4-Fc. Trp and Tyr are the two 
major light-sensitive amino acids and are critical to maintain the conformational structures of 
proteins. Photo-induced side chain fragmentation at these amino acids typically leads to their 
transformation to Gly8, 9. To evaluate the impact of these photodegradation products, Y300G, 
Y373G, Y436G, W381G and W381A IgG4-Fc were representatively prepared. Y373G and Y436G 
reveal significantly reduced thermal stability, as compared to WT. W381A and W381G reveal an 
overall conformational structure perturbation, indicated by no detectable thermal transition on 
DSC. W381A, Y300G, and Y436G present a ca. 10-fold reduction in binding affinity to FcγRIIIA, 
as compared to WT. Nearly two thirds of an adjacent Ser375 was O-mannosylated in W381A and 
W381G IgG4-Fc. Results from this study demonstrate that photo-induced conversion of Trp and 
Tyr to Gly (e.g., at Trp381, Tyr373, Tyr300) notably modifies the physico-chemical properties and 
biological functions of IgG4-Fc.  
Chapter 4 characterizes the impact of N-glycan structures on physico-chemical stability, 
photostability, and receptor binding of IgG4-Fc. N297Q reveals the lowest thermal stability in the 
CH2 domain, as compared to HM, Man5, and GlcNAc1. Man5 presents two-fold higher in binding 
affinity to FcγRIIIA than HM, and ca. 36-fold higher as compared to GlcNAc1. N297Q does not 
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present measurable binding affinity to FcγRIIIA. Moreover, N-glycan structures at Asn297 were 
revealed to play a role in the yield of photoproduct formation including vinyl Cys and backbone 
cleavage products from Tyr side chain fragmentation.  
Chapter 5 investigates a reaction between N-terminal Cys of IgG4-Fc and a co-solvent 
(acetonitrile) under reducing conditions, where a five-membered cyclic product was formed at the 
N-terminal Cys.  
Chapter 6 discovers two hydrolysis products resulting from a hydrolysis reaction of IgG4-Fc 
during peptide mapping. Two factors were demonstrated to impact the relative quantity of the 
hydrolysis products analyzed by HPLC-MS, including the selection of alkylating agents and the 
application of a filtration device during sample preparation. 
 
7.2 Future directions 
Currently, several specific glycan patterns10, 11 and oxidation products12 of mAbs, known to impact 
their half-life, efficacy, and shelf-life, are listed as critical quality attributes, and need to be strictly 
controlled and monitored. The findings of this thesis elucidate the consequences of photo-induced 
Trp and Tyr side chain fragmentation and glycan structures of IgG4-Fc to its physicochemical 
properties, receptor binding, and photostability. Studying these characteristics of IgGs can advance 
our knowledge to maintain IgGs stability and functions, aid in the development of a better drug 
substance and product. 
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